

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/090530 A2

(51) International Patent Classification⁷: **C12N 9/00**

(21) International Application Number: PCT/US02/01369

(22) International Filing Date: 16 January 2002 (16.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/263,083	18 January 2001 (18.01.2001)	US
60/271,205	23 February 2001 (23.02.2001)	US
60/271,117	23 February 2001 (23.02.2001)	US
60/276,859	16 March 2001 (16.03.2001)	US
60/278,504	23 March 2001 (23.03.2001)	US
60/278,522	23 March 2001 (23.03.2001)	US
60/280,510	29 March 2001 (29.03.2001)	US
60/280,266	29 March 2001 (29.03.2001)	US

(71) Applicant (for all designated States except US): **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEE, Ernestine, A.** [US/US]; 624 Kains Street, Albany, CA 94706 (US). **WALIA, Narinder, K.** [US/US]; 890 Davis Street #205, San Leandro, CA 94577 (US). **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **ISON, Craig, H.** [US/US]; 1242 Weathersfield Way, San Jose, CA 95118 (US). **GURURAJAN, Rajagopal** [IN/US]; 5591 Dent Avenue, San Jose, CA 95118 (US). **ARVIZU, Chandra** [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). **YAO, Monique, G.** [US/US]; 1189 Woodgate Drive, Carmel, IN 40633 (US). **JACKSON, Jennifer, L.** [US/US]; 4913 Deep

Creek Road, Fremont, CA 94555 (US). **TANG, Tom, Y.** [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **TRAN, Bao** [US/US]; 750 Salberg Avenue, Santa Clara, CA 95051 (US). **DING, Li** [US/US]; 3353 Alma Street #146, Palo Alto, CA 94306 (US). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **LAL, Preeti, G.** [IN/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). **WARREN, Bridget, A.** [US/US]; 10130 Parkwood Drive #2, Cupertino, CA 95014 (US).

(74) Agents: **HAMLET-COX, Diana** et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: KINASES AND PHOSPHATASES

(57) Abstract: The invention provides human kinases and phosphatases (KPP) and polynucleotides which identify and encode KPP. The invention also provides expression vector, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.



WO 02/090530 A2

KINASES AND PHOSPHATASES

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of kinases and phosphatases and to the use of these sequences in the diagnosis, treatment, and prevention of cardiovascular diseases, immune system disorders, neurological disorders, disorders affecting growth and development, lipid disorders, cell proliferative disorders, and cancers, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of kinases and phosphatases.

BACKGROUND OF THE INVENTION

Reversible protein phosphorylation is the ubiquitous strategy used to control many of the intracellular events in eukaryotic cells. It is estimated that more than ten percent of proteins active in a typical mammalian cell are phosphorylated. Kinases catalyze the transfer of high-energy phosphate groups from adenosine triphosphate (ATP) to target proteins on the hydroxyamino acid residues serine, threonine, or tyrosine. Phosphatases, in contrast, remove these phosphate groups. Extracellular signals including hormones, neurotransmitters, and growth and differentiation factors can activate kinases, which can occur as cell surface receptors or as the activator of the final effector protein, as well as other locations along the signal transduction pathway. Cascades of kinases occur, as well as kinases sensitive to second messenger molecules. This system allows for the amplification of weak signals (low abundance growth factor molecules, for example), as well as the synthesis of many weak signals into an all-or-nothing response. Phosphatases, then, are essential in determining the extent of phosphorylation in the cell and, together with kinases, regulate key cellular processes such as metabolic enzyme activity, proliferation, cell growth and differentiation, cell adhesion, and cell cycle progression.

KINASES

Kinases comprise the largest known enzyme superfamily and vary widely in their target molecules. Kinases catalyze the transfer of high energy phosphate groups from a phosphate donor to a phosphate acceptor. Nucleotides usually serve as the phosphate donor in these reactions, with most kinases utilizing adenosine triphosphate (ATP). The phosphate acceptor can be any of a variety of molecules, including nucleosides, nucleotides, lipids, carbohydrates, and proteins. Proteins are phosphorylated on hydroxyamino acids. Addition of a phosphate group alters the local charge on the acceptor molecule, causing internal conformational changes and potentially influencing intermolecular contacts. Reversible protein phosphorylation is the primary method for regulating protein activity in eukaryotic cells. In general, proteins are activated by phosphorylation in response

to extracellular signals such as hormones, neurotransmitters, and growth and differentiation factors. The activated proteins initiate the cell's intracellular response by way of intracellular signaling pathways and second messenger molecules such as cyclic nucleotides, calcium-calmodulin, inositol, and various mitogens, that regulate protein phosphorylation.

5 Kinases are involved in all aspects of a cell's function, from basic metabolic processes, such as glycolysis, to cell-cycle regulation, differentiation, and communication with the extracellular environment through signal transduction cascades. Inappropriate phosphorylation of proteins in cells has been linked to changes in cell cycle progression and cell differentiation. Changes in the cell cycle have been linked to induction of apoptosis or cancer. Changes in cell differentiation have been linked
10 to diseases and disorders of the reproductive system, immune system, and skeletal muscle.

 There are two classes of protein kinases. One class, protein tyrosine kinases (PTKs), phosphorylates tyrosine residues, and the other class, protein serine/threonine kinases (STKs), phosphorylates serine and threonine residues. Some PTKs and STKs possess structural characteristics of both families and have dual specificity for both tyrosine and serine/threonine
15 residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain containing specific residues and sequence motifs characteristic of the kinase family. The protein kinase catalytic domain can be further divided into 11 subdomains. N-terminal subdomains I-IV fold into a two-lobed structure which binds and orients the ATP donor molecule, and subdomain V spans the two lobes. C-terminal subdomains VI-XI bind the protein substrate and transfer the gamma phosphate from ATP to
20 the hydroxyl group of a tyrosine, serine, or threonine residue. Each of the 11 subdomains contains specific catalytic residues or amino acid motifs characteristic of that subdomain. For example, subdomain I contains an 8-amino acid glycine-rich ATP binding consensus motif, subdomain II contains a critical lysine residue required for maximal catalytic activity, and subdomains VI through IX comprise the highly conserved catalytic core. PTKs and STKs also contain distinct sequence
25 motifs in subdomains VI and VIII which may confer hydroxyamino acid specificity.

 In addition, kinases may also be classified by additional amino acid sequences, generally between 5 and 100 residues, which either flank or occur within the kinase domain. These additional amino acid sequences regulate kinase activity and determine substrate specificity. (Reviewed in Hardie, G. and S. Hanks (1995) The Protein Kinase Facts Book, Vol I, pp. 17-20 Academic Press,
30 San Diego CA.). In particular, two protein kinase signature sequences have been identified in the kinase domain, the first containing an active site lysine residue involved in ATP binding, and the second containing an aspartate residue important for catalytic activity. If a protein analyzed includes the two protein kinase signatures, the probability of that protein being a protein kinase is close to 100% (PROSITE: PDOC00100, November 1995).

35 **Protein Tyrosine Kinases**

Protein tyrosine kinases (PTKs) may be classified as either transmembrane, receptor PTKs or nontransmembrane, nonreceptor PTK proteins. Transmembrane tyrosine kinases function as receptors for most growth factors. Growth factors bind to the receptor tyrosine kinase (RTK), which causes the receptor to phosphorylate itself (autophosphorylation) and specific intracellular second messenger proteins. Growth factors (GF) that associate with receptor PTKs include epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Nontransmembrane, nonreceptor PTKs lack transmembrane regions and, instead, form signaling complexes with the cytosolic domains of plasma membrane receptors. Receptors that function through non-receptor PTKs include those for cytokines and hormones (growth hormone and prolactin), and antigen-specific receptors on T and B lymphocytes.

Many PTKs were first identified as oncogene products in cancer cells in which PTK activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs. Furthermore, cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Charbonneau, H. and N.K. Tonks (1992) Annu. Rev. Cell Biol. 8:463-493). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

Protein Serine/Threonine Kinases

Protein serine/threonine kinases (STKs) are nontransmembrane proteins. A subclass of STKs are known as ERKs (extracellular signal regulated kinases) or MAPs (mitogen-activated protein kinases) and are activated after cell stimulation by a variety of hormones and growth factors. Cell stimulation induces a signaling cascade leading to phosphorylation of MEK (MAP/ERK kinase) which, in turn, activates ERK via serine and threonine phosphorylation. A varied number of proteins represent the downstream effectors for the active ERK and implicate it in the control of cell proliferation and differentiation, as well as regulation of the cytoskeleton. Activation of ERK is normally transient, and cells possess dual specificity phosphatases that are responsible for its down-regulation. Also, numerous studies have shown that elevated ERK activity is associated with some cancers. Other STKs include the second messenger dependent protein kinases such as the cyclic-AMP dependent protein kinases (PKA), calcium-calmodulin (CaM) dependent protein kinases, and the mitogen-activated protein kinases (MAP); the cyclin-dependent protein kinases; checkpoint and cell cycle kinases; Numb-associated kinase (Nak); human Fused (hFu); proliferation-related kinases; 5'-AMP-activated protein kinases; and kinases involved in apoptosis.

One member of the ERK family of MAP kinases, ERK 7, is a novel 61-kDa protein that has motif similarities to ERK1 and ERK2, but is not activated by extracellular stimuli as are ERK1 and ERK2 nor by the common activators, c-Jun N-terminal kinase (JNK) and p38 kinase. ERK7 regulates

its nuclear localization and inhibition of growth through its C-terminal tail, not through the kinase domain as is typical with other MAP kinases (Abe, M.K. (1999) Mol. Cell. Biol. 19:1301-1312).

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate, cyclic ADP ribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The PKAs are involved in mediating hormone-induced cellular responses and are activated by cAMP produced within the cell in response to hormone stimulation. cAMP is an intracellular mediator of hormone action in all animal cells that have been studied. Hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in all animal cells and is thought to account for the effects of cAMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York NY, pp. 416-431, 1887).

The casein kinase I (CKI) gene family is another subfamily of serine/threonine protein kinases. This continuously expanding group of kinases have been implicated in the regulation of numerous cytoplasmic and nuclear processes, including cell metabolism and DNA replication and repair. CKI enzymes are present in the membranes, nucleus, cytoplasm and cytoskeleton of eukaryotic cells, and on the mitotic spindles of mammalian cells (Fish, K.J. et al. (1995) J. Biol. Chem. 270:14875-14883).

The CKI family members all have a short amino-terminal domain of 9-76 amino acids, a highly conserved kinase domain of 284 amino acids, and a variable carboxyl-terminal domain that ranges from 24 to over 200 amino acids in length (Cegielska, A. et al. (1998) J. Biol. Chem. 273:1357-1364). The CKI family is comprised of highly related proteins, as seen by the identification of isoforms of casein kinase I from a variety of sources. There are at least five mammalian isoforms, α , β , γ , δ , and ϵ . Fish et al. identified CKI-epsilon from a human placenta cDNA library. It is a basic protein of 416 amino acids and is closest to CKI-delta. Through recombinant expression, it was determined to phosphorylate known CKI substrates and was inhibited by the CKI-specific inhibitor CKI-7. The human gene for CKI-epsilon was able to rescue yeast with a slow-growth phenotype caused by deletion of the yeast CKI locus, HRR250 (Fish et al., supra).

The mammalian circadian mutation tau was found to be a semidominant autosomal allele of CKI-epsilon that markedly shortens period length of circadian rhythms in Syrian hamsters. The tau locus is encoded by casein kinase I-epsilon, which is also a homolog of the *Drosophila* circadian gene double-time. Studies of both the wildtype and tau mutant CKI-epsilon enzyme indicated that the mutant enzyme has a noticeable reduction in the maximum velocity and autophosphorylation state.

Further, *in vitro*, CKI-epsilon is able to interact with mammalian PERIOD proteins, while the mutant enzyme is deficient in its ability to phosphorylate PERIOD. Lowrey et al. have proposed that CKI-epsilon plays a major role in delaying the negative feedback signal within the transcription-translation-based autoregulatory loop that composes the core of the circadian mechanism. Therefore the CKI-epsilon enzyme is an ideal target for pharmaceutical compounds influencing circadian rhythms, jet-lag and sleep, in addition to other physiologic and metabolic processes under circadian regulation (Lowrey, P.L. et al. (2000) Science 288:483-491).

Homeodomain-interacting protein kinases (HIPKs) are serine/threonine kinases and novel members of the DYRK kinase subfamily (Hofmann, T.G. et al. (2000) Biochimie 82:1123-1127).

HIPKs contain a conserved protein kinase domain separated from a domain that interacts with homeoproteins. HIPKs are nuclear kinases, and HIPK2 is highly expressed in neuronal tissue (Kim, Y.H. et al. (1998) J. Biol. Chem. 273:25875-25879; Wang, Y. et al. (2001) Biochim. Biophys. Acta 1518:168-172). HIPKs act as corepressors for homeodomain transcription factors. This corepressor activity is seen in posttranslational modifications such as ubiquitination and phosphorylation, each of which are important in the regulation of cellular protein function (Kim, Y.H. et al. (1999) Proc. Natl. Acad. Sci. USA 96:12350-12355).

The human h-warts protein, a homolog of Drosophila warts tumor suppressor gene, maps to chromosome 6q24-25.1. It has a serine/threonine kinase domain and is localized to centrosomes in interphase cells. It is involved in mitosis and functions as a component of the mitotic apparatus (Nishiyama, Y. et al. (1999) FEBS Lett. 459:159-165).

Calcium-Calmodulin Dependent Protein Kinases

Calcium-calmodulin dependent (CaM) kinases are involved in regulation of smooth muscle contraction, glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and CaM kinase II). CaM dependent protein kinases are activated by calmodulin, an intracellular calcium receptor, in response to the concentration of free calcium in the cell. Many CaM kinases are also activated by phosphorylation. Some CaM kinases are also activated by autophosphorylation or by other regulatory kinases. CaM kinase I phosphorylates a variety of substrates including the neurotransmitter-related proteins synapsin I and II, the gene transcription regulator, CREB, and the cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. et al. (1995) EMBO J. 14:3679-3686). CaM kinase II also phosphorylates synapsin at different sites and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. CaM kinase II controls the synthesis of catecholamines and serotonin, through phosphorylation/activation of tyrosine hydroxylase and tryptophan hydroxylase, respectively (Fujisawa, H. (1990) BioEssays 12:27-29). The mRNA encoding a calmodulin-binding protein kinase-like protein was found to be enriched in mammalian forebrain. This protein is associated with vesicles in both axons and

dendrites and accumulates largely postnatally. The amino acid sequence of this protein is similar to CaM-dependent STKs, and the protein binds calmodulin in the presence of calcium (Godbout, M. et al. (1994) J. Neurosci. 14:1-13).

Mitogen-Activated Protein Kinases

5 The mitogen-activated protein kinases (MAP), which mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades, are another STK family that regulates intracellular signaling pathways. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S.E. and R.A. Weinberg (1993) Nature 365:781-783). There are three kinase modules comprising the MAP kinase
10 cascade: MAPK (MAP), MAPK kinase (MAP2K, MAPKK, or MKK), and MKK kinase (MAP3K, MAPKKK, OR MEKK) (Wang, X.S. et al (1998) Biochem. Biophys. Res. Commun. 253:33-37). The extracellular-regulated kinase (ERK) pathway is activated by growth factors and mitogens, for example, epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, or endotoxic lipopolysaccharide (LPS). The closely related though distinct parallel pathways, the c-Jun
15 N-terminal kinase (JNK), or stress-activated kinase (SAPK) pathway, and the p38 kinase pathway are activated by stress stimuli and proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1). Altered MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.. MAP kinase signaling pathways are present in mammalian cells as well as in yeast.

Cyclin-Dependent Protein Kinases

20 The cyclin-dependent protein kinases (CDKs) are STKs that control the progression of cells through the cell cycle. The entry and exit of a cell from mitosis are regulated by the synthesis and destruction of a family of activating proteins called cyclins. Cyclins are small regulatory proteins that bind to and activate CDKs, which then phosphorylate and activate selected proteins involved in the
25 mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to cyclin binding, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue on the CDK.

 Another family of STKs associated with the cell cycle are the NIMA (never in mitosis)-related kinases (Neks). Both CDKs and Neks are involved in duplication, maturation, and separation
30 of the microtubule organizing center, the centrosome, in animal cells (Fry, A.M. et al. (1998) EMBO J. 17:470-481).

Checkpoint and Cell Cycle Kinases

 In the process of cell division, the order and timing of cell cycle transitions are under control of cell cycle checkpoints, which ensure that critical events such as DNA replication and chromosome
35 segregation are carried out with precision. If DNA is damaged, e.g. by radiation, a checkpoint

pathway is activated that arrests the cell cycle to provide time for repair. If the damage is extensive, apoptosis is induced. In the absence of such checkpoints, the damaged DNA is inherited by aberrant cells which may cause proliferative disorders such as cancer. Protein kinases play an important role in this process. For example, a specific kinase, checkpoint kinase 1 (Chk1), has been identified in yeast and mammals, and is activated by DNA damage in yeast. Activation of Chk1 leads to the arrest of the cell at the G2/M transition (Sanchez, Y. et al. (1997) Science 277:1497-1501). Specifically, Chk1 phosphorylates the cell division cycle phosphatase CDC25, inhibiting its normal function which is to dephosphorylate and activate the cyclin-dependent kinase Cdc2. Cdc2 activation controls the entry of cells into mitosis (Peng, C.-Y. et al. (1997) Science 277:1501-1505). Thus, activation of Chk1 prevents the damaged cell from entering mitosis. A deficiency in a checkpoint kinase, such as Chk1, may also contribute to cancer by failure to arrest cells with damaged DNA at other checkpoints such as G2/M.

Proliferation-Related Kinases

Proliferation-related kinase is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakaryocytic cells (Li, B. et al. (1996) J. Biol. Chem. 271:19402-19408). Proliferation-related kinase is related to the polo (derived from *Drosophila* polo gene) family of STKs implicated in cell division. Proliferation-related kinase is downregulated in lung tumor tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to oncogenic transformation.

5'-AMP-activated protein kinase

A ligand-activated STK protein kinase is 5'-AMP-activated protein kinase (AMPK) (Gao, G. et al. (1996) J. Biol. Chem. 271:8675-8681). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotrimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

Kinases in Apoptosis

Apoptosis is a highly regulated signaling pathway leading to cell death that plays a crucial role in tissue development and homeostasis. Deregulation of this process is associated with the pathogenesis of a number of diseases including autoimmune diseases, neurodegenerative disorders, and cancer. Various STKs play key roles in this process. ZIP kinase is an STK containing a C-terminal leucine zipper domain in addition to its N-terminal protein kinase domain. This

C-terminal domain appears to mediate homodimerization and activation of the kinase as well as interactions with transcription factors such as activating transcription factor, ATF4, a member of the cyclic-AMP responsive element binding protein (ATF/CREB) family of transcriptional factors (Sanjo, H. et al. (1998) J. Biol. Chem. 273:29066-29071). DRAK1 and DRAK2 are STKs that share
5 homology with the death-associated protein kinases (DAP kinases), known to function in interferon- γ induced apoptosis (Sanjo et al., supra). Like ZIP kinase, DAP kinases contain a C-terminal protein-protein interaction domain, in the form of ankyrin repeats, in addition to the N-terminal kinase domain. ZIP, DAP, and DRAK kinases induce morphological changes associated with apoptosis when transfected into NIH3T3 cells (Sanjo et al., supra). However, deletion of either the
10 N-terminal kinase catalytic domain or the C-terminal domain of these proteins abolishes apoptosis activity, indicating that in addition to the kinase activity, activity in the C-terminal domain is also necessary for apoptosis, possibly as an interacting domain with a regulator or a specific substrate.

RICK is another STK recently identified as mediating a specific apoptotic pathway involving the death receptor, CD95 (Inohara, N. et al. (1998) J. Biol. Chem. 273:12296-12300). CD95 is a
15 member of the tumor necrosis factor receptor superfamily and plays a critical role in the regulation and homeostasis of the immune system (Nagata, S. (1997) Cell 88:355-365). The CD95 receptor signaling pathway involves recruitment of various intracellular molecules to a receptor complex following ligand binding. This process includes recruitment of the cysteine protease caspase-8 which, in turn, activates a caspase cascade leading to cell death. RICK is composed of an N-terminal
20 kinase catalytic domain and a C-terminal "caspase-recruitment" domain that interacts with caspase-like domains, indicating that RICK plays a role in the recruitment of caspase-8. This interpretation is supported by the fact that the expression of RICK in human 293T cells promotes activation of caspase-8 and potentiates the induction of apoptosis by various proteins involved in the CD95 apoptosis pathway (Inohara et al., supra).

25 **Mitochondrial Protein Kinases**

A novel class of eukaryotic kinases, related by sequence to prokaryotic histidine protein kinases, are the mitochondrial protein kinases (MPKs) which seem to have no sequence similarity with other eukaryotic protein kinases. These protein kinases are located exclusively in the mitochondrial matrix space and may have evolved from genes originally present in respiration-
30 dependent bacteria which were endocytosed by primitive eukaryotic cells. MPKs are responsible for phosphorylation and inactivation of the branched-chain alpha-ketoacid dehydrogenase and pyruvate dehydrogenase complexes (Harris, R.A. et al. (1995) Adv. Enzyme Regul. 34:147-162). Five MPKs have been identified. Four members correspond to pyruvate dehydrogenase kinase isozymes, regulating the activity of the pyruvate dehydrogenase complex, which is an important regulatory
35 enzyme at the interface between glycolysis and the citric acid cycle. The fifth member corresponds to

a branched-chain alpha-ketoacid dehydrogenase kinase, important in the regulation of the pathway for the disposal of branched-chain amino acids. (Harris, R.A. et al. (1997) Adv. Enzyme Regul. 37:271-293). Both starvation and the diabetic state are known to result in a great increase in the activity of the pyruvate dehydrogenase kinase in the liver, heart and muscle of the rat. This increase contributes in both disease states to the phosphorylation and inactivation of the pyruvate dehydrogenase complex and conservation of pyruvate and lactate for gluconeogenesis (Harris (1995) supra).

KINASES WITH NON-PROTEIN SUBSTRATES

Lipid and Inositol kinases

Lipid kinases phosphorylate hydroxyl residues on lipid head groups. A family of kinases involved in phosphorylation of phosphatidylinositol (PI) has been described, each member phosphorylating a specific carbon on the inositol ring (Leevers, S.J. et al. (1999) Curr. Opin. Cell. Biol. 11:219-225). The phosphorylation of phosphatidylinositol is involved in activation of the protein kinase C signaling pathway. The inositol phospholipids (phosphoinositides) intracellular signaling pathway begins with binding of a signaling molecule to a G-protein linked receptor in the plasma membrane. This leads to the phosphorylation of phosphatidylinositol (PI) residues on the inner side of the plasma membrane by inositol kinases, thus converting PI residues to the biphosphate state (PIP₂). PIP₂ is then cleaved into inositol triphosphate (IP₃) and diacylglycerol. These two products act as mediators for separate signaling pathways. Cellular responses that are mediated by these pathways are glycogen breakdown in the liver in response to vasopressin, smooth muscle contraction in response to acetylcholine, and thrombin-induced platelet aggregation.

PI 3-kinase (PI3K), which phosphorylates the D3 position of PI and its derivatives, has a central role in growth factor signal cascades involved in cell growth, differentiation, and metabolism. PI3K is a heterodimer consisting of an adapter subunit and a catalytic subunit. The adapter subunit acts as a scaffolding protein, interacting with specific tyrosine-phosphorylated proteins, lipid moieties, and other cytosolic factors. When the adapter subunit binds tyrosine phosphorylated targets, such as the insulin responsive substrate (IRS)-1, the catalytic subunit is activated and converts PI (4,5) bisphosphate (PIP₂) to PI (3,4,5) P₃ (PIP₃). PIP₃ then activates a number of other proteins, including PKA, protein kinase B (PKB), protein kinase C (PKC), glycogen synthase kinase (GSK)-3, and p70 ribosomal s6 kinase. PI3K also interacts directly with the cytoskeletal organizing proteins, Rac, rho, and cdc42 (Shepherd, P.R. et al. (1998) Biochem. J. 333:471-490). Animal models for diabetes, such as *obese* and *fat* mice, have altered PI3K adapter subunit levels. Specific mutations in the adapter subunit have also been found in an insulin-resistant Danish population, suggesting a role for PI3K in type-2 diabetes (Shepard, supra).

An example of lipid kinase phosphorylation activity is the phosphorylation of

D-erythro-sphingosine to the sphingolipid metabolite, sphingosine-1-phosphate (SPP). SPP has emerged as a novel lipid second-messenger with both extracellular and intracellular actions (Kohama, T. et al. (1998) J. Biol. Chem. 273:23722-23728). Extracellularly, SPP is a ligand for the G-protein coupled receptor EDG-1 (endothelial-derived, G-protein coupled receptor). Intracellularly, SPP regulates cell growth, survival, motility, and cytoskeletal changes. SPP levels are regulated by sphingosine kinases that specifically phosphorylate D-erythro-sphingosine to SPP. The importance of sphingosine kinase in cell signaling is indicated by the fact that various stimuli, including platelet-derived growth factor (PDGF), nerve growth factor, and activation of protein kinase C, increase cellular levels of SPP by activation of sphingosine kinase, and the fact that competitive inhibitors of the enzyme selectively inhibit cell proliferation induced by PDGF (Kohama et al., supra).

Purine Nucleotide Kinases

The purine nucleotide kinases, adenylate kinase (ATP:AMP phosphotransferase, or AdK) and guanylate kinase (ATP:GMP phosphotransferase, or GuK) play a key role in nucleotide metabolism and are crucial to the synthesis and regulation of cellular levels of ATP and GTP, respectively. These two molecules are precursors in DNA and RNA synthesis in growing cells and provide the primary source of biochemical energy in cells (ATP), and signal transduction pathways (GTP). Inhibition of various steps in the synthesis of these two molecules has been the basis of many antiproliferative drugs for cancer and antiviral therapy (Pillwein, K. et al. (1990) Cancer Res. 50:1576-1579).

AdK is found in almost all cell types and is especially abundant in cells having high rates of ATP synthesis and utilization such as skeletal muscle. In these cells AdK is physically associated with mitochondria and myofibrils, the subcellular structures that are involved in energy production and utilization, respectively. Recent studies have demonstrated a major function for AdK in transferring high energy phosphoryls from metabolic processes generating ATP to cellular components consuming ATP (Zelevnikar, R.J. et al. (1995) J. Biol. Chem. 270:7311-7319). Thus AdK may have a pivotal role in maintaining energy production in cells, particularly those having a high rate of growth or metabolism such as cancer cells, and may provide a target for suppression of its activity in order to treat certain cancers. Alternatively, reduced AdK activity may be a source of various metabolic, muscle-energy disorders that can result in cardiac or respiratory failure and may be treatable by increasing AdK activity.

GuK, in addition to providing a key step in the synthesis of GTP for RNA and DNA synthesis, also fulfills an essential function in signal transduction pathways of cells through the regulation of GDP and GTP. Specifically, GTP binding to membrane associated G proteins mediates the activation of cell receptors, subsequent intracellular activation of adenylyl cyclase, and production of the second messenger, cyclic AMP. GDP binding to G proteins inhibits these processes. GDP and

GTP levels also control the activity of certain oncogenic proteins such as p21^{ras} known to be involved in control of cell proliferation and oncogenesis (Bos, J.L. (1989) *Cancer Res.* 49:4682-4689). High ratios of GTP:GDP caused by suppression of GuK cause activation of p21^{ras} and promote oncogenesis. Increasing GuK activity to increase levels of GDP and reduce the GTP:GDP ratio may provide a therapeutic strategy to reverse oncogenesis.

GuK is an important enzyme in the phosphorylation and activation of certain antiviral drugs useful in the treatment of herpes virus infections. These drugs include the guanine homologs acyclovir and bucidovir (Miller, W.H. and R.L. Miller (1980) *J. Biol. Chem.* 255:7204-7207; Stenberg, K. et al. (1986) *J. Biol. Chem.* 261:2134-2139). Increasing GuK activity in infected cells may provide a therapeutic strategy for augmenting the effectiveness of these drugs and possibly for reducing the necessary dosages of the drugs.

Pyrimidine Kinases

The pyrimidine kinases are deoxycytidine kinase and thymidine kinase 1 and 2. Deoxycytidine kinase is located in the nucleus, and thymidine kinase 1 and 2 are found in the cytosol (Johansson, M. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:11941-11945). Phosphorylation of deoxyribonucleosides by pyrimidine kinases provides an alternative pathway for *de novo* synthesis of DNA precursors. The role of pyrimidine kinases, like purine kinases, in phosphorylation is critical to the activation of several chemotherapeutically important nucleoside analogues (Arner E.S. and S. Eriksson (1995) *Pharmacol. Ther.* 67:155-186).

PHOSPHATASES

Protein phosphatases are generally characterized as either serine/threonine- or tyrosine-specific based on their preferred phospho-amino acid substrate. However, some phosphatases (DSPs, for dual specificity phosphatases) can act on phosphorylated tyrosine, serine, or threonine residues. The protein serine/threonine phosphatases (PSPs) are important regulators of many cAMP-mediated hormone responses in cells. Protein tyrosine phosphatases (PTPs) play a significant role in cell cycle and cell signaling processes. Another family of phosphatases is the acid phosphatase or histidine acid phosphatase (HAP) family whose members hydrolyze phosphate esters at acidic pH conditions.

PSPs are found in the cytosol, nucleus, and mitochondria and in association with cytoskeletal and membranous structures in most tissues, especially the brain. Some PSPs require divalent cations, such as Ca²⁺ or Mn²⁺, for activity. PSPs play important roles in glycogen metabolism, muscle contraction, protein synthesis, T cell function, neuronal activity, oocyte maturation, and hepatic metabolism (reviewed in Cohen, P. (1989) *Annu. Rev. Biochem.* 58:453-508). PSPs can be separated into two classes. The PPP class includes PP1, PP2A, PP2B/calcineurin, PP4, PP5, PP6, and PP7.

Members of this class are composed of a homologous catalytic subunit bearing a very highly

conserved signature sequence, coupled with one or more regulatory subunits (PROSITE PDOC00115). Further interactions with scaffold and anchoring molecules determine the intracellular localization of PSPs and substrate specificity. The PPM class consists of several closely related isoforms of PP2C and is evolutionarily unrelated to the PPP class.

- 5 PP1 dephosphorylates many of the proteins phosphorylated by cyclic AMP-dependent protein kinase (PKA) and is an important regulator of many cAMP-mediated hormone responses in cells. A number of isoforms have been identified, with the alpha and beta forms being produced by alternative splicing of the same gene. Both ubiquitous and tissue-specific targeting proteins for PP1 have been identified. In the brain, inhibition of PP1 activity by the dopamine and adenosine 3',5'-
- 10 monophosphate-regulated phosphoprotein of 32kDa (DARPP-32) is necessary for normal dopamine response in neostriatal neurons (reviewed in Price, N.E. and M.C. Mumby (1999) Curr. Opin. Neurobiol. 9:336-342). PP1, along with PP2A, has been shown to limit motility in microvascular endothelial cells, suggesting a role for PSPs in the inhibition of angiogenesis (Gabel, S. et al. (1999) Otolaryngol. Head Neck Surg. 121:463-468).
- 15 PP2A is the main serine/threonine phosphatase. The core PP2A enzyme consists of a single 36 kDa catalytic subunit (C) associated with a 65 kDa scaffold subunit (A), whose role is to recruit additional regulatory subunits (B). Three gene families encoding B subunits are known (PR55, PR61, and PR72), each of which contain multiple isoforms, and additional families may exist (Millward, T.A et al. (1999) Trends Biosci. 24:186-191). These "B-type" subunits are cell type- and tissue-
- 20 specific and determine the substrate specificity, enzymatic activity, and subcellular localization of the holoenzyme. The PR55 family is highly conserved and bears a conserved motif (PROSITE PDOC00785). PR55 increases PP2A activity toward mitogen-activated protein kinase (MAPK) and MAPK kinase (MEK). PP2A dephosphorylates the MAPK active site, inhibiting the cell's entry into mitosis. Several proteins can compete with PR55 for PP2A core enzyme binding, including the CKII
- 25 kinase catalytic subunit, polyomavirus middle and small T antigens, and SV40 small t antigen. Viruses may use this mechanism to commandeer PP2A and stimulate progression of the cell through the cell cycle (Pallas, D.C. et al. (1992) J. Virol. 66:886-893). Altered MAP kinase expression is also implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development. PP2A, in fact, can dephosphorylate and modulate the
- 30 activities of more than 30 protein kinases in vitro, and other evidence suggests that the same is true in vivo for such kinases as PKB, PKC, the calmodulin-dependent kinases, ERK family MAP kinases, cyclin-dependent kinases, and the I κ B kinases (reviewed in Millward et al., supra). PP2A is itself a substrate for CKI and CKII kinases, and can be stimulated by polycationic macromolecules. A PP2A-like phosphatase is necessary to maintain the G1 phase destruction of mammalian cyclins A and B
- 35 (Bastians, H. et al. (1999) Mol. Biol. Cell 10:3927-3941). PP2A is a major activity in the brain and is

implicated in regulating neurofilament stability and normal neural function, particularly the phosphorylation of the microtubule-associated protein tau. Hyperphosphorylation of tau has been proposed to lead to the neuronal degeneration seen in Alzheimer's disease (reviewed in Price and Mumby, supra).

5 PP2B, or calcineurin, is a Ca^{2+} -activated dimeric phosphatase and is particularly abundant in the brain. It consists of catalytic and regulatory subunits, and is activated by the binding of the calcium/calmodulin complex. Calcineurin is the target of the immunosuppressant drugs cyclosporine and FK506. Along with other cellular factors, these drugs interact with calcineurin and inhibit phosphatase activity. In T cells, this blocks the calcium dependent activation of the NF-AT family of
10 transcription factors, leading to immunosuppression. This family is widely distributed, and it is likely that calcineurin regulates gene expression in other tissues as well. In neurons, calcineurin modulates functions which range from the inhibition of neurotransmitter release to desensitization of postsynaptic NMDA-receptor coupled calcium channels to long term memory (reviewed in Price and Mumby, supra).

15 Other members of the PPP class have recently been identified (Cohen, P.T. (1997) Trends Biochem. Sci. 22:245-251). One of them, PP5, contains regulatory domains with tetratricopeptide repeats. It can be activated by polyunsaturated fatty acids and anionic phospholipids in vitro and appears to be involved in a number of signaling pathways, including those controlled by atrial natriuretic peptide or steroid hormones (reviewed in Andreeva, A.V. and M.A. Kutuzov (1999) Cell
20 Signal. 11:555-562).

PP2C is a ~42kDa monomer with broad substrate specificity and is dependent on divalent cations (mainly Mn^{2+} or Mg^{2+}) for its activity. PP2C proteins share a conserved N-terminal region with an invariant DGH motif, which contains an aspartate residue involved in cation binding (PROSITE PDOC00792). Targeting proteins and mechanisms regulating PP2C activity have not
25 been identified. PP2C has been shown to inhibit the stress-responsive p38 and Jun kinase (JNK) pathways (Takekawa, M. et al. (1998) EMBO J. 17:4744-4752).

In contrast to PSPs, tyrosine-specific phosphatases (PTPs) are generally monomeric proteins of very diverse size (from 20kDa to greater than 100kDa) and structure that function primarily in the transduction of signals across the plasma membrane. PTPs are categorized as either soluble
30 phosphatases or transmembrane receptor proteins that contain a phosphatase domain. All PTPs share a conserved catalytic domain of about 300 amino acids which contains the active site. The active site consensus sequence includes a cysteine residue which executes a nucleophilic attack on the phosphate moiety during catalysis (Neel, B.G. and N.K. Tonks (1997) Curr. Opin. Cell Biol. 9:193-204). Receptor PTPs are made up of an N-terminal extracellular domain of variable length, a
35 transmembrane region, and a cytoplasmic region that generally contains two copies of the catalytic

domain. Although only the first copy seems to have enzymatic activity, the second copy apparently affects the substrate specificity of the first. The extracellular domains of some receptor PTPs contain fibronectin-like repeats, immunoglobulin-like domains, MAM domains (an extracellular motif likely to have an adhesive function), or carbonic anhydrase-like domains (PROSITE PDOC 00323). This wide variety of structural motifs accounts for the diversity in size and specificity of PTPs.

PTPs play important roles in biological processes such as cell adhesion, lymphocyte activation, and cell proliferation. PTPs μ and κ are involved in cell-cell contacts, perhaps regulating cadherin/catenin function. A number of PTPs affect cell spreading, focal adhesions, and cell motility, most of them via the integrin/tyrosine kinase signaling pathway (reviewed in Neel and Tonks, supra). CD45 phosphatases regulate signal transduction and lymphocyte activation (Ledbetter, J.A. et al. (1988) Proc. Natl. Acad. Sci. USA 85:8628-8632). Soluble PTPs containing Src-homology-2 domains have been identified (SHPs), suggesting that these molecules might interact with receptor tyrosine kinases. SHP-1 regulates cytokine receptor signaling by controlling the Janus family PTKs in hematopoietic cells, as well as signaling by the T-cell receptor and c-Kit (reviewed in Neel and Tonks, supra). M-phase inducer phosphatase plays a key role in the induction of mitosis by dephosphorylating and activating the PTK CDC2, leading to cell division (Sadhu, K. et al. (1990) Proc. Natl. Acad. Sci. USA 87:5139-5143). In addition, the genes encoding at least eight PTPs have been mapped to chromosomal regions that are translocated or rearranged in various neoplastic conditions, including lymphoma, small cell lung carcinoma, leukemia, adenocarcinoma, and neuroblastoma (reviewed in Charbonneau, H. and N.K. Tonks (1992) Annu. Rev. Cell Biol. 8:463-493). The PTP enzyme active site comprises the consensus sequence of the MTM1 gene family. The MTM1 gene is responsible for X-linked recessive myotubular myopathy, a congenital muscle disorder that has been linked to Xq28 (Kioschis, P. et al., (1998) Genomics 54:256-266). Many PTKs are encoded by oncogenes, and it is well known that oncogenesis is often accompanied by increased tyrosine phosphorylation activity. It is therefore possible that PTPs may serve to prevent or reverse cell transformation and the growth of various cancers by controlling the levels of tyrosine phosphorylation in cells. This is supported by studies showing that overexpression of PTP can suppress transformation in cells and that specific inhibition of PTP can enhance cell transformation (Charbonneau and Tonks, supra).

Dual specificity phosphatases (DSPs) are structurally more similar to the PTPs than the PSPs. DSPs bear an extended PTP active site motif with an additional 7 amino acid residues. DSPs are primarily associated with cell proliferation and include the cell cycle regulators cdc25A, B, and C. The phosphatases DUSP1 and DUSP2 inactivate the MAPK family members ERK (extracellular signal-regulated kinase), JNK (c-Jun N-terminal kinase), and p38 on both tyrosine and threonine residues (PROSITE PDOC 00323, supra). In the activated state, these kinases have been implicated

in neuronal differentiation, proliferation, oncogenic transformation, platelet aggregation, and apoptosis. Thus, DSPs are necessary for proper regulation of these processes (Muda, M. et al. (1996) J. Biol. Chem. 271:27205-27208). The tumor suppressor PTEN is a DSP that also shows lipid phosphatase activity. It seems to negatively regulate interactions with the extracellular matrix and maintains sensitivity to apoptosis. PTEN has been implicated in the prevention of angiogenesis (Giri, D. and M. Ittmann (1999) Hum. Pathol. 30:419-424) and abnormalities in its expression are associated with numerous cancers (reviewed in Tamura, M. et al. (1999) J. Natl. Cancer Inst. 91:1820-1828).

Histidine acid phosphatase (HAP; EXPASY EC 3.1.3.2), also known as acid phosphatase, hydrolyzes a wide spectrum of substrates including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins at low pH. HAPs share two regions of conserved sequences, each centered around a histidine residue which is involved in catalytic activity. Members of the HAP family include lysosomal acid phosphatase (LAP) and prostatic acid phosphatase (PAP), both sensitive to inhibition by L-tartrate (PROSITE PDOC00538).

LAP, an orthophosphoric monoester of the endosomal/lysosomal compartment is a housekeeping gene whose enzymatic activity has been detected in all tissues examined (Geier, C. et al. (1989) Eur. J. Biochem. 183:611-616). LAP-deficient mice have progressive skeletal disorder and an increased disposition toward generalized seizures (Saftig, P. et al. (1997) J. Biol. Chem. 272:18628-18635). LAP-deficient patients were found to have the following clinical features: intermittent vomiting, hypotonia, lethargy, opisthotonos, terminal bleeding, seizures, and death in early infancy (Online Mendelian Inheritance in Man (OMIM) *200950).

PAP, a prostate epithelium-specific differentiation antigen produced by the prostate gland, has been used to diagnose and stage prostate cancer. In prostate carcinomas, the enzymatic activity of PAP was shown to be decreased compared with normal or benign prostate hypertrophy cells (Foti, A. G. et al. (1977) Cancer Res. 37: 4120-4124). Two forms of PAP have been identified, secreted and intracellular. Mature secreted PAP is detected in the seminal fluid and is active as a glycosylated homodimer with a molecular weight of approximately 100-kilodalton. Intracellular PAP is found to exhibit endogenous phosphotyrosyl protein phosphatase activity and is involved in regulating prostate cell growth (Meng, T.C. and Lin, M.F. (1998) J. Biol. Chem. 34: 22096-22104).

Synaptojanin, a polyphosphoinositide phosphatase, dephosphorylates phosphoinositides at positions 3, 4 and 5 of the inositol ring. Synaptojanin is a major presynaptic protein found at clathrin-coated endocytic intermediates in nerve terminals, and binds the clathrin coat-associated protein, EPS15. This binding is mediated by the C-terminal region of synaptojanin-170, which has 3 Asp-Pro-Phe amino acid repeats. Further, this 3 residue repeat had been found to be the binding site for the EH domains of EPS15 (Haffner, C. et al. (1997) FEBS Lett. 419:175-180). Additionally,

synaptojanin may potentially regulate interactions of endocytic proteins with the plasma membrane, and be involved in synaptic vesicle recycling (Brodin, L. et al. (2000) Curr. Opin. Neurobiol. 10:312-320). Studies in mice with a targeted disruption in the synaptojanin 1 gene (Synj1) were shown to support coat formation of endocytic vesicles more effectively than was seen in wild-type mice, suggesting that Synj1 can act as a negative regulator of membrane-coat protein interactions. These findings provide genetic evidence for a crucial role of phosphoinositide metabolism in synaptic vesicle recycling (Cremona, O. et al. (1999) Cell 99:179-188).

The discovery of new kinases and phosphatases, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cardiovascular diseases, immune system disorders, neurological disorders, disorders affecting growth and development, lipid disorders, cell proliferative disorders, and cancers, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of kinases and phosphatases.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, kinases and phosphatases, referred to collectively as "KPP" and individually as "KPP-1," "KPP-2," "KPP-3," "KPP-4," "KPP-5," "KPP-6," "KPP-7," and "KPP-8." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-8.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-8. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:9-16.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least
5 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention
10 provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least
15 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a
20 polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected
25 from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

The invention further provides an isolated polynucleotide selected from the group consisting
30 of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the
35 polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-8. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional KPP, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional KPP, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional KPP, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test

compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, iii) a polynucleotide

complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability scores for the matches between each polypeptide and its homolog(s) are also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a

reference to “a host cell” includes a plurality of such host cells, and a reference to “an antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

“KPP” refers to the amino acid sequences of substantially purified KPP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term “agonist” refers to a molecule which intensifies or mimics the biological activity of KPP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of KPP either by directly interacting with KPP or by acting on components of the biological pathway in which KPP participates.

An “allelic variant” is an alternative form of the gene encoding KPP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

“Altered” nucleic acid sequences encoding KPP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as KPP or a polypeptide with at least one functional characteristic of KPP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding KPP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding KPP. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent KPP. Deliberate amino acid substitutions may be made on the basis of similarity in

polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of KPP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of KPP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of KPP either by directly interacting with KPP or by acting on components of the biological pathway in which KPP participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind KPP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "aptamer" refers to a nucleic acid or oligonucleotide molecule that binds to a

specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Patent No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include

- 5 deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH₂), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system.
- 10 Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E.N. and L. Gold (2000) J. Biotechnol. 74:5-13.)

The term "intramer" refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).

- 15 The term "spiegelmer" refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

- The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense
- 25 molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

- 30 The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic KPP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

- 35 "Complementary" describes the relationship between two single-stranded nucleic acid

sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding KPP or fragments of KPP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
25	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
30	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
35	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
40	Trp	Phe, Tyr
	Tyr	His, Phe, Trp

Val

Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation,
 5 (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide.

10 Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

15 A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

"Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a
 20 diseased and a normal sample.

"Exon shuffling" refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

25 A "fragment" is a unique portion of KPP or the polynucleotide encoding KPP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10,
 30 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the
 35 specification, including the Sequence Listing, tables, and figures, may be encompassed by the present

embodiments.

A fragment of SEQ ID NO:9-16 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:9-16, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:9-16 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:9-16 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:9-16 and the region of SEQ ID NO:9-16 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-8 is encoded by a fragment of SEQ ID NO:9-16. A fragment of SEQ ID NO:1-8 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-8. For example, a fragment of SEQ ID NO:1-8 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-8. The precise length of a fragment of SEQ ID NO:1-8 and the region of SEQ ID NO:1-8 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A “full length” polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full length” polynucleotide sequence encodes a “full length” polypeptide sequence.

“Homology” refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms

is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at

<http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence

5 analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed below). BLAST
10 programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the “BLAST 2 Sequences” tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

15 *Penalty for mismatch: -2*

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

20 *Filter: on*

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous
25 nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes
30 in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases “percent identity” and “% identity,” as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some
35 alignment methods take into account conservative amino acid substitutions. Such conservative

substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity.

Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide

sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of KPP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of KPP which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of KPP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of KPP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.

PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an KPP may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of KPP.

“Probe” refers to nucleic acid sequences encoding KPP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

5 “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

10 Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

15 Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs
20 can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to
25 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from
30 megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection
35 programs may also be obtained from their respective sources and modified to meet the user’s specific

needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both
5 unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

10 A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have
15 been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a
20 vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A “regulatory element” refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription,
25 translation, or RNA stability.

“Reporter molecules” are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

30 An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term “sample” is used in its broadest sense. A sample suspected of containing KPP,
35 nucleic acids encoding KPP, or fragments thereof may comprise a bodily fluid; an extract from a cell,

chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" or "expression profile" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with

a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human kinases and phosphatases (KPP), the polynucleotides encoding KPP, and the use of these compositions for the diagnosis, treatment, or prevention of cardiovascular diseases, immune system disorders, neurological disorders, disorders affecting growth and development, lipid disorders, cell proliferative disorders, and cancers.

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (GenBank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability scores for the matches between each polypeptide and its homolog(s). Column 5 shows the annotation of the GenBank homolog(s) along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are kinases and phosphatases. For example, SEQ ID NO:1 is 33% identical to human MAP kinase phosphatase 6 (GenBank ID g6840994) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $1.3\text{e-}19$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:1 also contains a dual specificity phosphatase catalytic domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM

database of conserved protein family domains. (See Table 3.) Data from BLAST analysis of the DOMO database provides further corroborative evidence that SEQ ID NO:1 is a MAP kinase phosphatase.

In an alternative example, SEQ ID NO:2 is 86% identical, from residue M1 to residue M2299, to Rattus norvegicus glomerular mesangial cell receptor protein-tyrosine phosphatase precursor (GenBank ID g3300096) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:2 also contains a protein-tyrosine phosphatase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:2 is a protein-tyrosine phosphatase.

In an alternative example, SEQ ID NO:3 is 96% identical, from residue M1 to residue Q316, to a mouse tau tubulin kinase (GenBank ID g15341198) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.0e-179, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:3 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from MOTIFS, and additional BLAST analyses provide further corroborative evidence that SEQ ID NO:3 is a protein kinase.

In an alternative example, SEQ ID NO:4 is 98% identical, from residue H234 to residue C1863, to human nuclear dual-specificity phosphatase (GenBank ID g3015538) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:4 also contains a DENN (AEX-3) domain and a pleckstrin homology domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLAST analysis using the PRODOM database provides further corroborative evidence that SEQ ID NO:4 is a nuclear phosphatase.

In an alternative example, SEQ ID NO:5 is 76% identical, from residue M1 to residue T382, to mouse serine/threonine kinase 33 (GenBank ID g14148952) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.0e-163, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:5 also contains a protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family

domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:5 is a protein kinase.

In an alternative example, SEQ ID NO:6 is 42% identical, from residue V107 to residue L331, to a Caenorhabditis elegans protein similar to the protein phosphatases 2c family (GenBank ID g2804429) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $5.4e-41$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:6 also contains a protein phosphatase 2C domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and BLAST_DOMO analyses provide further corroborative evidence that SEQ ID NO:6 is a protein phosphatase 2C.

In an alternative example, SEQ ID NO:7 is 75% identical, from residue F46 to residue V292, to Mus musculus PFTAIRE kinase (GenBank ID g2392814) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $1.3e-103$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:7 is also 73% identical, from residue F46 to residue R296, to human serine/threonine protein kinase PFTAIRE-1 (GenBank ID g12002201), with a BLAST probability score of $9.0e-103$. SEQ ID NO:7 also contains a protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from MOTIFS and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:7 is a protein kinase.

In an alternative example, SEQ ID NO:8 is 58% identical, from residue K2 to residue L281, to human pyrimidine 5'-nucleotidase (GenBank ID g11245474) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $1.1e-90$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. The algorithms and parameters for the analysis of SEQ ID NO:1-8 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Column 1 lists the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:), the corresponding Incyte polynucleotide consensus sequence number (Incyte ID) for each polynucleotide of the invention, and the length of each polynucleotide sequence in basepairs. Column 2 shows the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences used to assemble the full length polynucleotide sequences of the invention, and of fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:9-16 or that

distinguish between SEQ ID NO:9-16 and related polynucleotide sequences.

The polynucleotide fragments described in Column 2 of Table 4 may refer specifically, for example, to Incyte cDNAs derived from tissue-specific cDNA libraries or from pooled cDNA libraries. Alternatively, the polynucleotide fragments described in column 2 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. In addition, the polynucleotide fragments described in column 2 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the polynucleotide fragments described in column 2 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the designation "NP"). Alternatively, the polynucleotide fragments described in column 2 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, a polynucleotide sequence identified as FL_XXXXXX_N₁_N₂_YYYYY_N₃_N₄ represents a "stitched" sequence in which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and N_{1,2,3...}, if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the polynucleotide fragments in column 2 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, a polynucleotide sequence identified as FLXXXXXX_gAAAAA_gBBBBB_1_N is a "stretched" sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, gBBBBB).

Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).

Prefix	Type of analysis and/or examples of programs
GNN, GFG, ENST	Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).

GBI	Hand-edited analysis of genomic sequences.
FL	Stitched or stretched genomic sequences (see Example V).
INCY	Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

5 In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in Table 4 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is
10 the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses KPP variants. A preferred KPP variant is one which has at
15 least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the KPP amino acid sequence, and which contains at least one functional or structural characteristic of KPP.

The invention also encompasses polynucleotides which encode KPP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected
20 from the group consisting of SEQ ID NO:9-16, which encodes KPP. The polynucleotide sequences of SEQ ID NO:9-16, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding KPP. In
25 particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding KPP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:9-16 which has at least about 70%, or alternatively at least about 85%, or even at least about 95%
30 polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:9-16. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of KPP.

In addition, or in the alternative, a polynucleotide variant of the invention is a splice variant

of a polynucleotide sequence encoding KPP. A splice variant may have portions which have significant sequence identity to the polynucleotide sequence encoding KPP, but will generally have a greater or lesser number of polynucleotides due to additions or deletions of blocks of sequence arising from alternate splicing of exons during mRNA processing. A splice variant may have less than about 5 70%, or alternatively less than about 60%, or alternatively less than about 50% polynucleotide sequence identity to the polynucleotide sequence encoding KPP over its entire length; however, portions of the splice variant will have at least about 70%, or alternatively at least about 85%, or alternatively at least about 95%, or alternatively 100% polynucleotide sequence identity to portions of the polynucleotide sequence encoding KPP. Any one of the splice variants described above can 10 encode an amino acid sequence which contains at least one functional or structural characteristic of KPP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding KPP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be 15 produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring KPP, and all such variations are to be considered as being specifically disclosed.

20 Although nucleotide sequences which encode KPP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring KPP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding KPP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide 25 occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding KPP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

30 The invention also encompasses production of DNA sequences which encode KPP and KPP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding KPP or any fragment thereof.

35 Also encompassed by the invention are polynucleotide sequences that are capable of

hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:9-16 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.*

152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in
5 "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or
10 combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA
15 sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

20 The nucleic acid sequences encoding KPP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.)

25 Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme
30 digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries
35 (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries

and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of
5 about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence
10 into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the
15 emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode KPP may be cloned in recombinant DNA molecules that direct expression of KPP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally
20 equivalent amino acid sequence may be produced and used to express KPP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter KPP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic
25 oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction
30 sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat.
35 Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or

improve the biological properties of KPP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding KPP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, KPP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of KPP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active KPP, the nucleotide sequences encoding KPP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding KPP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding KPP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where

sequences encoding KPP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding KPP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding KPP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509; Engelhard, E.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-3227; Sandig, V. et al. (1996) *Hum. Gene Ther.* 7:1937-1945; Takamatsu, N. (1987) *EMBO J.* 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659; and Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) *Cancer Gen. Ther.* 5(6):350-356; Yu, M. et al. (1993) *Proc. Natl. Acad. Sci. USA* 90(13):6340-6344; Buller, R.M. et al. (1985) *Nature* 317(6040):813-815; McGregor, D.P. et al. (1994) *Mol. Immunol.* 31(3):219-226; and Verma, I.M. and N. Somia (1997) *Nature* 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding KPP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding KPP can be achieved using a

multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding KPP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for

5 in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of KPP are needed, e.g. for the production of antibodies, vectors which direct high level expression of KPP may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

10 Yeast expression systems may be used for production of KPP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel,

15 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of KPP. Transcription of sequences encoding KPP may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J.

20 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology

25 (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding KPP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain

30 infective virus which expresses KPP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of

35 DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are

constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression
5 of KPP in cell lines is preferred. For example, sequences encoding KPP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance
10 to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine
15 phosphoribosyltransferase genes, for use in *tk⁻* and *apr⁻* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g.,
20 Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate
25 luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the
30 sequence encoding KPP is inserted within a marker gene sequence, transformed cells containing sequences encoding KPP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding KPP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

35 In general, host cells that contain the nucleic acid sequence encoding KPP and that express

KPP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

5 Immunological methods for detecting and measuring the expression of KPP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on KPP is preferred, but a competitive
10 binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

15 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding KPP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding KPP, or any fragments thereof, may be cloned into a vector for
20 the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for
25 ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding KPP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence
30 and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode KPP may be designed to contain signal sequences which direct secretion of KPP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of
35 the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation,

phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” or “pro” form of the protein may also be used to specify protein targeting, folding, and/or activity.

Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding KPP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric KPP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of KPP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the KPP encoding sequence and the heterologous protein sequence, so that KPP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled KPP may be achieved *in vitro* using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

KPP of the present invention or fragments thereof may be used to screen for compounds that specifically bind to KPP. At least one and up to a plurality of test compounds may be screened for specific binding to KPP. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of KPP, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a

natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which KPP binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express KPP, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing KPP or cell membrane fractions which contain KPP are then contacted with a test compound and binding, stimulation, or inhibition of activity of either KPP or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with KPP, either in solution or affixed to a solid support, and detecting the binding of KPP to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

KPP of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of KPP. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for KPP activity, wherein KPP is combined with at least one test compound, and the activity of KPP in the presence of a test compound is compared with the activity of KPP in the absence of the test compound. A change in the activity of KPP in the presence of the test compound is indicative of a compound that modulates the activity of KPP. Alternatively, a test compound is combined with an in vitro or cell-free system comprising KPP under conditions suitable for KPP activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of KPP may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding KPP or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science

244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330).

- 5 Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

- 10 Polynucleotides encoding KPP may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

- 15 Polynucleotides encoding KPP can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding KPP is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease.
- 20 Alternatively, a mammal inbred to overexpress KPP, e.g., by secreting KPP in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

- Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of KPP and kinases and phosphatases. In addition, examples of tissues expressing KPP are brain, testes, uterine, breast and lymph node tissues and also can be found in Table 6.
- 25 Therefore, KPP appears to play a role in cardiovascular diseases, immune system disorders, neurological disorders, disorders affecting growth and development, lipid disorders, cell proliferative disorders, and cancers. In the treatment of disorders associated with increased KPP expression or activity, it is desirable to decrease the expression or activity of KPP. In the treatment of disorders
- 30 associated with decreased KPP expression or activity, it is desirable to increase the expression or activity of KPP.

- Therefore, in one embodiment, KPP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of KPP. Examples of such disorders include, but are not limited to, a cardiovascular disease such as
- 35 arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial

dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis,

5 congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism,

10 pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis,

15 hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung

20 transplantation; an immune system disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema,

25 episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic

30 anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other

35 extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive

neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-

5 Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other

10 neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration,

15 and familial frontotemporal dementia; a disorder affecting growth and development such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR

20 syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural

25 hearing loss; a lipid disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such as Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM₂ gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus,

30 lipodystrophy, lipomatosis, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease,

35 hyperlipidemia, hyperlipemia, lipid myopathies, and obesity; and a cell proliferative disorder such as

actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, uterus, leukemias such as multiple myeloma, and lymphomas such as Hodgkin's disease.

In another embodiment, a vector capable of expressing KPP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of KPP including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified KPP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of KPP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of KPP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of KPP including, but not limited to, those listed above.

In a further embodiment, an antagonist of KPP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of KPP. Examples of such disorders include, but are not limited to, those cardiovascular diseases, immune system disorders, neurological disorders, disorders affecting growth and development, lipid disorders, cell proliferative disorders, and cancers described above. In one aspect, an antibody which specifically binds KPP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express KPP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding KPP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of KPP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of KPP may be produced using methods which are generally known in the art. In particular, purified KPP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind KPP. Antibodies to KPP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with KPP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to KPP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of KPP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to KPP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce KPP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

5 Antibody fragments which contain specific binding sites for KPP may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. 10 et al. (1989) Science 246:1275-1281.)

 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between KPP and its specific 15 antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering KPP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

 Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for KPP. Affinity is expressed as an 20 association constant, K_a , which is defined as the molar concentration of KPP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple KPP epitopes, represents the average affinity, or avidity, of the antibodies for KPP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a 25 particular KPP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the KPP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of KPP, preferably in active form, from the antibody 30 (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

 The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For 35 example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml,

preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of KPP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

5 In another embodiment of the invention, the polynucleotides encoding KPP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding KPP. Such technology is well known in the art, and antisense oligonucleotides or larger fragments
10 can be designed from various locations along the coding or control regions of sequences encoding KPP. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence
15 complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other
20 gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding KPP may be used for
25 somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475),
30 cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated
35 cell proliferation), or (iii) express a protein which affords protection against intracellular parasites

(e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in KPP expression or regulation causes disease, the expression of KPP from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in KPP are treated by constructing mammalian expression vectors encoding KPP and introducing these vectors by mechanical means into KPP-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev. Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr. Opin. Biotechnol.* 9:445-450).

Expression vectors that may be effective for the expression of KPP include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). KPP may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Gossen, M. et al. (1995) *Science* 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) *Curr. Opin. Biotechnol.* 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and H.M. Blau, supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding KPP from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to KPP expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding KPP under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent No. 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding KPP to cells which have one or more genetic abnormalities with respect to the expression of KPP. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent No. 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding KPP to target cells which have one or more genetic abnormalities with respect to the expression of KPP. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing KPP to cells of the central nervous system, for which HSV has a

tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S.

5 Patent No. 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22.

10 For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of
15 ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding KPP to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During
20 alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for KPP into the alphavirus genome in place of the capsid-coding region results in the production of a large number of KPP-
25 coding RNAs and the synthesis of high levels of KPP in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the
30 introduction of KPP into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions
35 -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly,

inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding KPP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding KPP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding KPP. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased KPP expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding KPP may be therapeutically useful, and in the treatment of disorders associated with decreased KPP expression or activity, a compound which specifically promotes expression of the polynucleotide encoding KPP may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding KPP is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding KPP are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding KPP. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide

sequence (Bruce, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruce, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of KPP, antibodies to KPP, and mimetics, agonists, antagonists, or inhibitors of KPP.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising KPP or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of

the macromolecule. Alternatively, KPP or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

5 For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

10 A therapeutically effective dose refers to that amount of active ingredient, for example KPP or fragments thereof, antibodies of KPP, and agonists, antagonists or inhibitors of KPP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose
15 lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity.
20 The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the
25 severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of
30 about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind KPP may be used for the diagnosis of disorders characterized by expression of KPP, or in assays to monitor patients being treated with KPP or agonists, antagonists, or inhibitors of KPP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for KPP include methods which utilize the antibody and a label to detect KPP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring KPP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of KPP expression. Normal or standard values for KPP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to KPP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of KPP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding KPP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of KPP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of KPP, and to monitor regulation of KPP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding KPP or closely related molecules may be used to identify nucleic acid sequences which encode KPP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding KPP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the KPP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:9-16 or from genomic sequences including promoters, enhancers, and introns of the KPP gene.

Means for producing specific hybridization probes for DNAs encoding KPP include the

cloning of polynucleotide sequences encoding KPP or KPP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding KPP may be used for the diagnosis of disorders associated with expression of KPP. Examples of such disorders include, but are not limited to, a cardiovascular disease such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung transplantation; an immune system disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis,

glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic

5 lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders,

10 amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal

15 familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral

20 nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial

25 frontotemporal dementia; a disorder affecting growth and development such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms'

30 tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a lipid

35 disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine

palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such as Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM₂ gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatosis, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, uterus, leukemias such as multiple myeloma, and lymphomas such as Hodgkin's disease. The polynucleotide sequences encoding KPP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered KPP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding KPP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding KPP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding KPP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of KPP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding KPP, under conditions suitable for hybridization or amplification.

Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to
5 establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several
10 days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals
15 to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding KPP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide
20 encoding KPP, or a fragment of a polynucleotide complementary to the polynucleotide encoding KPP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences
25 encoding KPP may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding KPP are used to amplify
30 DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-
35 throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis

methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

SNPs may be used to study the genetic basis of human disease. For example, at least 16 common SNPs have been associated with non-insulin-dependent diabetes mellitus. SNPs are also useful for examining differences in disease outcomes in monogenic disorders, such as cystic fibrosis, sickle cell anemia, or chronic granulomatous disease. For example, variants in the mannose-binding lectin, MBL2, have been shown to be correlated with deleterious pulmonary outcomes in cystic fibrosis. SNPs also have utility in pharmacogenomics, the identification of genetic variants that influence a patient's response to a drug, such as life-threatening toxicity. For example, a variation in N-acetyl transferase is associated with a high incidence of peripheral neuropathy in response to the anti-tuberculosis drug isoniazid, while a variation in the core promoter of the ALOX5 gene results in diminished clinical response to treatment with an anti-asthma drug that targets the 5-lipoxygenase pathway. Analysis of the distribution of SNPs in different populations is useful for investigating genetic drift, mutation, recombination, and selection, as well as for tracing the origins of populations and their migrations. (Taylor, J.G. et al. (2001) *Trends Mol. Med.* 7:507-512; Kwok, P.-Y. and Z. Gu (1999) *Mol. Med. Today* 5:538-543; Nowotny, P. et al. (2001) *Curr. Opin. Neurobiol.* 11:637-641.)

Methods which may also be used to quantify the expression of KPP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used

to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

5 In another embodiment, KPP, fragments of KPP, or antibodies specific for KPP may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

 A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by
10 quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of
15 transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

 Transcript images may be generated using transcripts isolated from tissues, cell lines,
20 biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

 Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental
25 compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share
30 those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for
35 comparison of expression data after treatment with different compounds. While the assignment of

gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at

5 <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of
10 the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present
15 invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by
20 separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by
25 staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the
30 spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

35 A proteomic profile may also be generated using antibodies specific for KPP to quantify the

levels of KPP expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoz, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a
5 variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor
10 correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such
15 cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological
20 sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological
25 sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated
30 sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:2150-
35 2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are

well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding KPP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding KPP on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, KPP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug

screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between KPP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with KPP, or fragments thereof, and washed. Bound KPP is then detected by methods well known in the art. Purified KPP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding KPP specifically compete with a test compound for binding KPP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with KPP.

In additional embodiments, the nucleotide sequences which encode KPP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/263,083, U.S. Ser. No. 60/271,205, U.S. Ser. No. 60/271,117, U.S. Ser. No. 60/276,859, U.S. Ser. No. 60/278,504, U.S. Ser. No. 60/278,522, U.S. Ser. No. 60/280,510 and U.S. Ser. No. 60/280,266 are expressly incorporated by reference herein.

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA). Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and

ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectromAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by *in vivo* excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically

using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (LabSystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows.

5 Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as
10 the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading
15 frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and
20 programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM; PROTEOME databases with sequences from Homo sapiens, Rattus norvegicus, Mus musculus, Caenorhabditis elegans, Saccharomyces cerevisiae,
25 Schizosaccharomyces pombe, and Candida albicans (Incyte Genomics, Palo Alto CA); and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to
30 produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length
35 polynucleotide sequences were translated to derive the corresponding full length polypeptide

sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, the PROTEOME databases, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:9-16. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 2.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative kinases and phosphatases were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode kinases and phosphatases, the encoded polypeptides were analyzed by querying against PFAM models for kinases and phosphatases. Potential kinases and phosphatases were also identified by homology to Incyte cDNA sequences that had been annotated as kinases and phosphatases. These selected Genscan-predicted sequences were then compared by

BLAST analysis to the genpept and gbpr public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpr public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases

using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of KPP Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:9-16 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:9-16 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related

molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

5

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum} \{ \text{length}(\text{Seq. 1}), \text{length}(\text{Seq. 2}) \}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding KPP are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding KPP. cDNA sequences and cDNA library/tissue

information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of KPP Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones

were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Identification of Single Nucleotide Polymorphisms in KPP Encoding Polynucleotides

Common DNA sequence variants known as single nucleotide polymorphisms (SNPs) were identified in SEQ ID NO:9-16 using the LIFESEQ database (Incyte Genomics). Sequences from the same gene were clustered together and assembled as described in Example III, allowing the identification of all sequence variants in the gene. An algorithm consisting of a series of filters was used to distinguish SNPs from other sequence variants. Preliminary filters removed the majority of basecall errors by requiring a minimum Phred quality score of 15, and removed sequence alignment errors and errors resulting from improper trimming of vector sequences, chimeras, and splice variants. An automated procedure of advanced chromosome analysis analysed the original chromatogram files in the vicinity of the putative SNP. Clone error filters used statistically generated algorithms to identify errors introduced during laboratory processing, such as those caused by reverse transcriptase, polymerase, or somatic mutation. Clustering error filters used statistically generated algorithms to identify errors resulting from clustering of close homologs or pseudogenes, or due to contamination by non-human sequences. A final set of filters removed duplicates and SNPs found in immunoglobulins or T-cell receptors.

Certain SNPs were selected for further characterization by mass spectrometry using the high throughput MASSARRAY system (Sequenom, Inc.) to analyze allele frequencies at the SNP sites in four different human populations. The Caucasian population comprised 92 individuals (46 male, 46

female), including 83 from Utah, four French, three Venezuelan, and two Amish individuals. The African population comprised 194 individuals (97 male, 97 female), all African Americans. The Hispanic population comprised 324 individuals (162 male, 162 female), all Mexican Hispanic. The Asian population comprised 126 individuals (64 male, 62 female) with a reported parental breakdown of 43% Chinese, 31% Japanese, 13% Korean, 5% Vietnamese, and 8% other Asian. Allele frequencies were first analyzed in the Caucasian population; in some cases those SNPs which showed no allelic variance in this population were not further tested in the other three populations.

X. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:9-16 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

XI. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Skena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g.,

Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia

Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in U.S. Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.

Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XII. Complementary Polynucleotides

Sequences complementary to the KPP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring KPP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of KPP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the KPP-encoding transcript.

XIII. Expression of KPP

Expression and purification of KPP is achieved using bacterial or virus-based expression systems. For expression of KPP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express KPP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of KPP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding KPP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, KPP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from KPP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified KPP obtained by these methods can be used directly in the assays shown in Examples XVII, XVIII, XIX, XX and XXI where applicable.

XIV. Functional Assays

KPP function is assessed by expressing the sequences encoding KPP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome

formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of KPP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding KPP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding KPP and other genes of interest can be analyzed by northern analysis or microarray techniques.

XV. Production of KPP Specific Antibodies

KPP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the KPP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to

increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-KPP activity by, for example, binding the peptide or KPP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XVI. Purification of Naturally Occurring KPP Using Specific Antibodies

Naturally occurring or recombinant KPP is substantially purified by immunoaffinity chromatography using antibodies specific for KPP. An immunoaffinity column is constructed by covalently coupling anti-KPP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing KPP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of KPP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/KPP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and KPP is collected.

XVII. Identification of Molecules Which Interact with KPP

KPP, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton, A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled KPP, washed, and any wells with labeled KPP complex are assayed. Data obtained using different concentrations of KPP are used to calculate values for the number, affinity, and association of KPP with the candidate molecules.

Alternatively, molecules interacting with KPP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) *Nature* 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

KPP may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

XVIII. Demonstration of KPP Activity

Generally, protein kinase activity is measured by quantifying the phosphorylation of a protein substrate by KPP in the presence of $[\gamma\text{-}^{32}\text{P}]\text{ATP}$. KPP is incubated with the protein substrate, ^{32}P -ATP, and an appropriate kinase buffer. The ^{32}P incorporated into the substrate is separated from free ^{32}P -ATP by electrophoresis and the incorporated ^{32}P is counted using a radioisotope counter. The

amount of incorporated ^{32}P is proportional to the activity of KPP. A determination of the specific amino acid residue phosphorylated is made by phosphoamino acid analysis of the hydrolyzed protein.

In one alternative, protein kinase activity is measured by quantifying the transfer of gamma phosphate from adenosine triphosphate (ATP) to a serine, threonine or tyrosine residue in a protein substrate. The reaction occurs between a protein kinase sample with a biotinylated peptide substrate and gamma ^{32}P -ATP. Following the reaction, free avidin in solution is added for binding to the biotinylated ^{32}P -peptide product. The binding sample then undergoes a centrifugal ultrafiltration process with a membrane which will retain the product-avidin complex and allow passage of free gamma ^{32}P -ATP. The reservoir of the centrifuged unit containing the ^{32}P -peptide product as retentate is then counted in a scintillation counter. This procedure allows the assay of any type of protein kinase sample, depending on the peptide substrate and kinase reaction buffer selected. This assay is provided in kit form (ASUA, Affinity Ultrafiltration Separation Assay, Transbio Corporation, Baltimore MD, U.S. Patent No. 5,869,275). Suggested substrates and their respective enzymes include but are not limited to: Histone H1 (Sigma) and p34^{cdc2}kinase, Annexin I, Angiotensin (Sigma) and EGF receptor kinase, Annexin II and *src* kinase, ERK1 & ERK2 substrates and MEK, and myelin basic protein and ERK (Pearson, J.D. et al. (1991) Methods Enzymol. 200:62-81).

In another alternative, protein kinase activity of KPP is demonstrated in vitro in an assay containing KPP, 50 μl of kinase buffer, 1 μg substrate, such as myelin basic protein (MBP) or synthetic peptide substrates, 1 mM DTT, 10 μg ATP, and 0.5 μCi [γ - ^{32}P]ATP. The reaction is incubated at 30°C for 30 minutes and stopped by pipetting onto P81 paper. The unincorporated [γ - ^{32}P]ATP is removed by washing and the incorporated radioactivity is measured using a scintillation counter. Alternatively, the reaction is stopped by heating to 100°C in the presence of SDS loading buffer and resolved on a 12% SDS polyacrylamide gel followed by autoradiography. Incorporated radioactivity is corrected for reactions carried out in the absence of PKIN or in the presence of the inactive kinase, K38A. The amount of incorporated ^{32}P is proportional to the activity of KPP.

In yet another alternative, adenylate kinase or guanylate kinase activity of KPP may be measured by the incorporation of ^{32}P from [γ - ^{32}P]ATP into ADP or GDP using a gamma radioisotope counter. KPP, in a kinase buffer, is incubated together with the appropriate nucleotide mono-phosphate substrate (AMP or GMP) and ^{32}P -labeled ATP as the phosphate donor. The reaction is incubated at 37°C and terminated by addition of trichloroacetic acid. The acid extract is neutralized and subjected to gel electrophoresis to separate the mono-, di-, and triphosphonucleotide fractions. The diphosphonucleotide fraction is excised and counted. The radioactivity recovered is proportional to the activity of KPP.

In yet another alternative, other assays for KPP include scintillation proximity assays (SPA), scintillation plate technology and filter binding assays. Useful substrates include recombinant

proteins tagged with glutathione transferase, or synthetic peptide substrates tagged with biotin. Inhibitors of KPP activity, such as small organic molecules, proteins or peptides, may be identified by such assays.

In another alternative, phosphatase activity of KPP is measured by the hydrolysis of para-nitrophenyl phosphate (PNPP). KPP is incubated together with PNPP in HEPES buffer pH 7.5, in the presence of 0.1% β -mercaptoethanol at 37°C for 60 min. The reaction is stopped by the addition of 6 ml of 10 N NaOH (Diamond, R.H. et al. (1994) Mol. Cell. Biol. 14:3752-62). Alternatively, acid phosphatase activity of KPP is demonstrated by incubating KPP-containing extract with 100 μ l of 10 mM PNPP in 0.1 M sodium citrate, pH 4.5, and 50 μ l of 40 mM NaCl at 37°C for 20 min. The reaction is stopped by the addition of 0.5 ml of 0.4 M glycine/NaOH, pH 10.4 (Saftig, P. et al. (1997) J. Biol. Chem. 272:18628-18635). The increase in light absorbance at 410 nm resulting from the hydrolysis of PNPP is measured using a spectrophotometer. The increase in light absorbance is proportional to the activity of KPP in the assay.

In the alternative, KPP activity is determined by measuring the amount of phosphate removed from a phosphorylated protein substrate. Reactions are performed with 2 or 4 nM KPP in a final volume of 30 μ l containing 60 mM Tris, pH 7.6, 1 mM EDTA, 1 mM EGTA, 0.1% β -mercaptoethanol and 10 μ M substrate, 32 P-labeled on serine/threonine or tyrosine, as appropriate. Reactions are initiated with substrate and incubated at 30°C for 10-15 min. Reactions are quenched with 450 μ l of 4% (w/v) activated charcoal in 0.6 M HCl, 90 mM $\text{Na}_4\text{P}_2\text{O}_7$, and 2 mM NaH_2PO_4 , then centrifuged at 12,000 \times g for 5 min. Acid-soluble ^{32}Pi is quantified by liquid scintillation counting (Sinclair, C. et al. (1999) J. Biol. Chem. 274:23666-23672).

XIX. Kinase Binding Assay

Binding of KPP to a FLAG-CD44 cyt fusion protein can be determined by incubating KPP with anti-KPP-conjugated immunoaffinity beads followed by incubating portions of the beads (having 10-20 ng of protein) with 0.5 ml of a binding buffer (20 mM Tris-HCL (pH 7.4), 150 mM NaCl, 0.1% bovine serum albumin, and 0.05% Triton X-100) in the presence of ^{125}I -labeled FLAG-CD44cyt fusion protein (5,000 cpm/ng protein) at 4 °C for 5 hours. Following binding, beads were washed thoroughly in the binding buffer and the bead-bound radioactivity measured in a scintillation counter (Bourguignon, L.Y.W. et al. (2001) J. Biol. Chem. 276:7327-7336). The amount of incorporated ^{32}P is proportional to the amount of bound KPP.

XX. Identification of KPP Inhibitors and Activators

Compounds to be tested are arrayed in the wells of a 384-well plate in varying concentrations along with an appropriate buffer and substrate, as described in the assays in Example XVIII. KPP activity is measured for each well and the ability of each compound to inhibit KPP activity can be determined, as well as the dose-response kinetics. This assay could also be used to identify molecules

which enhance KPP activity.

Agonists or antagonists of KPP activation or inhibition may be tested using assays described in section XVIII. Agonists cause an increase in KPP activity and antagonists cause a decrease in KPP activity.

5 XXI. Identification of KPP Substrates

A KPP "substrate-trapping" assay takes advantage of the increased substrate affinity that may be conferred by certain mutations in the PTP signature sequence of protein tyrosine phosphatases. KPP bearing these mutations form a stable complex with their substrate; this complex may be isolated biochemically. Site-directed mutagenesis of invariant residues in the PTP signature sequence in a
10 clone encoding the catalytic domain of KPP is performed using a method standard in the art or a commercial kit, such as the MUTA-GENE kit from BIO-RAD. For expression of KPP mutants in Escherichia coli, DNA fragments containing the mutation are exchanged with the corresponding wild-type sequence in an expression vector bearing the sequence encoding KPP or a glutathione S-transferase (GST)-KPP fusion protein. KPP mutants are expressed in E. coli and purified by
15 chromatography.

The expression vector is transfected into COS1 or 293 cells via calcium phosphate-mediated transfection with 20 μ g of CsCl-purified DNA per 10-cm dish of cells or 8 μ g per 6-cm dish. Forty-eight hours after transfection, cells are stimulated with 100 ng/ml epidermal growth factor to increase tyrosine phosphorylation in cells, as the tyrosine kinase EGFR is abundant in COS cells. Cells are
20 lysed in 50 mM Tris·HCl, pH 7.5/5 mM EDTA/150 mM NaCl/1% Triton X-100/5 mM iodoacetic acid/10 mM sodium phosphate/10 mM NaF/5 μ g/ml leupeptin/5 μ g/ml aprotinin/1 mM benzamidine (1 ml per 10-cm dish, 0.5 ml per 6-cm dish). KPP is immunoprecipitated from lysates with an appropriate antibody. GST-KPP fusion proteins are precipitated with glutathione-Sepharose, 4 μ g of mAb or 10 μ l of beads respectively per mg of cell lysate. Complexes can be visualized by PAGE or
25 further purified to identify substrate molecules (Flint, A.J. et al. (1997) Proc. Natl. Acad. Sci. USA 94:1680-1685).

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the
30 invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
55074884	1	55074884CD1	9	55074884CB1
7480588	2	7480588CD1	10	7480588CB1
7482931	3	7482931CD1	11	7482931CB1
2080788	4	2080788CD1	12	2080788CB1
71918969	5	71918969CD1	13	71918969CB1
8187571	6	8187571CD1	14	8187571CB1
7494145	7	7494145CD1	15	7494145CB1
5807954	8	5807954CD1	16	5807954CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
1	55074884CD1	g6840994	1.3E-19	[Homo sapiens] MAP kinase phosphatase 6 Martí, F. et al. (2001) J Immunol 166:197-206
2	7480588CD1	g3300096	0	[Rattus norvegicus] glomerular mesangial cell receptor protein-tyrosine phosphatase precursor Wright, M.B. et al. (1998) J. Biol. Chem. 273:23929-23937
3	7482931CD1	g15341198	1.0E-179	[Mus musculus] Tau-tubulin kinase Tomizawa, K., et al. (2001) FEBS letters. 492:221-227
4	2080788CD1	g3015538	0	[Homo sapiens] nuclear dual-specificity phosphatase Cui, X. et al. (1998) Nature Genet. 18:331-337
5	71918969CD1	g14148952	1.0E-163	[Mus musculus] Serine/Threonine kinase 33 Mujica, A.O., et al. (2001) Gene 280:175-181
6	8187571CD1	g2804429	5.4E-41	[Caenorhabditis elegans] similar to the protein phosphatase 2c family
7	7494145CD1	g2392814	1.3E-103	[Mus musculus] PPTAIRE kinase Lazzaro, M.A. et al. (1997) J. Neurochem. 69:348-364.
8	5807954CD1	g11245474	1.1E-90	[Homo sapiens] pyrimidine 5'-nucleotidase Amici, A. et al. (2000) Blood 96:1596-1598

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	55074884CD1	176	S30 S135	N50	Signal_cleavage: M1-A36 Signal Peptide: M1-G35 Dual specificity phosphatase, catalytic domain: P18-A156	SPSCAN HMIMER HMIMER_PFAM
					VH1-TYPE DUAL SPECIFICITY PHOSPHATASE DM03823 P28562 169-314: V20-A159 I38890 29-320: V20-L157 A56115 51-336: V20-A159 Q02256 1-174: G97-E155	BLAST_DOMO
2	7480588CD1	2299	S104 S182 S186 S200 S298 S332 S350 S490 S557 S567 S649 S661 S668 S687 S715 S733 S751 S761 S772 S862 S898 S912 S927 S1277 S1312 S1338 S1381 S1385 S1411 S1530 S1558 S1590 S1628 S1836 S1900 S1941 S1975 S1979 S1984 S2018 S2237 S2261	N155 N162 N311 N349 N384 N575 N713 N731 N765 N770 N809 N895 N903 N959 N988 N996 N1008 N1038 N1059 N1071 N1161 N1194 N1248 N1253 N1292 N1380 N1399 N1524 N1584 N1594 N1618 N1647 N1694 N1719 N1802 N2059 N2162 N2273	Signal Peptide: M1-T17, M1-V19	HMIMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
2 (cont.)			T17 T28 T120 T208 T249 T313 T328 T365 T389 T413 T511 T607 T614 T623 T633 T660 T678 T757 T767 T824 T834 T849 T870 T907 T998 T1013 T1048 T1095 T1129 T1145 T1158 T1223 T1334 T1424 T1635 T1759 T1770 T1884 T1894 T1959 T2020 T2082 T2143 T2157		Protein-tyrosine phosphatase: N2027-D2258	HMMER_PFAM
			Y710 Y1940		Fibronectin type III domain: P51-S138, P665-V746, P854-R936, P759-S842, P1340-S1418, P1150-S1231, L1243-S1328, P1430-S1526, P948-S1040, P565-S651, P1538-S1620, P300-S383, P1641-V1734, P1053-S1134, P150-G286, P394-T554	HMMER_PFAM
					Predicted transmembrane segments: I1604-A1622, R1902-I1930	TMAP
					Tyrosine specific protein phosphatases proteins BL00383: K2030-V2044, S2055-I2063, Q2160-P2172, V2198-G2208, R2236-F2251	BLIMPS_BLOCKS

Table 3

SEQ ID NO:	Incye Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
2 (cont.)					Receptor tyrosine kinase class V proteins BL00790: G66-V91, N115-T145	BLIMPS_BLOCKS
					Tyrosine specific protein phosphatases signature and profiles tyr_phosphatase.prf: L2178-R2236	PROFILESCAN
					Fibronectin type III repeat signature PR00014: T1165-P1174, Y1402-D1416	BLIMPS_PRINTS
					Protein tyrosine phosphatase signature PR00700: D2056-I2063, F2072-E2092, M2156-E2173, P2195-L2213, V2226-C2241, M2242-L2252	BLIMPS_PRINTS
					GLOMERULAR MESANGIAL CELL RECEPTOR PROTEINTYROSINE PHOSPHATASE PRECURSOR PD178547: C1913-W2026 PD174021: W1528-K1642 PD184208: T145-D205	BLAST_PRODROM
					HYDROLASE PHOSPHATASE PROTEIN TYROSINE PRECURSOR PD000167: N2027-N2221	BLAST_PRODROM
					PROTEIN-TYROSINE-PHOSPHATASE DM00089 A57064 896-1170: H1991-I2256 S60613 924-1198: H1991-I2256 I49372 113-387: H1991-I2256 I49374 1-269: L1995-I2256	BLAST_DOMO
					ATP/GTP-binding site motif A (P-loop) A1621-S1628	MOTIFS

Table 3

SEQ ID NO:	Incyle Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
2					Tyrosine specific protein phosphatases active site: V2198-F2210	MOTIFS
3	748293ICD1	478	S173 S237 S263 S278 S283 S353 T118 T155 T189 T269 T300 T402 T431 T456 T463 Y471		Eukaryotic protein kinase domain: W21-S256	HMMER_PFAM
					SIMILAR TO CASEIN KINASES PD115501: F213-E298, L11-T114	BLAST_PRODOR
					PROTEIN KINASE DOMAIN DM00004 P42169 74-330: I27-E240 DM00004 P48730 11-265: R25-Y273 DM00004 P35506 19-273: V23-Y273 DM00004 P40235 13-267: R25-Y273	BLAST_DOMO
					Protein kinases ATP-binding region signature I27-K50	MOTIFS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
4	2080788CD1	1867	S75 S137 S182 S359 S430 S559 S637 S659 S716 S722 S773 S803 S812 S873 S968 S1047 S1094 S1113 S1120 S1174 S1199 S1232 S1237 S1259 S1280 S1284 S1362 S1387 S1465 S1517 S1527 S1552 S1561 S1630 T84 T95 T96 T102 T313 T538 T636 T933 T971 T1069 T1599 T1747 T1827 T1838 T1839 Y1769	N1585 N1761	DENN (AEX-3) domain: L171-G310	HMMER_PFAM
					PH domain: R1762-S1865	HMMER_PFAM
					Transmembrane Segments: A212-S240, L246-P268, L274-F292, N629-K657, L1394-L1410 N-terminus non-cytosolic	TMAP

Table 3

SEQ ID NO:	Incye Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
4	(cont.)				HYDROLASE PROTEIN MYOTUBULARIN DISEASE MUTATION F53A2.8 PROTEIN TYROSINE PHOSPHATASE C19A8.03 CPA2NNF1 PD014611: P1379-H1470, D1129-G1266, G1474-Y1556, G927-F938	BLAST_PRODOR
					PROTEIN REGULATOR OF PRESYNAPTIC ACTIVITY SERINE PROTEASE INHIBITOR RAB3 GDP/GTP PD008900: P177-D340, R3-H115, D364-R408	BLAST_PRODOR
					Leucine zipper pattern L239-L260:	MOTIFS
5	71918969CD1	514	S4, S10, S20, S29, S71, S80, S87, S169, S211, S249, S274, S296, S326, S349, S388, S407, S420, S441, S473, T11, T70, T134, T184, T371, T412, T440, T450, T459, T510	N95, N213, N411, N438	Eukaryotic protein kinase domain: Y116-L381	HMMER-PFAM
					Protein kinases signatures and profile (protein_kinase_tyr.prf): E214-A269	PROFILESAN
					Tyrosine kinase catalytic domain signature: PR00109: M192-D205, Y228-V246, C304-S326, T184-R206	BLIMPS-PRINTS
					PROTEIN KINASE DOMAIN: DM00004[S57347[21-266: F118-T371	BLAST-DOMO

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
5					Protein kinases ATP-binding region signature: L122-K145	MOTIFS
					Serine/Threonine protein kinases active-site signature: I234-V246	MOTIFS
6	818757ICD1	338	S55 S220 S281 S320 T134 T155 T246 T268 T305 Y248	N178	Protein phosphatase 2C: S63-R128, V212-A282	HMMER_PFAM
					Transmembrane domain: V89-I117 N terminus is non-cytosolic.	TMAP
					Protein phosphatase 2C proteins BL01032: L64-A81, N109-E148, R205-D218, D253-D265, S320-I329	BLIMPS_BLOCKS
					PROTEIN PHOSPHATASE 2C DM00377[P49596]1-295: S55-G143, R205-S281 DM00377[Q09173]1-296: V66-L141, E188-A282 DM00377[S62462]1-297: V66-L141, E188-A282	BLAST_DOMO
7	7494145CD1	321	S19 S24 S228 Y63		Eukaryotic protein kinase domain: Y52-P275	HMMER-PFAM
					Transmembrane domain: D231-L248; N-terminus is cytosolic	TMAP
					Protein kinases signatures and profile (protein_kinase_tyr.prf): N149-A197	PROFILES SCAN
					KINASE TRANSFERASE PROTEIN SERINE/THREONINE PROTEIN ATP-BINDING II PHOSPHORYLATION CASEIN ALPHA CHAIN: PD002608: Q203-P281	BLAST-PRODROM
					PROTEIN KINASE DOMAIN: DM00004 Q00536 166-436: L53-L305	BLAST-DOMO

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					KINASE TRANSFERASE PROTEIN SERINE/THREONINE PROTEIN ATP-BINDING II PHOSPHORYLATION CASEIN ALPHA CHAIN: PD002608: Q203-P281	BLAST-PRODOM
					PROTEIN KINASE DOMAIN: DM00004 Q00536 166-436: L53-L305	BLAST-DOMO
7 (cont.)					Protein kinases ATP-binding region signature: L58- K81	MOTIFS
					Serine/Threonine protein kinases active-site signature: V169-I181	MOTIFS
8	5807954CD1	292	S32 S200 S223 T86 T228	N198	Transmembrane domain: N135-K163 N-terminus is cytosolic	TMAP

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
9/55074884CBI/ 1605	1-361, 1-830, 4-517, 188-830, 346-731, 437-731, 440-493, 440-495, 440-516, 440-517, 440-528, 440-731, 440-1205, 440-1285, 443-731, 450-731, 480-731, 520-774, 526-774, 540-774, 541-731, 544-731, 596-731, 616-731, 645-731, 651-731, 672-731, 683-731, 777-1605, 1026-1191, 1052-1191, 1102-1377, 1337-1440
10/7480588CBI/ 7225	1-148, 1-460, 159-377, 376-894, 646-1584, 1351-2448, 1517-1882, 1700-2082, 1883-1955, 1883-2556, 1883-3153, 2242-2678, 2272-2680, 2719-3351, 2986-3351, 3154-3444, 3171-3283, 3171-3477, 3171-3513, 3171-3522, 3171-3551, 3171-3573, 3171-3604, 3171-3620, 3171-3646, 3171-3680, 3171-3689, 3179-3689, 3202-3689, 3220-3682, 3242-3689, 3244-3689, 3246-3691, 3446-4285, 3459-4284, 4234-4915, 4234-4925, 4235-4920, 4237-4925, 4245-4925, 4254-4925, 4271-4925, 4288-5687, 4291-4925, 4297-4925, 4303-4925, 4307-4925, 4324-4925, 4330-4509, 4330-4678, 4330-4685, 4382-4677, 4382-4681, 4382-4682, 4382-4684, 4382-4685, 4384-4684, 4405-4683, 4435-4684, 4467-4680, 5110-5794, 5110-5852, 5110-5854, 5110-5862, 5110-5908, 5110-5916, 5111-5854, 5230-6114, 5444-6104, 5686-6861, 6047-6781, 6047-6784, 6047-6834, 6047-6854, 6047-6863, 6047-6885, 6047-6891, 6470-7225, 6495-7225, 6507-7225, 6510-7225, 6541-7225, 6567-7225, 6582-7225, 6738-6864, 6861-6883
11/7482931CBI/ 1691	1-243, 1-576, 32-235, 93-230, 95-378, 186-377, 307-703, 307-763, 307-803, 307-836, 307-845, 307-1049, 307-1054, 307-1056, 307-1063, 307-1076, 307-1078, 307-1080, 307-1112, 307-1127, 308-845, 311-372, 377-787, 377-797, 427-797, 465-1132, 577-1082, 757-1630, 816-1618, 822-1608, 826-1624, 878-1567, 887-1314, 907-1614, 933-1614, 935-1167, 940-1608, 982-1085, 982-1543, 1020-1691, 1021-1691, 1038-1691, 1052-1604, 1053-1431, 1053-1614, 1053-1628, 1053-1642, 1053-1667, 1053-1680, 1053-1691, 1054-1691, 1055-1680, 1055-1691, 1063-1691, 1072-1691, 1163-1691
12/2080788CBI/ 6146	1-540, 4-335, 4-580, 11-216, 11-464, 19-359, 19-647, 240-412, 265-595, 271-719, 343-931, 446-1064, 522-1140, 539-821, 617-1206, 661-1241, 664-977, 696-1261, 696-1293, 700-1230, 756-1259, 756-1364, 801-1374, 814-1393, 848-1376, 953-1448, 956-1526, 974-1304, 1005-1465, 1005-1655, 1192-1838, 1206-1743, 1234-1784, 1244-1439, 1258-1819, 1259-1534, 1263-1524, 1271-1543, 1302-1734, 1307-1906, 1319-1672, 1362-1865, 1363-1784, 1368-1749, 1377-1610, 1378-1589, 1378-1640, 1378-1643, 1388-2021, 1415-1689, 1415-1756, 1415-1816, 1415-1986, 1429-1972, 1466-1973, 1475-1756, 1501-1769, 1525-1926, 1527-2112, 1539-1844, 1559-2049, 1584-1782, 1584-2191, 1584-2213, 1586-1828, 1586-2154, 1590-2153, 1603-2222, 1616-2168, 1643-2102, 1671-2212, 1692-2313, 1715-2249, 1734-2404, 1743-2341, 1754-2015, 1777-2361, 1779-2378, 1800-2352, 1800-2422, 1806-2253, 1806-2271, 1812-2343, 1836-2130, 1837-2140, 1840-2110, 1845-2434, 1846-2188, 1848-2188, 1848-2387, 1863-2420, 1878-2304, 1883-2411, 1889-2475, 1890-2426, 1892-2508, 1901-2401, 1906-2401, 1909-2415, 1919-2169, 1919-2436, 1921-2533, 1927-2271, 1945-2507, 1951-2454, 1972-2417, 1987-2515, 2028-2611, 2036-2562, 2036-2641, 2041-2292, 2041-2337, 2043-2658, 2045-2620, 2068-2509, 2100-

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
I2 (cont.)	2699, 2134-2674, 2149-2396, 2149-2397, 2149-2416, 2149-2425, 2149-2427, 2149-2428, 2149-2431, 2158-2360, 2170-2734, 2180-2769, 2188-2433, 2188-2550, 2188-2648, 2199-2532, 2206-2847, 2208-2847, 2213-2847, 2216-2790, 2218-2764, 2221-2693, 2226-2847, 2229-2842, 2229-2847, 2230-2602, 2231-2847, 2235-2842, 2235-2847, 2242-2847, 2247-2790, 2255-2842, 2258-2847, 2259-2847, 2266-2847, 2290-2847, 2295-2780, 2296-2846, 2308-2847, 2309-2842, 2310-2605, 2312-2847, 2314-2596, 2321-2842, 2322-2586, 2337-2847, 2339-2616, 2348-2838, 2356-2816, 2357-2847, 2360-2829, 2364-2847, 2365-2824, 2365-2847, 2366-2847, 2371-2847, 2375-2847, 2380-2838, 2383-2847, 2386-2754, 2400-2847, 2406-2838, 2413-2829, 2413-2841, 2417-2829, 2417-2847, 2421-2847, 2424-2756, 2425-2500, 2431-2658, 2441-2780, 2443-2847, 2452-2846, 2476-2847, 2478-2847, 2479-3129, 2482-2785, 2487-2784, 2496-2735, 2496-2847, 2507-2846, 2523-2744, 2523-2847, 2539-2842, 2540-2847, 2559-3031, 2569-2847, 2572-2847, 2575-2847, 2577-2847, 2601-2811, 2637-2847, 2719-3332, 2751-2828, 2801-3359, 2840-3228, 2840-3266, 2840-3288, 2840-3293, 2840-3303, 2840-3443, 2840-3452, 2843-3221, 2908-3491, 2928-3321, 2936-3257, 2981-3245, 3333-3753, 3354-3585, 3398-3932, 3446-3942, 3447-3714, 3617-4204, 3637-3753, 3665-3887, 3748-3772, 3905-4425, 4011-4321, 4045-4664, 4173-4445, 4186-4463, 4197-4459, 4244-4523, 4250-4489, 4250-4794, 4255-4510, 4296-4536, 4296-4814, 4302-4514, 4303-4596, 4304-4773, 4385-4655, 4398-4632, 4493-4768, 4519-4771, 4526-4784, 4526-5055, 4538-4940, 4542-4689, 4542-4924, 4550-4784, 4589-5001, 4594-4855, 4640-4899, 4669-4958, 4689-4874, 4731-5023, 4737-4982, 4757-5017, 4764-5064, 4777-5026, 4777-5196, 4784-5043, 4788-5087, 4793-5051, 4793-5297, 4800-5254, 4819-5107, 4832-5140, 4846-5072, 4901-5155, 4907-5184, 4910-5177, 4960-5351, 5006-5236, 5020-5245, 5022-5314, 5022-5632, 5040-5324, 5055-5256, 5123-5372, 5135-5405, 5153-5394, 5183-5481, 5213-5456, 5214-5456, 5216-5500, 5226-5424, 5282-5555, 5311-5569, 5320-5559, 5322-5524, 5322-5798, 5368-5623, 5380-5698, 5440-5914, 5452-5654, 5463-5709, 5463-6000, 5464-5722, 5468-5722, 5468-5815, 5484-5784, 5502-5736, 5525-5722, 5525-5786, 5526-5892, 5539-6109, 5543-5800, 5544-6102, 5554-6085, 5588-6077, 5601-5813, 5601-5910, 5604-5739, 5604-5864, 5604-5871, 5604-6115, 5605-5876, 5619-6103, 5637-5889, 5638-6146, 5667-6104, 5669-5853, 5673-5918, 5740-5970, 5760-6048, 5790-6128, 5909-6092, 5933-6130, 5939-6127, 5946-6124, 5950-6124, 5981-6131

Table 4

Polynucleotide SEQ ID NO./ Incyte ID/ Sequence Length	Sequence Fragments
13/71918969CBI/ 2362	1-341, 1-450, 1-488, 1-546, 1-590, 1-753, 25-325, 25-443, 30-341, 66-338, 249-638, 249-958, 251-597, 457-951, 457-969, 457-1091, 520-785, 523-1161, 580-1032, 606-1177, 625-1147, 630-883, 631-1368, 634-1297, 755-1422, 762-1323, 816-1493, 818-1529, 822-1520, 829-1113, 829-1339, 842-1520, 847-1120, 865-1395, 915-1584, 920-1638, 936-1575, 951-1623, 995-1622, 1003-1594, 1021-1735, 1030-1620, 1082-1820, 1086-1769, 1111-1785, 1135-1309, 1145-1309, 1169-1309, 1169-1769, 1192-1620, 1198-1897, 1205-1899, 1209-1309, 1218-1785, 1220-1920, 1222-1460, 1222-1505, 1223-1309, 1224-1309, 1235-1307, 1235-1754, 1243-1831, 1247-1309, 1248-1882, 1250-1309, 1253-1880, 1276-1961, 1277-1908, 1291-1866, 1301-1703, 1311-1929, 1358-1948, 1386-1926, 1454-1969, 1455-1698, 1468-1871, 1477-2276, 1481-1677, 1482-2128, 1498-2010, 1504-2130, 1504-2152, 1511-2169, 1511-2245, 1544-2319, 1557-2310, 1566-2134, 1580-2240, 1581-2325, 1590-2152, 1597-2132, 1602-2325, 1620-2266, 1624-2171, 1632-2277, 1643-2325, 1650-1903, 1660-2151, 1666-2054, 1685-2325, 1686-1906, 1686-1920, 1686-2163, 1686-2206, 1699-1925, 1718-2174, 1722-2171, 1748-2020, 1749-2170, 1756-2338, 1761-2325, 1783-2042, 1804-2168, 1805-2166, 1812-2212, 1827-2362, 1828-2173, 1890-2325, 1900-2325, 1901-2077, 1903-2325, 1920-2166
14/8187571CBI/ 1535	1-617, 142-828, 175-330, 178-348, 181-459, 239-814, 258-487, 270-795, 311-855, 400-640, 400-983, 557-812, 711-938, 715-988, 783-1079, 803-1371, 810-1509, 854-1431, 886-1528, 1022-1519, 1089-1533, 1124-1535, 1131-1527, 1133-1379, 1145-1373, 1182-1531, 1188-1531, 1215-1336, 1215-1518, 1215-1528, 1215-1535, 1216-1531, 1242-1533, 1254-1528, 1259-1325, 1277-1532, 1294-1526, 1330-1531, 1331-1535, 1343-1531
15/7494145CBI/ 1376	1-469, 149-469, 153-207, 161-213, 189-521, 268-417, 268-778, 268-812, 268-951, 268-982, 556-1142, 556-1145, 556-1147, 556-1149, 568-1149, 842-1147, 864-1154, 904-1376
16/5807954CBI/ 1482	1-41, 1-298, 14-485, 34-381, 69-264, 144-642, 191-891, 196-438, 238-482, 259-460, 259-470, 259-473, 271-575, 283-635, 293-581, 293-961, 359-570, 359-639, 378-639, 382-1008, 438-1020, 483-762, 562-891, 635-879, 640-895, 653-1172, 654-941, 654-1003, 691-938, 886-1117, 906-1155, 909-1156, 918-1146, 929-1191, 932-1122, 932-1178, 932-1186, 932-1238, 934-1173, 945-1136, 995-1429, 1007-1203, 1007-1272, 1009-1227, 1009-1236, 1009-1381, 1009-1408, 1009-1447, 1138-1477, 1170-1333, 1237-1482, 1284-1477

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID:	Representative Library
9	55074884CB1	HEARNON03
10	7480588CB1	LUNGFER04
11	7482931CB1	BRAQNOT01
12	2080788CB1	BRAUNOR01
13	71918969CB1	TESTNOT03
14	8187571CB1	UTRSNOT01
15	7494145CB1	BRSTTMC01
16	5807954CB1	LNODNOT03

Table 6

Library	Vector	Library Description
BRAQNOT01	pINCY	Library was constructed using RNA isolated from midbrain tissue removed from a 35-year-old Caucasian male. No neuropathology was found. Patient history included dilated cardiomyopathy, congestive heart failure, and an enlarged spleen and liver.
BRAUNOR01	pINCY	This random primed library was constructed using RNA isolated from striatum, globus pallidus and posterior putamen tissue removed from an 81-year-old Caucasian female who died from a hemorrhage and ruptured thoracic aorta due to atherosclerosis. Pathology indicated moderate atherosclerosis involving the internal carotids, bilaterally; microscopic infarcts of the frontal cortex and hippocampus; and scattered diffuse amyloid plaques and neurofibrillary tangles, consistent with age. Grossly, the leptomeninges showed only mild thickening and hyalinization along the superior sagittal sinus. The remainder of the leptomeninges was thin and contained some congested blood vessels. Mild atrophy was found mostly in the frontal poles and lobes, and temporal lobes, bilaterally. Microscopically, there were pairs of Alzheimer type II astrocytes within the deep layers of the neocortex. There was increased satellitosis around neurons in the deep gray matter in the middle frontal cortex. The amygdala contained rare diffuse plaques and neurofibrillary tangles. The posterior hippocampus contained a microscopic area of cystic cavitation with hemosiderin-laden macrophages surrounded by reactive gliosis. Patient history included sepsis, cholangitis, post-operative atelectasis, pneumonia CAD, cardiomegaly due to left ventricular hypertrophy, splenomegaly, arteriolonephrosclerosis, nodular colloid goiter, emphysema, CHF, hypothyroidism, and peripheral vascular disease.
BRSTTMC01	pINCY	This large size-fractionated library was constructed using pooled cDNA from four donors. cDNA was generated using mRNA isolated from diseased breast tissue removed from a 40-year-old Caucasian female (donor A) during a bilateral reduction mammoplasty; from breast tissue removed from a 46-year-old Caucasian female (donor B) during unilateral extended simple mastectomy with breast reconstruction; from breast tissue removed from a 56-year-old Caucasian female (donor C) during unilateral extended simple mastectomy with open breast biopsy; and from breast tissue removed from a 57-year-old Caucasian female (donor D) during a unilateral extended simple mastectomy. Pathology indicated bilateral mild fibrocystic and proliferative changes (A); deep fascia was negative for tumor (B); non-proliferative fibrocystic change (C); and benign fat replaced breast parenchyma (D). Pathology for the matched tumor tissue (B) indicated invasive grade 3 adenocarcinoma, ductal type, with apocrine features. Pathology for the matched tumor tissue (C) indicated invasive grade 3 ductal adenocarcinoma. Pathology for the matched tumor tissue (D) indicated residual microscopic infiltrating grade 3

Table 6

Library	Vector	Library Description
BRSTTMC01 (cont.)		ductal adenocarcinoma and extensive grade 2 intraductal carcinoma. Patient history included breast hypertrophy and pure hypercholesterolemia (A); breast cancer (B); chronic airway obstruction and emphysema (C); and benign hypertension, hyperlipidemia, cardiac dysrhythmia, a benign colon neoplasm, a solitary breast cyst, and a breast neoplasm of uncertain behavior (D). Previous surgeries included open breast biopsy (B). Donor B's medications included Cytosan and Adriamycin.
HEARNON03	pINCY	This normalized heart tissue library was constructed from 8.4 million independent clones from a heart tissue library. Starting RNA was made from heart tissue removed from a 44-year-old Caucasian male, who died from intracranial hemorrhage. Serology was positive for anti-CMV (cytomegalovirus). Patient history included back and neck pain, hypertension, pneumonia, sinus infection, alcohol use, and daily pipe tobacco use (x3 years). Patient medications included Procordia. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
LNODNOT03	pINCY	Library was constructed using RNA isolated from lymph node tissue obtained from a 67-year-old Caucasian male during a segmental lung resection and bronchoscopy. On microscopic exam, this tissue was found to be extensively necrotic with 10% viable tumor. Pathology for the associated tumor tissue indicated invasive grade 3-4 squamous cell carcinoma. Patient history included hemangioma. Family history included atherosclerotic coronary artery disease, benign hypertension, congestive heart failure, atherosclerotic coronary artery disease.
LUNGFER04	PCDNA2.1	This random primed library was constructed using RNA isolated from lung tissue removed from a Caucasian male fetus who died from fetal demise.
TESTNOT03	PBLUESCRIPT	Library was constructed using RNA isolated from testicular tissue removed from a 37-year-old Caucasian male, who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure.
UTRSNOT01	PSPORT1	Library was constructed using RNA isolated from the uterine tissue of a 59-year-old female who died of a myocardial infarction. Patient history included cardiomyopathy, coronary artery disease, previous myocardial infarctions, hypercholesterolemia, hypotension, and arthritis.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, ffasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLOCKS IMPROVED Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less Signal peptide hits: Score=0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:

- 5 a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8,
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8,
- 10 c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and
- d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

15 2. An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

20 4. An isolated polynucleotide encoding a polypeptide of claim 2.

5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16.

25 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. A cell transformed with a recombinant polynucleotide of claim 6.

30 8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

9. A method of producing a polypeptide of claim 1, the method comprising:

- 35 a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

- b) recovering the polypeptide so expressed.

10. A method of claim 9, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

5

11. An isolated antibody which specifically binds to a polypeptide of claim 1.

12. An isolated polynucleotide selected from the group consisting of:

10

- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16,
b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16,
c) a polynucleotide complementary to a polynucleotide of a),
d) a polynucleotide complementary to a polynucleotide of b), and
e) an RNA equivalent of a)-d).

15

13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.

20

14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

25

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

30

15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.

16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

35

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain

reaction amplification, and

- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

5 17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

18. A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

10

19. A method for treating a disease or condition associated with decreased expression of functional KPP, comprising administering to a patient in need of such treatment the composition of claim 17.

15 20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20 21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with decreased expression of functional KPP, comprising administering to a patient in need of such treatment a composition of
25 claim 21.

23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- 30 b) detecting antagonist activity in the sample.

24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.

35 25. A method for treating a disease or condition associated with overexpression of functional

KPP, comprising administering to a patient in need of such treatment a composition of claim 24.

26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:

- 5 a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

10 27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test
15 compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity
20 of the polypeptide of claim 1.

28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

- 25 a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

30

29. A method of assessing toxicity of a test compound, the method comprising:

- a) treating a biological sample containing nucleic acids with the test compound,
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions
35 whereby a specific hybridization complex is formed between said probe and a target

polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,

c) quantifying the amount of hybridization complex, and

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

30. A diagnostic test for a condition or disease associated with the expression of KPP in a biological sample, the method comprising:

- a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

31. The antibody of claim 11, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')₂ fragment, or
- e) a humanized antibody.

32. A composition comprising an antibody of claim 11 and an acceptable excipient.

33. A method of diagnosing a condition or disease associated with the expression of KPP in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. A composition of claim 32, wherein the antibody is labeled.

35. A method of diagnosing a condition or disease associated with the expression of KPP in a subject, comprising administering to said subject an effective amount of the composition of claim 34.

36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from said animal, and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

37. A polyclonal antibody produced by a method of claim 36.

38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal,
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

40. A monoclonal antibody produced by a method of claim 39.

41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant

immunoglobulin library.

44. A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 in a sample, the method comprising:

- 5 a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 in the sample.

10

45. A method of purifying a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 from a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- 15 b) separating the antibody from the sample and obtaining the purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

20 13. 46. A microarray wherein at least one element of the microarray is a polynucleotide of claim

47. A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:

- 25 a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

30 48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim 12.

35

49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is
5 completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.

10 52. An array of claim 48, which is a microarray.

53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.

15 54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical
20 location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.

25 56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

30 59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

35 61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

5 64. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:9.

65. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:10.

10 66. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:11.

67. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:12.

15 68. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:13.

20 69. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:14.

70. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:15.

25 71. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:16.

<110> INCYTE GENOMICS, INC.
 LEE, Ernestine A.
 WALIA, Narinder K.
 BAUGHN, Mariah R.
 ISON, Craig H.
 GURURAJAN, Rajagopal
 ARVIZU, Chandra
 YAO, Monique G.
 HILLMAN, Jennifer L.
 TANG, Y. Tom
 YUE, Henry
 TRAN, Bao
 DING, Li
 LU, Dyung Aina
 LAL, Preeti G.
 WARREN, Bridget A.

<120> KINASES AND PHOSPHATASES

<130> PI-0344 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/263,083; 60/271,205; 60/271,117; 60/276,859; 60/278,504;
 60/278,522; 60/280,510; 60/280,266

<151> 2001-01-18; 2001-02-23; 2001-02-23; 2001-03-16; 2001-03-23;
 2001-03-23; 2001-03-29; 2001-03-29

<160> 16

<170> PERL Program

<210> 1

<211> 176

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55074884CD1

<400> 1

Met	Gly	Pro	Ala	Glu	Ala	Gly	Arg	Arg	Gly	Ala	Ala	Ser	Pro	Val
1				5					10					15
Pro	Pro	Pro	Leu	Val	Arg	Val	Ala	Pro	Ser	Leu	Phe	Leu	Gly	Ser
				20					25					30
Ala	Arg	Ala	Ala	Gly	Ala	Glu	Glu	Gln	Leu	Ala	Arg	Ala	Gly	Val
				35					40					45
Thr	Leu	Cys	Val	Asn	Val	Ser	Arg	Gln	Gln	Pro	Gly	Pro	Arg	Ala
				50					55					60
Pro	Gly	Val	Ala	Glu	Leu	Arg	Val	Pro	Val	Phe	Asp	Asp	Pro	Ala
				65					70					75
Glu	Asp	Leu	Leu	Ala	His	Leu	Glu	Pro	Thr	Cys	Ala	Ala	Met	Glu
				80					85					90
Ala	Ala	Val	Arg	Ala	Gly	Gly	Ala	Cys	Leu	Val	Tyr	Cys	Lys	Asn
				95					100					105
Gly	Arg	Ser	Arg	Ser	Ala	Ala	Val	Cys	Thr	Ala	Tyr	Leu	Met	Arg
				110					115					120
His	Arg	Gly	Leu	Ser	Leu	Ala	Lys	Ala	Phe	Gln	Met	Val	Lys	Ser
				125					130					135
Ala	Arg	Pro	Val	Ala	Glu	Pro	Asn	Pro	Gly	Phe	Trp	Ser	Gln	Leu
				140					145					150
Gln	Lys	Tyr	Glu	Glu	Ala	Leu	Gln	Ala	Gln	Ser	Cys	Leu	Gln	Gly

	155	160	165
Glu Pro Pro Ala	Leu Gly Leu Gly Pro	Glu Ala	
	170	175	

<210> 2
 <211> 2299
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7480588CD1

<400> 2

Met	Asp	Phe	Leu	Ile	Ile	Phe	Leu	Leu	Leu	Phe	Ile	Gly	Thr	Ser
1				5					10					15
Glu	Thr	Gln	Val	Asp	Val	Ser	Asn	Val	Val	Pro	Gly	Thr	Arg	Tyr
				20					25					30
Asp	Ile	Thr	Ile	Ser	Ser	Ile	Ser	Thr	Thr	Tyr	Thr	Ser	Pro	Val
				35					40					45
Thr	Arg	Ile	Gly	Glu	Pro	Gly	Pro	Pro	Val	Phe	Leu	Ala	Gly	Glu
				50					55					60
Arg	Val	Gly	Ser	Ala	Gly	Ile	Leu	Leu	Ser	Trp	Asn	Thr	Pro	Pro
				65					70					75
Asn	Pro	Asn	Gly	Arg	Ile	Ile	Ser	Tyr	Ile	Val	Lys	Tyr	Lys	Glu
				80					85					90
Val	Cys	Pro	Trp	Met	Gln	Thr	Val	Tyr	Thr	Gln	Val	Arg	Ser	Lys
				95					100					105
Pro	Asp	Ser	Leu	Glu	Val	Leu	Leu	Thr	Asn	Leu	Asn	Pro	Gly	Thr
				110					115					120
Thr	Tyr	Glu	Ile	Lys	Val	Ala	Ala	Glu	Asn	Ser	Ala	Gly	Ile	Gly
				125					130					135
Val	Phe	Ser	Asp	Pro	Phe	Leu	Phe	Gln	Thr	Ala	Glu	Ser	Ala	Pro
				140					145					150
Gly	Lys	Val	Val	Asn	Leu	Thr	Val	Glu	Ala	Tyr	Asn	Ala	Ser	Ala
				155					160					165
Val	Lys	Leu	Ile	Trp	Tyr	Leu	Pro	Arg	Gln	Pro	Asn	Gly	Lys	Ile
				170					175					180
Thr	Ser	Phe	Lys	Ile	Ser	Val	Lys	His	Ala	Arg	Ser	Gly	Ile	Val
				185					190					195
Val	Lys	Asp	Val	Ser	Ile	Arg	Val	Glu	Asp	Ile	Leu	Thr	Gly	Lys
				200					205					210
Leu	Pro	Glu	Cys	Asn	Glu	Asn	Ser	Glu	Ser	Phe	Leu	Trp	Ser	Thr
				215					220					225
Ala	Ser	Pro	Ser	Pro	Thr	Leu	Gly	Arg	Val	Thr	Pro	Pro	Ser	Arg
				230					235					240
Thr	Thr	His	Ser	Ser	Ser	Thr	Leu	Thr	Gln	Asn	Glu	Ile	Ser	Ser
				245					250					255
Val	Trp	Lys	Glu	Pro	Ile	Ser	Phe	Val	Val	Thr	His	Leu	Arg	Pro
				260					265					270
Tyr	Thr	Thr	Tyr	Leu	Phe	Glu	Val	Ser	Ala	Ala	Thr	Thr	Glu	Ala
				275					280					285
Gly	Tyr	Ile	Asp	Ser	Thr	Ile	Val	Arg	Thr	Pro	Glu	Ser	Val	Pro
				290					295					300
Glu	Gly	Pro	Pro	Gln	Asn	Cys	Val	Thr	Gly	Asn	Ile	Thr	Gly	Lys
				305					310					315
Ser	Phe	Ser	Ile	Leu	Trp	Asp	Pro	Pro	Thr	Ile	Val	Thr	Gly	Lys
				320					325					330
Phe	Ser	Tyr	Arg	Val	Glu	Leu	Tyr	Gly	Pro	Ser	Gly	Ala	Gly	Arg
				335					340					345
Ile	Leu	Asp	Asn	Ser	Thr	Lys	Asp	Leu	Lys	Phe	Ala	Phe	Thr	Asn
				350					355					360
Leu	Thr	Pro	Phe	Thr	Met	Tyr	Asp	Val	Tyr	Ile	Ala	Ala	Glu	Thr

	365		370		375
Ser Ala Gly Thr	Gly Pro Lys Ser Asn	Ile Ser Val Phe Thr	Pro		
	380		385		390
Pro Asp Val Pro	Gly Ala Val Phe Asp	Leu Gln Leu Ala Glu	Val		
	395		400		405
Glu Ser Thr Gln	Val Arg Ile Thr Trp	Lys Lys Pro Arg Gln	Pro		
	410		415		420
Asn Gly Ile Ile	Asn Gln Tyr Arg Val	Lys Val Leu Val Pro	Glu		
	425		430		435
Thr Gly Ile Ile	Leu Glu Asn Thr Leu	Leu Thr Gly Asn Asn	Glu		
	440		445		450
Ile Asn Asp Pro	Met Ala Pro Glu Ile	Val Asn Ile Val Gln	Pro		
	455		460		465
Met Val Gly Leu	Tyr Glu Gly Ser Ala	Glu Met Ser Ser Asp	Leu		
	470		475		480
His Ser Leu Ala	Thr Phe Ile Tyr Asn	Ser His Pro Asp Lys	Asn		
	485		490		495
Phe Pro Ala Arg	Asn Arg Ala Glu Asp	Gln Thr Ser Pro Val	Val		
	500		505		510
Thr Thr Arg Asn	Gln Tyr Ile Thr Asp	Ile Ala Ala Glu Gln	Leu		
	515		520		525
Ser Tyr Val Ile	Arg Arg Leu Val Pro	Phe Thr Glu His Met	Ile		
	530		535		540
Ser Val Ser Ala	Phe Thr Ile Met Gly	Glu Gly Pro Pro Thr	Val		
	545		550		555
Leu Ser Val Arg	Thr Arg Gln Gln Val	Pro Ser Ser Ile Lys	Ile		
	560		565		570
Ile Asn Tyr Lys	Asn Ile Ser Ser Ser	Ser Ile Leu Leu Tyr	Trp		
	575		580		585
Asp Pro Pro Glu	Tyr Pro Asn Gly Lys	Ile Thr His Tyr Thr	Ile		
	590		595		600
Tyr Ala Met Glu	Leu Asp Thr Asn Arg	Ala Phe Gln Ile Thr	Thr		
	605		610		615
Ile Asp Asn Ser	Phe Leu Ile Thr Gly	Arg Lys Gln Trp Leu	Lys		
	620		625		630
Lys Tyr Thr Lys	Tyr Lys Met Arg Val	Ala Ala Ser Thr His	Val		
	635		640		645
Gly Glu Ser Ser	Leu Ser Glu Glu Asn	Asp Ile Phe Val Arg	Thr		
	650		655		660
Ser Glu Asp Glu	Pro Glu Ser Ser Pro	Gln Asp Val Glu Val	Ile		
	665		670		675
Asp Val Thr Ala	Asp Glu Ile Arg Leu	Lys Trp Ser Pro Pro	Glu		
	680		685		690
Lys Pro Asn Gly	Ile Ile Ile Ala Tyr	Glu Val Leu Tyr Lys	Asn		
	695		700		705
Ile Asp Thr Leu	Tyr Met Lys Asn Thr	Ser Thr Thr Asp Ile	Ile		
	710		715		720
Leu Arg Asn Leu	Arg Pro His Thr Leu	Tyr Asn Ile Ser Val	Arg		
	725		730		735
Ser Tyr Thr Arg	Phe Gly His Gly Asn	Gln Val Ser Ser Leu	Leu		
	740		745		750
Ser Val Arg Thr	Ser Glu Thr Val Pro	Asp Ser Ala Pro Glu	Asn		
	755		760		765
Ile Thr Tyr Lys	Asn Ile Ser Ser Gly	Glu Ile Glu Leu Ser	Phe		
	770		775		780
Leu Pro Pro Ser	Ser Pro Asn Gly Ile	Ile Gln Lys Tyr Thr	Ile		
	785		790		795
Tyr Leu Lys Arg	Ser Asn Gly Asn Glu	Glu Arg Thr Ile Asn	Thr		
	800		805		810
Thr Ser Leu Thr	Gln Asn Ile Lys Gly	Leu Lys Lys Tyr Thr	Gln		
	815		820		825
Tyr Ile Ile Glu	Val Ser Ala Ser Thr	Leu Lys Gly Glu Gly	Val		
	830		835		840

Arg	Ser	Ala	Pro	Ile	Ser	Ile	Leu	Thr	Glu	Glu	Asp	Ala	Pro	Asp
				845					850					855
Ser	Pro	Pro	Gln	Asp	Phe	Ser	Val	Lys	Gln	Leu	Ser	Gly	Val	Thr
				860					865					870
Val	Lys	Leu	Ser	Trp	Gln	Pro	Pro	Leu	Glu	Pro	Asn	Gly	Ile	Ile
				875					880					885
Leu	Tyr	Tyr	Thr	Val	Tyr	Val	Trp	Arg	Asn	Arg	Ser	Ser	Leu	Lys
				890					895					900
Thr	Ile	Asn	Val	Thr	Glu	Thr	Ser	Leu	Glu	Leu	Ser	Asp	Leu	Asp
				905					910					915
Tyr	Asn	Val	Glu	Tyr	Ser	Ala	Tyr	Val	Thr	Ala	Ser	Thr	Arg	Phe
				920					925					930
Gly	Asp	Gly	Lys	Thr	Arg	Ser	Asn	Ile	Ile	Ser	Phe	Gln	Thr	Pro
				935					940					945
Glu	Gly	Pro	Ser	Asp	Pro	Pro	Lys	Asp	Val	Tyr	Tyr	Ala	Asn	Leu
				950					955					960
Ser	Ser	Ser	Ser	Ile	Ile	Leu	Phe	Trp	Thr	Pro	Pro	Ser	Lys	Pro
				965					970					975
Asn	Gly	Ile	Ile	Gln	Tyr	Tyr	Ser	Val	Tyr	Tyr	Arg	Asn	Thr	Ser
				980					985					990
Gly	Thr	Phe	Met	Gln	Asn	Phe	Thr	Leu	His	Glu	Val	Thr	Asn	Asp
				995					1000					1005
Phe	Asp	Asn	Met	Thr	Val	Ser	Thr	Ile	Ile	Asp	Lys	Leu	Thr	Ile
				1010					1015					1020
Phe	Ser	Tyr	Tyr	Thr	Phe	Trp	Leu	Thr	Ala	Ser	Thr	Ser	Val	Gly
				1025					1030					1035
Asn	Gly	Asn	Lys	Ser	Ser	Asp	Ile	Ile	Glu	Val	Tyr	Thr	Asp	Gln
				1040					1045					1050
Asp	Val	Pro	Glu	Gly	Phe	Val	Gly	Asn	Leu	Thr	Tyr	Glu	Ser	Ile
				1055					1060					1065
Ser	Ser	Thr	Ala	Ile	Asn	Val	Ser	Trp	Val	Pro	Pro	Ala	Gln	Pro
				1070					1075					1080
Asn	Gly	Leu	Val	Phe	Tyr	Tyr	Val	Ser	Leu	Ile	Leu	Gln	Gln	Thr
				1085					1090					1095
Pro	Arg	His	Val	Arg	Pro	Pro	Leu	Val	Thr	Tyr	Glu	Arg	Ser	Ile
				1100					1105					1110
Tyr	Phe	Asp	Asn	Leu	Glu	Lys	Tyr	Thr	Asp	Tyr	Ile	Leu	Lys	Ile
				1115					1120					1125
Thr	Pro	Ser	Thr	Glu	Lys	Gly	Phe	Ser	Asp	Thr	Tyr	Thr	Ala	Gln
				1130					1135					1140
Leu	Tyr	Ile	Lys	Thr	Glu	Glu	Asp	Val	Pro	Glu	Thr	Ser	Pro	Ile
				1145					1150					1155
Ile	Asn	Thr	Phe	Lys	Asn	Leu	Ser	Ser	Thr	Ser	Val	Leu	Leu	Ser
				1160					1165					1170
Trp	Asp	Pro	Pro	Val	Lys	Pro	Asn	Gly	Ala	Ile	Ile	Ser	Tyr	Asp
				1175					1180					1185
Leu	Thr	Leu	Gln	Gly	Pro	Asn	Glu	Asn	Tyr	Ser	Phe	Ile	Thr	Ser
				1190					1195					1200
Asp	Asn	Tyr	Ile	Ile	Leu	Glu	Glu	Leu	Ser	Pro	Phe	Thr	Leu	Tyr
				1205					1210					1215
Ser	Phe	Phe	Ala	Ala	Ala	Arg	Thr	Arg	Lys	Gly	Leu	Gly	Pro	Ser
				1220					1225					1230
Ser	Ile	Leu	Phe	Phe	Tyr	Thr	Asp	Glu	Ser	Val	Pro	Leu	Ala	Pro
				1235					1240					1245
Pro	Gln	Asn	Leu	Thr	Leu	Ile	Asn	Cys	Thr	Ser	Asp	Phe	Val	Trp
				1250					1255					1260
Leu	Lys	Trp	Ser	Pro	Ser	Pro	Leu	Pro	Gly	Gly	Ile	Val	Lys	Val
				1265					1270					1275
Tyr	Ser	Phe	Lys	Ile	His	Glu	His	Glu	Thr	Asp	Thr	Ile	Tyr	Tyr
				1280					1285					1290
Lys	Asn	Ile	Ser	Gly	Phe	Lys	Thr	Glu	Ala	Lys	Leu	Val	Gly	Leu
				1295					1300					1305
Glu	Pro	Val	Ser	Thr	Tyr	Ser	Ile	Arg	Val	Ser	Ala	Phe	Thr	Lys

Val Gly Asn Gly Asn Gln Phe Ser Asn Val	1310	1315	Val Lys Phe Thr Thr	1320
Gln Glu Ser Val Pro Asp Val Val Gln Asn Met Gln Cys Met Ala	1325	1330		1335
Thr Ser Trp Gln Ser Val Leu Val Lys Trp Asp Pro Pro Lys Lys	1340	1345		1350
Ala Asn Gly Ile Ile Thr Gln Tyr Met Val Thr Val Glu Arg Asn	1355	1360		1365
Ser Thr Lys Val Ser Pro Gln Asp His Met Tyr Thr Phe Ile Lys	1370	1375		1380
Leu Leu Ala Asn Thr Ser Tyr Val Phe Lys Val Arg Ala Ser Thr	1385	1390		1395
Ser Ala Gly Glu Gly Asp Glu Ser Thr Cys His Val Ser Thr Leu	1400	1405		1410
Pro Glu Thr Val Pro Ser Val Pro Thr Asn Ile Ala Phe Ser Asp	1415	1420		1425
Val Gln Ser Thr Ser Ala Thr Leu Thr Trp Ile Arg Pro Asp Thr	1430	1435		1440
Ile Leu Gly Tyr Phe Gln Asn Tyr Lys Ile Thr Thr Gln Leu Arg	1445	1450		1455
Ala Gln Lys Cys Lys Glu Trp Glu Ser Glu Glu Cys Val Glu Tyr	1460	1465		1470
Gln Lys Ile Gln Tyr Leu Tyr Glu Ala His Leu Thr Glu Glu Thr	1475	1480		1485
Val Tyr Gly Leu Lys Lys Phe Arg Trp Tyr Arg Phe Gln Val Ala	1490	1495		1500
Ser Ser Thr Asn Ala Gly Tyr Gly Asn Ala Ser Asn Trp Ile Ser	1505	1510		1515
Thr Lys Thr Leu Pro Gly Pro Pro Asp Gly Pro Pro Glu Asn Val	1520	1525		1530
His Val Val Ala Thr Ser Pro Phe Ser Ile Ser Ile Ser Trp Ser	1535	1540		1545
Glu Pro Ala Val Ile Thr Gly Pro Thr Cys Tyr Leu Ile Asp Val	1550	1555		1560
Lys Ser Val Asp Asn Asp Glu Phe Asn Ile Ser Phe Ile Lys Ser	1565	1570		1575
Asn Glu Glu Asn Lys Thr Ile Glu Ile Lys Asp Leu Glu Ile Phe	1580	1585		1590
Thr Arg Tyr Ser Val Val Ile Thr Ala Phe Thr Gly Asn Ile Ser	1595	1600		1605
Ala Ala Tyr Val Glu Gly Lys Ser Ser Ala Glu Met Ile Val Thr	1610	1615		1620
Thr Leu Glu Ser Ala Pro Lys Asp Pro Pro Asn Asn Met Thr Phe	1625	1630		1635
Gln Lys Ile Pro Asp Glu Val Thr Lys Phe Gln Leu Thr Phe Leu	1640	1645		1650
Pro Pro Ser Gln Pro Asn Gly Asn Ile Gln Val Tyr Gln Ala Leu	1655	1660		1665
Val Tyr Arg Glu Asp Asp Pro Thr Ala Val Gln Ile His Asn Leu	1670	1675		1680
Ser Ile Ile Gln Lys Thr Asn Thr Phe Val Ile Ala Met Leu Glu	1685	1690		1695
Gly Leu Lys Gly Gly His Thr Tyr Asn Ile Ser Val Tyr Ala Val	1700	1705		1710
Asn Ser Ala Gly Ala Gly Pro Lys Val Pro Met Arg Ile Thr Met	1715	1720		1725
Asp Ile Lys Ala Pro Ala Arg Pro Lys Thr Lys Pro Thr Pro Ile	1730	1735		1740
Tyr Asp Ala Thr Gly Lys Leu Leu Val Thr Ser Thr Thr Ile Thr	1745	1750		1755
Ile Arg Met Pro Ile Cys Tyr Tyr Ser Asp Asp His Gly Pro Ile	1760	1765		1770
	1775	1780		1785

Lys	Asn	Val	Gln	Val	Leu	Val	Thr	Glu	Thr	Gly	Ala	Gln	His	Asp	
				1790					1795					1800	
Gly	Asn	Val	Thr	Lys	Trp	Tyr	Asp	Ala	Tyr	Phe	Asn	Lys	Ala	Arg	
				1805					1810					1815	
Pro	Tyr	Phe	Thr	Asn	Glu	Gly	Phe	Pro	Asn	Pro	Pro	Cys	Thr	Glu	
				1820					1825					1830	
Gly	Lys	Thr	Lys	Phe	Ser	Gly	Asn	Glu	Glu	Ile	Tyr	Ile	Ile	Gly	
				1835					1840					1845	
Ala	Asp	Asn	Ala	Cys	Met	Ile	Pro	Gly	Asn	Glu	Asp	Lys	Ile	Cys	
				1850					1855					1860	
Asn	Gly	Pro	Leu	Lys	Pro	Lys	Lys	Gln	Tyr	Leu	Phe	Lys	Phe	Arg	
				1865					1870					1875	
Ala	Thr	Asn	Ile	Met	Gly	Gln	Phe	Thr	Asp	Ser	Asp	Tyr	Ser	Asp	
				1880					1885					1890	
Pro	Val	Lys	Thr	Leu	Gly	Glu	Gly	Leu	Ser	Glu	Arg	Thr	Val	Glu	
				1895					1900					1905	
Ile	Ile	Leu	Ser	Val	Thr	Leu	Cys	Ile	Leu	Ser	Ile	Ile	Leu	Leu	
				1910					1915					1920	
Gly	Thr	Ala	Ile	Phe	Ala	Phe	Ala	Arg	Ile	Arg	Gln	Lys	Gln	Lys	
				1925					1930					1935	
Glu	Gly	Gly	Thr	Tyr	Ser	Pro	Gln	Asp	Ala	Glu	Ile	Ile	Asp	Thr	
				1940					1945					1950	
Lys	Leu	Lys	Leu	Asp	Gln	Leu	Ile	Thr	Val	Ala	Asp	Leu	Glu	Leu	
				1955					1960					1965	
Lys	Asp	Glu	Arg	Leu	Thr	Arg	Leu	Leu	Ser	Tyr	Arg	Lys	Ser	Ile	
				1970					1975					1980	
Lys	Pro	Ile	Ser	Lys	Lys	Ser	Phe	Leu	Gln	His	Val	Glu	Glu	Leu	
				1985					1990					1995	
Cys	Thr	Asn	Asn	Asn	Leu	Lys	Phe	Gln	Glu	Glu	Phe	Ser	Glu	Leu	
				2000					2005					2010	
Pro	Lys	Phe	Leu	Gln	Asp	Leu	Ser	Ser	Thr	Asp	Ala	Asp	Leu	Pro	
				2015					2020					2025	
Trp	Asn	Arg	Ala	Lys	Asn	Arg	Phe	Pro	Asn	Ile	Lys	Pro	Tyr	Asn	
				2030					2035					2040	
Asn	Asn	Arg	Val	Lys	Leu	Ile	Ala	Asp	Ala	Ser	Val	Pro	Gly	Ser	
				2045					2050					2055	
Asp	Tyr	Ile	Asn	Ala	Ser	Tyr	Ile	Ser	Gly	Tyr	Leu	Cys	Pro	Asn	
				2060					2065					2070	
Glu	Phe	Ile	Ala	Thr	Gln	Gly	Pro	Leu	Pro	Gly	Thr	Val	Gly	Asp	
				2075					2080					2085	
Phe	Trp	Arg	Met	Val	Trp	Glu	Thr	Arg	Ala	Lys	Thr	Leu	Val	Met	
				2090					2095					2100	
Leu	Thr	Gln	Cys	Phe	Glu	Lys	Gly	Arg	Ile	Arg	Cys	His	Gln	Tyr	
				2105					2110					2115	
Trp	Pro	Glu	Asp	Asn	Lys	Pro	Val	Thr	Val	Phe	Gly	Asp	Ile	Val	
				2120					2125					2130	
Ile	Thr	Lys	Leu	Met	Glu	Asp	Val	Gln	Ile	Asp	Trp	Thr	Ile	Arg	
				2135					2140					2145	
Asp	Leu	Lys	Ile	Glu	Arg	His	Gly	Asp	Cys	Met	Thr	Val	Arg	Gln	
				2150					2155					2160	
Cys	Asn	Phe	Thr	Ala	Trp	Pro	Glu	His	Gly	Val	Pro	Glu	Asn	Ser	
				2165					2170					2175	
Ala	Pro	Leu	Ile	His	Phe	Val	Lys	Leu	Val	Arg	Ala	Ser	Arg	Ala	
				2180					2185					2190	
His	Asp	Thr	Thr	Pro	Met	Ile	Val	His	Cys	Ser	Ala	Gly	Val	Gly	
				2195					2200					2205	
Arg	Thr	Gly	Val	Phe	Ile	Ala	Leu	Asp	His	Leu	Thr	Gln	His	Ile	
				2210					2215					2220	
Asn	Asp	His	Asp	Phe	Val	Asp	Ile	Tyr	Gly	Leu	Val	Ala	Glu	Leu	
				2225					2230					2235	
Arg	Ser	Glu	Arg	Met	Cys	Met	Val	Gln	Asn	Leu	Ala	Gln	Tyr	Ile	
				2240					2245					2250	
Phe	Leu	His	Gln	Cys	Ile	Leu	Asp	Leu	Leu	Ser	Asn	Lys	Gly	Ser	

	2255		2260		2265
Asn	Gln	Pro	Ile	Cys	Phe
	2270		2275		2280
Asp	Ser	Leu	Asp	Ala	Met
	2285		2290		2295
Glu	Thr	Thr	Met		

<210> 3
 <211> 478
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7482931CD1

<400> 3

Met	Ser	Gly	Gly	Gly	Glu	Gln	Leu	Asp	Ile	Leu	Ser	Val	Gly	Ile
1				5					10					15
Leu	Val	Lys	Glu	Arg	Trp	Lys	Val	Leu	Arg	Lys	Ile	Gly	Gly	Gly
				20					25					30
Gly	Phe	Gly	Glu	Ile	Tyr	Asp	Ala	Leu	Asp	Met	Leu	Thr	Arg	Glu
				35					40					45
Asn	Val	Ala	Leu	Lys	Val	Glu	Ser	Ala	Gln	Gln	Pro	Lys	Gln	Val
				50					55					60
Leu	Lys	Met	Glu	Val	Ala	Val	Leu	Lys	Lys	Leu	Gln	Gly	Lys	Asp
				65					70					75
His	Val	Cys	Arg	Phe	Ile	Gly	Cys	Gly	Arg	Asn	Asp	Arg	Phe	Asn
				80					85					90
Tyr	Val	Val	Met	Gln	Leu	Gln	Gly	Arg	Asn	Leu	Ala	Asp	Leu	Arg
				95					100					105
Arg	Ser	Gln	Ser	Arg	Gly	Thr	Phe	Thr	Ile	Ser	Thr	Thr	Leu	Arg
				110					115					120
Leu	Gly	Arg	Gln	Ile	Leu	Glu	Ser	Ile	Glu	Ser	Ile	His	Ser	Val
				125					130					135
Gly	Phe	Leu	His	Arg	Asp	Ile	Lys	Pro	Ser	Asn	Phe	Ala	Met	Gly
				140					145					150
Arg	Phe	Pro	Ser	Thr	Cys	Arg	Lys	Cys	Tyr	Met	Leu	Asp	Phe	Gly
				155					160					165
Leu	Ala	Arg	Gln	Phe	Thr	Asn	Ser	Cys	Gly	Asp	Val	Arg	Pro	Pro
				170					175					180
Arg	Ala	Val	Ala	Gly	Phe	Arg	Gly	Thr	Val	Arg	Tyr	Ala	Ser	Ile
				185					190					195
Asn	Ala	His	Arg	Asn	Arg	Glu	Met	Gly	Arg	His	Asp	Asp	Leu	Trp
				200					205					210
Ser	Leu	Phe	Tyr	Met	Leu	Val	Glu	Phe	Val	Val	Gly	Gln	Leu	Pro
				215					220					225
Trp	Lys	Lys	Ile	Lys	Asp	Lys	Glu	Gln	Val	Gly	Ser	Ile	Lys	Glu
				230					235					240
Arg	Tyr	Asp	His	Arg	Leu	Met	Leu	Lys	His	Leu	Pro	Pro	Glu	Phe
				245					250					255
Ser	Ile	Phe	Leu	Asp	His	Ile	Ser	Ser	Leu	Asp	Tyr	Phe	Thr	Lys
				260					265					270
Pro	Asp	Tyr	Gln	Leu	Leu	Thr	Ser	Val	Phe	Asp	Asn	Ser	Ile	Lys
				275					280					285
Thr	Phe	Gly	Val	Ile	Glu	Ser	Asp	Pro	Phe	Asp	Trp	Glu	Lys	Thr
				290					295					300
Gly	Asn	Asp	Gly	Ser	Leu	Thr	Thr	Thr	Thr	Thr	Ser	Thr	Thr	Pro
				305					310					315
Gln	Leu	His	Thr	Arg	Leu	Thr	Pro	Ala	Ala	Ile	Gly	Ile	Ala	Asn
				320					325					330
Ala	Thr	Pro	Ile	Pro	Gly	Asp	Leu	Leu	Arg	Glu	Asn	Thr	Asp	Glu

	335		340		345
Val Phe Pro Asp	Glu Gln Leu Ser Asp	Gly Glu Asn Gly Ile	Pro		
	350		355		360
Val Gly Val Ser	Pro Asp Lys Leu Pro	Gly Ser Leu Gly His	Pro		
	365		370		375
Arg Pro Gln Glu	Lys Asp Val Trp Glu	Glu Met Asp Ala Asn	Lys		
	380		385		390
Asn Lys Ile Lys	Leu Gly Ile Cys Lys	Ala Ala Thr Glu Glu	Glu		
	395		400		405
Asn Ser His Gly	Gln Ala Asn Gly Leu	Leu Asn Ala Pro Ser	Leu		
	410		415		420
Gly Ser Pro Ile	Arg Val Arg Ser Glu	Ile Thr Gln Pro Asp	Arg		
	425		430		435
Asp Ile Pro Leu	Val Arg Lys Leu Arg	Ser Ile His Ser Phe	Glu		
	440		445		450
Leu Glu Lys Arg	Leu Thr Leu Glu Pro	Lys Pro Asp Thr Asp	Lys		
	455		460		465
Phe Leu Glu Thr	Trp Tyr Lys Ile Val	Tyr Phe Ser Phe			
	470		475		

<210> 4
 <211> 1867
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2080788CD1

<400> 4

Met Ala Arg Leu	Ala Asp Tyr Phe Val	Leu Val Ala Phe Gly	Pro
1	5	10	15
His Pro Arg Gly	Ser Gly Glu Gly Gln	Gly Gln Ile Leu Gln	Arg
	20	25	30
Phe Pro Glu Lys	Asp Trp Glu Asp Asn	Pro Phe Pro Gln Gly	Ile
	35	40	45
Glu Leu Phe Cys	Gln Pro Ser Gly Trp	Gln Leu Cys Pro Glu	Arg
	50	55	60
Asn Pro Pro Thr	Phe Phe Val Ala Val	Leu Thr Asp Ile Asn	Ser
	65	70	75
Glu Arg His Tyr	Cys Ala Cys Leu Thr	Phe Trp Glu Pro Ala	Glu
	80	85	90
Pro Ser Gln Glu	Thr Thr Arg Val Glu	Asp Ala Thr Glu Arg	Glu
	95	100	105
Glu Glu Gly Asp	Glu Gly Gly Gln Thr	His Leu Ser Pro Thr	Ala
	110	115	120
Pro Ala Pro Ser	Ala Gln Leu Phe Ala	Pro Lys Thr Leu Val	Leu
	125	130	135
Val Ser Arg Leu	Asp His Thr Glu Val	Phe Arg Asn Ser Leu	Gly
	140	145	150
Leu Ile Tyr Ala	Ile His Val Glu Gly	Leu Asn Val Cys Leu	Glu
	155	160	165
Asn Val Ile Gly	Asn Leu Leu Thr Cys	Thr Val Pro Leu Ala	Gly
	170	175	180
Gly Ser Gln Arg	Thr Ile Ser Leu Gly	Ala Gly Asp Arg Gln	Val
	185	190	195
Ile Gln Thr Pro	Leu Ala Asp Ser Leu	Pro Val Ser Arg Cys	Ser
	200	205	210
Val Ala Leu Leu	Phe Arg Gln Leu Gly	Ile Thr Asn Val Leu	Ser
	215	220	225
Leu Phe Cys Ala	Ala Leu Thr Glu His	Lys Val Leu Phe Leu	Ser
	230	235	240
Arg Ser Tyr Gln	Arg Leu Ala Asp Ala	Cys Arg Gly Leu Leu	Ala

	245		250		255
Leu Leu Phe Pro	Leu Arg Tyr Ser Phe	Thr Tyr Val Pro Ile	Leu		
	260		265		270
Pro Ala Gln Leu	Leu Glu Val Leu Ser	Thr Pro Thr Pro Phe	Ile		
	275		280		285
Ile Gly Val Asn	Ala Ala Phe Gln Ala	Glu Thr Gln Glu Leu	Leu		
	290		295		300
Asp Val Ile Val	Ala Asp Leu Asp Gly	Gly Thr Val Thr Ile	Pro		
	305		310		315
Glu Cys Val His	Ile Pro Pro Leu Pro	Glu Pro Leu Gln Ser	Gln		
	320		325		330
Thr His Ser Val	Leu Ser Met Val Leu	Asp Pro Glu Leu Glu	Leu		
	335		340		345
Ala Asp Leu Ala	Phe Pro Pro Pro Thr	Thr Ser Thr Ser Ser	Leu		
	350		355		360
Lys Met Gln Asp	Lys Glu Leu Arg Ala	Val Phe Leu Arg Leu	Phe		
	365		370		375
Ala Gln Leu Leu	Gln Gly Tyr Arg Trp	Cys Leu His Val Val	Arg		
	380		385		390
Ile His Pro Glu	Pro Val Ile Arg Phe	His Lys Ala Ala Phe	Leu		
	395		400		405
Gly Gln Arg Gly	Leu Val Glu Asp Asp	Phe Leu Met Lys Val	Leu		
	410		415		420
Glu Gly Met Ala	Phe Ala Gly Phe Val	Ser Glu Arg Gly Val	Pro		
	425		430		435
Tyr Arg Pro Thr	Asp Leu Phe Asp Glu	Leu Val Ala His Glu	Val		
	440		445		450
Ala Arg Met Arg	Ala Asp Glu Asn His	Pro Gln Arg Val Leu	Arg		
	455		460		465
His Val Gln Glu	Leu Ala Glu Gln Leu	Tyr Lys Asn Glu Asn	Pro		
	470		475		480
Tyr Pro Ala Val	Ala Met His Lys Val	Gln Arg Pro Gly Glu	Ser		
	485		490		495
Ser His Leu Arg	Arg Val Pro Arg Pro	Phe Pro Arg Leu Asp	Glu		
	500		505		510
Gly Thr Val Gln	Trp Ile Val Asp Gln	Ala Ala Ala Lys Met	Gln		
	515		520		525
Gly Ala Pro Pro	Ala Val Lys Ala Glu	Arg Arg Thr Thr Val	Pro		
	530		535		540
Ser Gly Pro Pro	Met Thr Ala Ile Leu	Glu Arg Cys Ser Gly	Leu		
	545		550		555
His Val Asn Ser	Ala Arg Arg Leu Glu	Val Val Arg Asn Cys	Ile		
	560		565		570
Ser Tyr Val Phe	Glu Gly Lys Met Leu	Glu Ala Lys Lys Leu	Leu		
	575		580		585
Pro Ala Val Leu	Arg Ala Leu Lys Gly	Arg Ala Ala Arg Arg	Cys		
	590		595		600
Leu Ala Gln Glu	Leu His Leu His Val	Gln Gln Asn Arg Ala	Val		
	605		610		615
Leu Asp His Gln	Gln Phe Asp Phe Val	Val Arg Met Met Asn	Cys		
	620		625		630
Cys Leu Gln Asp	Cys Thr Ser Leu Asp	Glu His Gly Ile Ala	Ala		
	635		640		645
Ala Leu Leu Pro	Leu Val Thr Ala Phe	Cys Arg Lys Leu Ser	Pro		
	650		655		660
Gly Val Thr Gln	Phe Ala Tyr Ser Cys	Val Gln Glu His Val	Val		
	665		670		675
Trp Ser Thr Pro	Gln Phe Trp Glu Ala	Met Phe Tyr Gly Asp	Val		
	680		685		690
Gln Thr His Ile	Arg Ala Leu Tyr Leu	Glu Pro Thr Glu Asp	Leu		
	695		700		705
Ala Pro Ala Gln	Glu Val Gly Glu Ala	Pro Ser Gln Glu Asp	Glu		
	710		715		720

Arg	Ser	Ala	Leu	Asp	Val	Ala	Ser	Glu	Gln	Arg	Arg	Leu	Trp	Pro
				725					730					735
Thr	Leu	Ser	Arg	Glu	Lys	Gln	Gln	Glu	Leu	Val	Gln	Lys	Glu	Glu
				740					745					750
Ser	Thr	Val	Phe	Ser	Gln	Ala	Ile	His	Tyr	Ala	Asn	Arg	Met	Ser
				755					760					765
Tyr	Leu	Leu	Leu	Pro	Leu	Asp	Ser	Ser	Lys	Ser	Arg	Leu	Leu	Arg
				770					775					780
Glu	Arg	Ala	Gly	Leu	Gly	Asp	Leu	Glu	Ser	Ala	Ser	Asn	Ser	Leu
				785					790					795
Val	Thr	Asn	Ser	Met	Ala	Gly	Ser	Val	Ala	Glu	Ser	Tyr	Asp	Thr
				800					805					810
Glu	Ser	Gly	Phe	Glu	Asp	Ala	Glu	Thr	Cys	Asp	Val	Ala	Gly	Ala
				815					820					825
Val	Val	Arg	Phe	Ile	Asn	Arg	Phe	Val	Asp	Lys	Val	Cys	Thr	Glu
				830					835					840
Ser	Gly	Val	Thr	Ser	Asp	His	Leu	Lys	Gly	Leu	His	Val	Met	Val
				845					850					855
Pro	Asp	Ile	Val	Gln	Met	His	Ile	Glu	Thr	Leu	Glu	Ala	Val	Gln
				860					865					870
Arg	Glu	Ser	Arg	Arg	Leu	Pro	Pro	Ile	Gln	Lys	Pro	Lys	Leu	Leu
				875					880					885
Arg	Pro	Arg	Leu	Leu	Pro	Gly	Glu	Glu	Cys	Val	Leu	Asp	Gly	Leu
				890					895					900
Arg	Val	Tyr	Leu	Leu	Pro	Asp	Gly	Arg	Glu	Glu	Gly	Ala	Gly	Gly
				905					910					915
Ser	Ala	Gly	Gly	Pro	Ala	Leu	Leu	Pro	Ala	Glu	Gly	Ala	Val	Phe
				920					925					930
Leu	Thr	Thr	Tyr	Arg	Val	Ile	Phe	Thr	Gly	Met	Pro	Thr	Asp	Pro
				935					940					945
Leu	Val	Gly	Glu	Gln	Val	Val	Val	Arg	Ser	Phe	Pro	Val	Ala	Ala
				950					955					960
Leu	Thr	Lys	Glu	Lys	Arg	Ile	Ser	Val	Gln	Thr	Pro	Val	Asp	Gln
				965					970					975
Leu	Leu	Gln	Asp	Gly	Leu	Gln	Leu	Arg	Ser	Cys	Thr	Phe	Gln	Leu
				980					985					990
Leu	Lys	Met	Ala	Phe	Asp	Glu	Glu	Val	Gly	Ser	Asp	Ser	Ala	Glu
				995					1000					1005
Leu	Phe	Arg	Lys	Gln	Leu	His	Lys	Leu	Arg	Tyr	Pro	Pro	Asp	Ile
				1010					1015					1020
Arg	Ala	Thr	Phe	Ala	Phe	Thr	Leu	Gly	Ser	Ala	His	Thr	Pro	Gly
				1025					1030					1035
Arg	Pro	Pro	Arg	Val	Thr	Lys	Asp	Lys	Gly	Pro	Ser	Leu	Arg	Thr
				1040					1045					1050
Leu	Ser	Arg	Asn	Leu	Val	Lys	Asn	Ala	Lys	Lys	Thr	Ile	Gly	Arg
				1055					1060					1065
Gln	His	Val	Thr	Arg	Lys	Lys	Tyr	Asn	Pro	Pro	Ser	Trp	Glu	His
				1070					1075					1080
Arg	Gly	Gln	Pro	Pro	Glu	Asp	Gln	Glu	Asp	Glu	Ile	Ser	Val	
				1085					1090					1095
Ser	Glu	Glu	Leu	Glu	Pro	Ser	Thr	Leu	Thr	Pro	Ser	Ser	Ala	Leu
				1100					1105					1110
Lys	Pro	Ser	Asp	Arg	Met	Thr	Met	Ser	Ser	Leu	Val	Glu	Arg	Ala
				1115					1120					1125
Cys	Cys	Arg	Asp	Tyr	Gln	Arg	Leu	Gly	Leu	Gly	Thr	Leu	Ser	Ser
				1130					1135					1140
Ser	Leu	Ser	Arg	Ala	Lys	Ser	Glu	Pro	Phe	Arg	Ile	Ser	Pro	Val
				1145					1150					1155
Asn	Arg	Met	Tyr	Ala	Ile	Cys	Arg	Ser	Tyr	Pro	Gly	Leu	Leu	Ile
				1160					1165					1170
Val	Pro	Gln	Ser	Val	Gln	Asp	Asn	Ala	Leu	Gln	Arg	Val	Ser	Arg
				1175					1180					1185
Cys	Tyr	Arg	Gln	Asn	Arg	Phe	Pro	Val	Val	Cys	Trp	Arg	Ser	Gly

Arg Ser Lys	1190	Arg Ser Gly	1195	Gly Leu His	1200
Ala Val Leu Leu Arg	1205	Gly Leu His	1210	Gly Lys	1215
Gly Val Val Gly Leu Phe Lys Ala Gln Asn	1220	Ala Pro Ser	1225	Pro Gly	1230
Gln Ser Gln Ala Asp Ser Ser Ser Leu Glu Gln Glu Lys Tyr Leu	1235	Ala Asp Ala Ser Gly	1240		1245
Gln Ala Val Val Ser Ser Met Pro Arg Tyr	1250	Ala Asp Ala Ser Gly	1255		1260
Arg Asn Thr Leu Ser Gly Phe Ser Ser Ala His Met Gly Ser His	1265		1270		1275
Gly Lys Trp Gly Ser Val Arg Thr Ser Gly Arg Ser Ser Gly Leu	1280		1285		1290
Gly Thr Asp Val Gly Ser Arg Leu Ala Gly Arg Asp Ala Leu Ala	1295		1300		1305
Pro Pro Gln Ala Asn Gly Gly Pro Pro Asp Pro Gly Phe Leu Arg	1310		1315		1320
Pro Gln Arg Ala Ala Leu Tyr Ile Leu Gly Asp Lys Ala Gln Leu	1325		1330		1335
Lys Gly Val Arg Ser Asp Pro Leu Gln Gln Trp Glu Leu Val Pro	1340		1345		1350
Ile Glu Val Phe Glu Ala Arg Gln Val Lys Ala Ser Phe Lys Lys	1355		1360		1365
Leu Leu Lys Ala Cys Val Pro Gly Cys Pro Ala Ala Glu Pro Ser	1370		1375		1380
Pro Ala Ser Phe Leu Arg Ser Leu Glu Asp Ser Glu Trp Leu Ile	1385		1390		1395
Gln Ile His Lys Leu Leu Gln Val Ser Val Leu Val Val Glu Leu	1400		1405		1410
Leu Asp Ser Gly Ser Ser Val Leu Val Gly Leu Glu Asp Gly Trp	1415		1420		1425
Asp Ile Thr Thr Gln Val Val Ser Leu Val Gln Leu Leu Ser Asp	1430		1435		1440
Pro Phe Tyr Arg Thr Leu Glu Gly Phe Arg Leu Leu Val Glu Lys	1445		1450		1455
Glu Trp Leu Ser Phe Gly His Arg Phe Ser His Arg Gly Ala His	1460		1465		1470
Thr Leu Ala Gly Gln Ser Ser Gly Phe Thr Pro Val Phe Leu Gln	1475		1480		1485
Phe Leu Asp Cys Val His Gln Val His Leu Gln Phe Pro Met Glu	1490		1495		1500
Phe Glu Phe Ser Gln Phe Tyr Leu Lys Phe Leu Gly Tyr His His	1505		1510		1515
Val Ser Arg Arg Phe Arg Thr Phe Leu Leu Asp Ser Asp Tyr Glu	1520		1525		1530
Arg Ile Glu Leu Gly Leu Leu Tyr Glu Glu Lys Gly Glu Arg Arg	1535		1540		1545
Gly Gln Val Pro Cys Arg Ser Val Trp Glu Tyr Val Asp Arg Leu	1550		1555		1560
Ser Lys Arg Thr Pro Val Phe His Asn Tyr Met Tyr Ala Pro Glu	1565		1570		1575
Asp Ala Glu Val Leu Arg Pro Tyr Ser Asn Val Ser Asn Leu Lys	1580		1585		1590
Val Trp Asp Phe Tyr Thr Glu Glu Thr Leu Ala Glu Gly Pro Pro	1595		1600		1605
Tyr Asp Trp Glu Leu Ala Gln Gly Pro Pro Glu Pro Pro Glu Glu	1610		1615		1620
Glu Arg Ser Asp Gly Gly Ala Pro Gln Ser Arg Arg Arg Val Val	1625		1630		1635
Trp Pro Cys Tyr Asp Ser Cys Pro Arg Ala Gln Pro Asp Ala Ile	1640		1645		1650
Ser Arg Leu Leu Glu Glu Leu Gln Arg Leu Glu Thr Glu Leu Gly	1655		1660		1665

Gln	Pro	Ala	Glu	Arg	Trp	Lys	Asp	Thr	Trp	Asp	Arg	Val	Lys	Ala	
				1670					1675					1680	
Ala	Gln	Arg	Leu	Glu	Gly	Arg	Pro	Asp	Gly	Arg	Gly	Thr	Pro	Ser	
				1685					1690					1695	
Ser	Leu	Leu	Val	Ser	Thr	Ala	Pro	His	His	Arg	Arg	Ser	Leu	Gly	
				1700					1705					1710	
Val	Tyr	Leu	Gln	Glu	Gly	Pro	Val	Gly	Ser	Thr	Leu	Ser	Leu	Ser	
				1715					1720					1725	
Leu	Asp	Ser	Asp	Gln	Ser	Ser	Gly	Ser	Thr	Thr	Ser	Gly	Ser	Arg	
				1730					1735					1740	
Gln	Ala	Ala	Arg	Arg	Ser	Thr	Ser	Thr	Leu	Tyr	Ser	Gln	Phe	Gln	
				1745					1750					1755	
Thr	Ala	Glu	Ser	Glu	Asn	Arg	Ser	Tyr	Glu	Gly	Thr	Leu	Tyr	Lys	
				1760					1765					1770	
Lys	Gly	Ala	Phe	Met	Lys	Pro	Trp	Lys	Ala	Arg	Trp	Phe	Val	Leu	
				1775					1780					1785	
Asp	Lys	Thr	Lys	His	Gln	Leu	Arg	Tyr	Tyr	Asp	His	Arg	Val	Asp	
				1790					1795					1800	
Thr	Glu	Cys	Lys	Gly	Val	Ile	Asp	Leu	Ala	Glu	Val	Glu	Ala	Val	
				1805					1810					1815	
Ala	Pro	Gly	Thr	Pro	Thr	Met	Gly	Ala	Pro	Lys	Thr	Val	Asp	Glu	
				1820					1825					1830	
Lys	Ala	Phe	Phe	Asp	Val	Lys	Thr	Thr	Arg	Arg	Val	Tyr	Asn	Phe	
				1835					1840					1845	
Cys	Ala	Gln	Asp	Val	Pro	Ser	Ala	Gln	Gln	Trp	Val	Asp	Arg	Ile	
				1850					1855					1860	
Gln	Ser	Cys	Leu	Ser	Asp	Ala									
				1865											

<210> 5
 <211> 514
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 71918969CD1

<400>	5														
Met	Ala	Asp	Ser	Gly	Leu	Asp	Lys	Lys	Ser	Thr	Lys	Cys	Pro	Asp	
1				5					10					15	
Cys	Ser	Ser	Ala	Ser	Gln	Lys	Asp	Val	Leu	Cys	Val	Cys	Ser	Ser	
				20					25					30	
Lys	Thr	Arg	Val	Pro	Pro	Val	Leu	Val	Val	Glu	Met	Ser	Gln	Thr	
				35					40					45	
Ser	Ser	Ile	Gly	Ser	Ala	Glu	Ser	Leu	Ile	Ser	Leu	Glu	Arg	Lys	
				50					55					60	
Lys	Glu	Lys	Asn	Ile	Asn	Arg	Asp	Ile	Thr	Ser	Arg	Lys	Asp	Leu	
				65					70					75	
Pro	Ser	Arg	Thr	Ser	Asn	Val	Glu	Arg	Lys	Ala	Ser	Gln	Gln	Gln	
				80					85					90	
Trp	Gly	Arg	Gly	Asn	Phe	Thr	Glu	Gly	Lys	Val	Pro	His	Ile	Arg	
				95					100					105	
Ile	Glu	Asn	Gly	Ala	Ala	Ile	Glu	Glu	Ile	Tyr	Thr	Phe	Gly	Arg	
				110					115					120	
Ile	Leu	Gly	Lys	Gly	Ser	Phe	Gly	Ile	Val	Ile	Glu	Ala	Thr	Asp	
				125					130					135	
Lys	Glu	Thr	Glu	Thr	Lys	Trp	Ala	Ile	Lys	Lys	Val	Asn	Lys	Glu	
				140					145					150	
Lys	Ala	Gly	Ser	Ser	Ala	Val	Lys	Leu	Leu	Glu	Arg	Glu	Val	Asn	
				155					160					165	
Ile	Leu	Lys	Ser	Val	Lys	His	Glu	His	Ile	Ile	His	Leu	Glu	Gln	
				170					175					180	

Val	Phe	Glu	Thr	Pro	Lys	Lys	Met	Tyr	Leu	Val	Met	Glu	Leu	Cys
				185					190					195
Glu	Asp	Gly	Glu	Leu	Lys	Glu	Ile	Leu	Asp	Arg	Lys	Gly	His	Phe
				200					205					210
Ser	Glu	Asn	Glu	Thr	Arg	Trp	Ile	Ile	Gln	Ser	Leu	Ala	Ser	Ala
				215					220					225
Ile	Ala	Tyr	Leu	His	Asn	Asn	Asp	Ile	Val	His	Arg	Asp	Leu	Lys
				230					235					240
Leu	Glu	Asn	Ile	Met	Val	Lys	Ser	Ser	Leu	Ile	Asp	Asp	Asn	Asn
				245					250					255
Glu	Ile	Asn	Leu	Asn	Ile	Lys	Val	Thr	Asp	Phe	Gly	Leu	Ala	Val
				260					265					270
Lys	Lys	Gln	Ser	Arg	Ser	Glu	Ala	Met	Leu	Gln	Ala	Thr	Cys	Gly
				275					280					285
Thr	Pro	Ile	Tyr	Met	Ala	Pro	Glu	Val	Ile	Ser	Ala	His	Asp	Tyr
				290					295					300
Ser	Gln	Gln	Cys	Asp	Ile	Trp	Ser	Ile	Gly	Val	Val	Met	Tyr	Met
				305					310					315
Leu	Leu	Arg	Gly	Glu	Pro	Pro	Phe	Leu	Ala	Ser	Ser	Glu	Glu	Lys
				320					325					330
Leu	Phe	Glu	Leu	Ile	Arg	Lys	Gly	Glu	Leu	His	Phe	Glu	Asn	Ala
				335					340					345
Val	Trp	Asn	Ser	Ile	Ser	Asp	Cys	Ala	Lys	Ser	Val	Leu	Lys	Gln
				350					355					360
Leu	Met	Lys	Val	Asp	Pro	Ala	His	Arg	Ile	Thr	Ala	Lys	Glu	Leu
				365					370					375
Leu	Asp	Asn	Gln	Trp	Leu	Thr	Gly	Asn	Lys	Leu	Ser	Ser	Val	Arg
				380					385					390
Pro	Thr	Asn	Val	Leu	Glu	Met	Met	Lys	Glu	Trp	Lys	Asn	Asn	Pro
				395					400					405
Glu	Ser	Val	Glu	Gln	Asn	Thr	Thr	Glu	Glu	Lys	Asn	Lys	Pro	Ser
				410					415					420
Thr	Glu	Glu	Lys	Leu	Lys	Ser	Tyr	Gln	Pro	Trp	Gly	Asn	Val	Pro
				425					430					435
Asp	Ala	Asn	Tyr	Thr	Ser	Asp	Glu	Glu	Glu	Glu	Lys	Gln	Ser	Thr
				440					445					450
Ala	Tyr	Glu	Lys	Gln	Phe	Pro	Ala	Thr	Ser	Lys	Asp	Asn	Phe	Asp
				455					460					465
Met	Cys	Ser	Ser	Ser	Phe	Thr	Ser	Ser	Lys	Leu	Leu	Pro	Ala	Glu
				470					475					480
Ile	Lys	Gly	Glu	Met	Glu	Lys	Thr	Pro	Val	Thr	Pro	Ser	Gln	Gly
				485					490					495
Thr	Ala	Thr	Lys	Tyr	Pro	Ala	Lys	Ser	Gly	Ala	Leu	Ser	Arg	Thr
				500					505					510
Lys	Lys	Lys	Leu											

<210> 6
 <211> 338
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 8187571CD1

<400>	6													
Met	Ala	Ser	Arg	Leu	Leu	His	Arg	His	Ile	Arg	Glu	Gln	Leu	Lys
1				5					10					15
Asp	Leu	Val	Glu	Ile	Leu	Gln	Asp	Pro	Ser	Pro	Pro	Pro	Leu	Cys
				20					25					30
Leu	Pro	Thr	Thr	Pro	Gly	Thr	Pro	Asp	Ser	Ser	Asp	Pro	Ser	His
				35					40					45

Leu	Leu	Gly	Pro	Gln	Ser	Cys	Trp	Ser	Ser	Gln	Lys	Glu	Val	Ser	
				50					55					60	
His	Glu	Ser	Leu	Val	Val	Gly	Ala	Ile	Glu	Asn	Ala	Phe	Gln	Leu	
				65					70					75	
Met	Asp	Glu	Gln	Met	Ala	Arg	Glu	Arg	Arg	Gly	His	Gln	Val	Glu	
				80					85					90	
Gly	Gly	Cys	Cys	Ala	Leu	Val	Val	Ile	Tyr	Leu	Leu	Gly	Lys	Val	
				95					100					105	
Tyr	Val	Ala	Asn	Ala	Gly	Asp	Ser	Arg	Ala	Ile	Ile	Val	Arg	Asn	
				110					115					120	
Gly	Glu	Ile	Ile	Pro	Met	Ser	Arg	Glu	Phe	Thr	Pro	Glu	Thr	Glu	
				125					130					135	
Arg	Gln	Arg	Leu	Gln	Leu	Leu	Gly	Phe	Leu	Lys	Pro	Glu	Leu	Leu	
				140					145					150	
Gly	Ser	Glu	Phe	Thr	His	Leu	Glu	Phe	Pro	Arg	Arg	Val	Leu	Pro	
				155					160					165	
Lys	Glu	Leu	Gly	Gln	Arg	Met	Leu	Tyr	Arg	Asp	Gln	Asn	Met	Thr	
				170					175					180	
Gly	Trp	Ala	Tyr	Lys	Lys	Ile	Glu	Leu	Glu	Asp	Leu	Arg	Phe	Pro	
				185					190					195	
Leu	Val	Cys	Gly	Glu	Gly	Lys	Lys	Ala	Arg	Val	Met	Ala	Thr	Ile	
				200					205					210	
Gly	Val	Thr	Arg	Gly	Leu	Gly	Asp	His	Ser	Leu	Lys	Val	Cys	Ser	
				215					220					225	
Ser	Thr	Leu	Pro	Ile	Lys	Pro	Phe	Leu	Ser	Cys	Phe	Pro	Glu	Val	
				230					235					240	
Arg	Val	Tyr	Asp	Leu	Thr	Gln	Tyr	Glu	His	Cys	Pro	Asp	Asp	Val	
				245					250					255	
Leu	Val	Leu	Gly	Thr	Asp	Gly	Leu	Trp	Asp	Val	Thr	Thr	Asp	Cys	
				260					265					270	
Glu	Val	Ala	Ala	Thr	Val	Asp	Arg	Val	Leu	Ser	Ala	Tyr	Glu	Pro	
				275					280					285	
Asn	Asp	His	Ser	Arg	Tyr	Thr	Ala	Leu	Ala	Gln	Ala	Leu	Val	Leu	
				290					295					300	
Gly	Ala	Arg	Gly	Thr	Pro	Arg	Asp	Arg	Gly	Trp	Arg	Leu	Pro	Asn	
				305					310					315	
Asn	Lys	Leu	Gly	Ser	Gly	Asp	Asp	Ile	Ser	Val	Phe	Val	Ile	Pro	
				320					325					330	
Leu	Gly	Gly	Pro	Gly	Ser	Tyr	Ser								
				335											

<210> 7
 <211> 321
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7494145CD1

<400>	7														
Met	Thr	Ser	Phe	His	Pro	Arg	Gly	Leu	Gln	Ala	Ala	Arg	Ala	Gln	
1				5					10					15	
Lys	Phe	Lys	Ser	Lys	Arg	Pro	Arg	Ser	Asn	Ser	Asp	Cys	Phe	Gln	
				20					25					30	
Glu	Glu	Asp	Leu	Arg	Gln	Gly	Phe	Gln	Trp	Arg	Lys	Ser	Leu	Pro	
				35					40					45	
Phe	Gly	Ala	Ala	Ser	Ser	Tyr	Leu	Asn	Leu	Glu	Lys	Leu	Gly	Glu	
				50					55					60	
Gly	Ser	Tyr	Ala	Thr	Val	Tyr	Lys	Gly	Ile	Ser	Arg	Ile	Asn	Gly	
				65					70					75	
Gln	Leu	Val	Ala	Leu	Lys	Val	Ile	Ser	Met	Asn	Ala	Glu	Glu	Gly	
				80					85					90	

Val	Pro	Phe	Thr	Ala	Ile	Arg	Glu	Ala	Ser	Leu	Leu	Lys	Gly	Leu	
				95					100					105	
Lys	His	Ala	Asn	Ile	Val	Leu	Leu	His	Asp	Ile	Ile	His	Thr	Lys	
				110					115					120	
Glu	Thr	Leu	Thr	Phe	Val	Phe	Glu	Tyr	Met	His	Thr	Asp	Leu	Ala	
				125					130					135	
Gln	Tyr	Met	Ser	Gln	His	Pro	Gly	Gly	Leu	His	Pro	His	Asn	Val	
				140					145					150	
Arg	Leu	Phe	Met	Phe	Gln	Leu	Leu	Arg	Gly	Leu	Ala	Tyr	Ile	His	
				155					160					165	
His	Gln	His	Val	Leu	His	Arg	Asp	Leu	Lys	Pro	Gln	Asn	Leu	Leu	
				170					175					180	
Ile	Ser	His	Leu	Gly	Glu	Leu	Lys	Leu	Ala	Asp	Phe	Gly	Leu	Ala	
				185					190					195	
Arg	Ala	Lys	Ser	Ile	Pro	Ser	Gln	Thr	Tyr	Ser	Ser	Glu	Val	Val	
				200					205					210	
Thr	Leu	Trp	Tyr	Arg	Pro	Pro	Asp	Ala	Leu	Leu	Gly	Ala	Thr	Glu	
				215					220					225	
Tyr	Ser	Ser	Glu	Leu	Asp	Ile	Trp	Gly	Ala	Gly	Cys	Ile	Phe	Ile	
				230					235					240	
Glu	Met	Phe	Gln	Gly	Gln	Pro	Leu	Phe	Pro	Gly	Val	Ser	Asn	Ile	
				245					250					255	
Leu	Glu	Gln	Leu	Glu	Lys	Ile	Trp	Glu	Val	Leu	Gly	Val	Pro	Thr	
				260					265					270	
Glu	Asp	Thr	Trp	Pro	Gly	Val	Ser	Lys	Leu	Pro	Asn	Tyr	Asn	Pro	
				275					280					285	
Glu	Glu	Ser	Leu	Phe	Thr	Val	Ser	Gly	Val	Arg	Leu	Lys	Pro	Glu	
				290					295					300	
Met	Cys	Asp	Leu	Leu	Ala	Ser	Tyr	Gln	Lys	Gly	His	His	Pro	Ala	
				305					310					315	
Gln	Phe	Ser	Lys	Cys	Trp										
				320											

<210> 8
 <211> 292
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5807954CD1

<400> 8															
Met	Lys	Ala	Thr	Val	Leu	Met	Arg	Gln	Pro	Gly	Arg	Val	Gln	Glu	
1				5					10					15	
Ile	Val	Gly	Ala	Leu	Arg	Lys	Gly	Gly	Gly	Asp	Arg	Leu	Gln	Val	
				20					25					30	
Ile	Ser	Asp	Phe	Asp	Met	Thr	Leu	Ser	Arg	Phe	Ala	Tyr	Asn	Gly	
				35					40					45	
Lys	Arg	Cys	Pro	Ser	Ser	Tyr	Asn	Ile	Leu	Asp	Asn	Ser	Lys	Ile	
				50					55					60	
Ile	Ser	Glu	Glu	Cys	Arg	Lys	Glu	Leu	Thr	Ala	Leu	Leu	His	His	
				65					70					75	
Tyr	Tyr	Pro	Ile	Glu	Ile	Asp	Pro	His	Arg	Thr	Val	Lys	Glu	Lys	
				80					85					90	
Leu	Pro	His	Met	Val	Glu	Trp	Trp	Thr	Lys	Ala	His	Asn	Leu	Leu	
				95					100					105	
Cys	Gln	Gln	Lys	Ile	Gln	Lys	Phe	Gln	Ile	Ala	Gln	Val	Val	Arg	
				110					115					120	
Glu	Ser	Asn	Ala	Met	Leu	Arg	Glu	Gly	Tyr	Lys	Thr	Phe	Phe	Asn	
				125					130					135	
Thr	Leu	Tyr	His	Asn	Asn	Ile	Pro	Leu	Phe	Ile	Phe	Ser	Ala	Gly	
				140					145					150	

Ile Gly Asp Ile	Leu Glu Glu Ile Ile	Arg Gln Met Lys Val	Phe
	155	160	165
His Pro Asn Ile	His Ile Val Ser Asn	Tyr Met Asp Phe Asn	Glu
	170	175	180
Asp Gly Phe Leu	Gln Gly Phe Lys Gly	Gln Leu Ile His Thr	Tyr
	185	190	195
Asn Lys Asn Ser	Ser Ala Cys Glu Asn	Ser Gly Tyr Phe Gln	Gln
	200	205	210
Leu Glu Gly Lys	Thr Asn Val Ile Leu	Leu Gly Asp Ser Ile	Gly
	215	220	225
Asp Leu Thr Met	Ala Asp Gly Val Pro	Gly Val Gln Asn Ile	Leu
	230	235	240
Lys Ile Gly Phe	Leu Asn Asp Lys Val	Glu Glu Arg Arg Glu	Arg
	245	250	255
Tyr Met Asp Ser	Tyr Asp Ile Val Leu	Glu Lys Asp Glu Thr	Leu
	260	265	270
Asp Val Val Asn	Gly Leu Leu Gln His	Ile Leu Cys Gln Gly	Val
	275	280	285
Gln Leu Glu Met	Gln Gly Pro		
	290		

<210> 9
 <211> 1605
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte ID No: 55074884CB1

<400> 9
 ccaagcccca gcctgggtcca cctcgggaggc ctctaggacc cggggggcgcc cggcggccgc 60
 ccggctccca caaatagact cctggggcggg cgccctgagcc cccaaaatag atcctcaggg 120
 cccaaaagca gactcttcgg cgggcgccat gggaccggca gaagctgggc gccgcggggc 180
 cgcctcgccc gtacctccac cgttgggtgcg cgtcgcgccc tcaactcttc tcgggagcgc 240
 gcgagccgcg ggcgcgggagg agcagctggc gcgcgcggga gtcacgctgt gcgtcaacgt 300
 ctcccgcag cagccccggc cgcgcgcgcc cggcgtggca gagctgcgcg tgcccgtgtt 360
 cgacgacccg gctgaggacc tgctggcgca cctggagccc acgtgcgccc ccatggaggc 420
 cgcggtgcgc gccggcgggc cctgcctagt ctactgcaag aacggccgca gccgctcggc 480
 cgccgtctgc acccggtacc tcatgcggca ccgcggcctc agcctggcga aggccttcca 540
 gatggtgaag agcgtcgcgc cggtagcaga accgaacccg ggcttctggt ctacagctcca 600
 gaagtatgag gaggccctcc aggccagtc ctgcctgcag ggagagcccc cagccttagg 660
 gttgggcctt gaggcttgaa gcttgaaggc ctgctgcctg gaggaaggat gtcctgcac 720
 tgatacagaa ggttgggtctt tacccttctt cctcactgtc atatcgagtt ttcctttgtg 780
 tgtgtgtgtg tgaaacatag tgcttttaatt tttatatatt cggctgaggt gatgcacaaa 840
 ttatcttaca gacacaaaaa gaaatacatt tggtaaaaca tcgaagacaa attaagaaaa 900
 agcaaatagg gatcctccat tatttacact ccagaatctt gagtggtttgg ggggtgccggc 960
 gcattctacc agtctcaggg aaggacatga gtacagacta cagtaatcag aatctgagtc 1020
 ataggtgaaa tcaggaaaag caactcttct tgtgtttatt tttagtagtg tcataagaac 1080
 ggactagttc ttctcgcgtg accacgggatg cttctgtttg agaaaatgca taccacagtg 1140
 ggacatttag atcaagaaag ctgttgatga agacattggt gaagggcaac ttgggtgatt 1200
 ggggaattat tctcttcac agccctctct caatacagct ggagctgtcc cataggagtt 1260
 cggacaatta cggacatcct ttttctttct ctctttcttt tttttgttt gtttgtttga 1320
 gagcaggtct ctgttgccca ggctggagtg cagtggcgca atcttggctc actgcaacct 1380
 ccgcctccca ggttcaagt attctcctgc ctcagcctcc tgagtagctg ggactacagg 1440
 tgtgtgacac cagaccgggc taatttcttt agtattttta gtagagatgg ggggggtttca 1500
 accatgttac ccaggatgta tcgtactcct gacctcagag atccagccac ctccatcttc 1560
 aacaatcgtg atgtgaggaa aacagagtga cgaacattcg ggtac 1605

<210> 10
 <211> 7225
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7480588CB1

<400> 10

```

atggattttt ttatcatttt tcttttactt tttattggga cttcagagac acaggttgat 60
gtttccaatg tegttoctgg tactaggtac gatataacca tctcttcaat ttctacaaca 120
tacacctcac ctgttactag aataggggaa ccagggcctc cagtcttctt agccggggaa 180
agagtcggat ctgctgggat tcttctgtct tgggaatacac cacctaattc aaatggaagg 240
attatatctt acattgtcaa atataaggaa gtttgtccgt ggatgcaaac agtatataca 300
caagtcagat caaagccaga cagtctggaa gttcttctta ctaatcttaa tcctggaaca 360
acatatgaaa ttaaggttgc tgctgaaaac agtgctggca ttggagtgtt tagtgatcca 420
tttctcttcc aaactgcaga aagtgtccca ggaaaagtg tgaatctcac agttgaggcc 480
tacaacgctt cagcagttaa gctgatttgg tatttacctc ggcaacccaa tggcaaaatt 540
accagcttca agattagtgt caagcatgcc agaagtggga tagtagtgaa agatgtctca 600
atcagagtag aggacatttt gactgggaaa ttgccagaat gcaatgagaa tagtgaatct 660
tttttatgga gtacagccag cccttctcca acccttggtg gagttacacc tccatcgctg 720
accacacatt catcaagcac gttgacacag aatgagatca gctctgtgtg gaaagagcct 780
atcagttttg tagtgacaca cttgagacct tatacaacat atctttttga agtttcagct 840
gtcaacaact aagcaggtta tattgatagt acgattgtca gaacaccaga atcagtgcct 900
gaaggaccac caaaaactcg cgtaacaggc aacatcacag gaaagtcctt ttcaatttta 960
tgggaccac caactatagt aacagggaaa tttagttata gagttgaatt atatggacca 1020
tcaggtgcag gtgcattttt ggataacagc acaaagacc tcaagtttgc attcactaac 1080
ctaaccacat ttacaatgta tgatgtctat attgcggctg aaaccagtg agggactggg 1140
cccaagtcaa atatttcagt attcactcca ccagatgttc caggggcagt gtttgattta 1200
caacttgcag aggtagaatc cagcaagta agaattactt ggaagaaacc acgacaacca 1260
aatggaatta ttaaccaata ccgagtgaaa gtgctagttc cagagacagg aataattttg 1320
gaaaatactt tgctcactgg aaataatgag ataaatgacc ccatggctcc agaaattgtg 1380
aacatagtag agccaatgg aggattatat gaggggttcag cagagatgtc gtctgacctt 1440
cactcacttg ctacattttat atataacagc catccagata aaaactttcc tgcaagggaat 1500
agagctgaag accgacttcc accagttgta actacaagga atcagtatat tactgacatt 1560
gcagctgaac agctgtctta tgttatcagg agacttgtag ctttactga gcacatgatt 1620
agtgtatctg ctttcaccat catgggagaa ggaccacca cagttctcag tgttaggaca 1680
cgtcagcaag tgccaagctc cattaaaatt ataaactata aaaatattag ttcttcatct 1740
atthttgtat attgggatcc tccagaatat cccaatggaa aaataactca ctatacgatt 1800
tatgcaatgg aattggatac aaacagagca ttccagataa ctaccataga taacagcttt 1860
ctcataacag gtagaaaaca atggttaaag aaatacacaa aatacaaaat gagagtggca 1920
gctcaacccc agtttggaga aagttctttg tctgaagaaa atgacatctt tgtgagaact 1980
tcagaagatg aaccggaatc atcacctcaa gatgtogaag taattgatgt taccgcagat 2040
gaaataagggt tgaagtggtc accacccgaa aagcccaatg ggatcattat tgcttatgaa 2100
gtgctatata aaaatataga tacttttatat atgaagaaca catcaacaac agacataata 2160
ttaaggaact taagacctca caccctctat aacatttctg taaggtctta caccagattt 2220
gggtcaggca atcaggtatc ttctttactc tctgtaagga cttcggagac tgtgcctgat 2280
agtgaccag aaaatatcac ttacaaaaat atttctctg gagagattga gctatcattc 2340
cttcccccaa gtagtcccaa tggaaatcata caaaaatata caatttatct caagagaagt 2400
aatggaaatg aggaaagaac tataaatata acctctttaa cccaaaacat taaaggactg 2460
aagaaatata cccaatatat cattgaggtg tctgctagta cactcaaagg tgaaggagtt 2520
cggagtgtc ccataagtat actgacggag gaagatgtc ctgattctcc ccctcaagac 2580
ttctctgtaa aacagttgtc tgggtgcacg gtgaagttgt catggcaacc accctggag 2640
ccaaatggga ttatccttta ttacacagtt tatgtctgga ggaatagatc atcattaaaa 2700
actattaatg tcaactgaaac atcattggag ttatcagatt tggattataa tgttgaaatac 2760
agtgttatg taacagctag caccagattt ggtgatggga aaacaagaag caatatcatt 2820
agctttcaaa caccagaggg accaagcgat cctcccaaag atgtttatta tgcaaacctc 2880
agttcttcat caataattct ttcttggaac cctccttcaa aacctaatgg gattatacaa 2940
tattactctg ttattacag aaatacttca ggtactttta tgcagaattt tacactccat 3000
gaagtaacca atgactttga caatatgact gtatccacaa ttatagataa actgacaata 3060
ttcagctact atacattttg gttaacagca agtacttcag ttggaaatgg gaataaaagc 3120
agtgcacatc ttgaagtata cacagatcaa gacgtacctg aagggtttgt tggaaacctg 3180
acttacgaat ccatttcgtc aactgcaata aatgtaagct ggggtcccacc ggctcaacca 3240
aacggtctag tcttctacta tgtttcacg atcttacagc agactcctcg ccatgtgaga 3300
ccactcttgg ttacatatga gagaagcata tattttgata atctggaaaa atacactgat 3360
tatatatata aaattactcc atcaacagaa aagggattct ctgataccta tactgcccag 3420
ctatacatca agactgaaga agatgtccca gaaacttcac caataatcaa cactttttaa 3480

```

aacctttcct	ctacctcagt	tctcttatca	tgggatcccc	cagtaaagcc	aatgggtgca	3540
ataataagtt	atgattttaac	tttacaagga	ccaaatgaaa	attattcttt	cattactttct	3600
gataattaca	taatatggga	agagctttca	ccattttacat	tatatagctt	ttttgtctgcc	3660
gcaagaacta	gaaaaggact	tggtccttcc	agtattcttt	tcttttacac	agatgagtca	3720
gtgccgttag	cacctccaca	aaatttgact	ttaatcaact	gtacttcaga	ctttgtatgg	3780
ctgaaatgga	gcccaagtc	tcttccaggt	ggtattgtta	aagtatatag	ttttaaaatt	3840
catgaacatg	aaactgacac	tatatattat	aagaatatat	caggatttaa	aactgaagcc	3900
aaacttggtg	gactggaacc	agtcagcacc	tactctatcc	gtgtatctgc	gttcacccaa	3960
gttggaatg	gcaatcaatt	tagtaatgta	gtaaaattca	caaccacaaga	atcagttcca	4020
gatgtcgtgc	agaatatgca	gtgcatggca	actagctggc	agtcagtttt	agtgaaatgg	4080
gatccaccca	aaaaggcaaa	tggataata	acgcagtata	tggtaacagt	tgaaggaat	4140
tctacaaaag	tttctcccca	agatcacatg	tacactttca	taaagcttct	tgccaatacc	4200
tcatatgtct	ttaaagtaag	agcttcaacc	tcagctgggtg	aagggtgatga	aagcacatgc	4260
catgtcagca	cactacctga	aacagttccc	agtgttccca	caaattattgc	tttttctgat	4320
gttcagttca	ctagtgaac	attgacatgg	ataagacctg	acactatcct	tggctacttt	4380
caaaattaca	aaattaccac	tcaacttcgt	gctcaaaaat	gcaaagaatg	ggaatccgaa	4440
gaatgtgttg	aatatcaaaa	aattcaatac	ctctatgaag	ctcacttaac	tgaagagaca	4500
gtatatggat	taaagaaatt	tagatgggat	agattccaag	tggcttccag	caccaatgct	4560
ggctatggca	atgcttcaaa	ctggatttct	acaaaaactc	tgcctggccc	tccagatggt	4620
cctcctgaaa	atgttcatgt	agtagcaaca	tcacctttta	gcatcagcat	aagctggagt	4680
gaacctgctg	tcattactgg	accaacatgt	tatctgattg	atgtcaaatc	ggtagataat	4740
gatgaattta	atatatcctt	catcaagtca	aatgaagaaa	ataaaaaccat	agaaattaaa	4800
gatttagaaa	tattcacaa	gtattctgta	gtgatcactg	catttactgg	gaacattagt	4860
gctgcatatg	tagaagggaa	gtcaagtgtc	gaaatgattg	ttactacttt	agaatcagcc	4920
caaaggacc	cacctaacaa	catgacattt	cagaagatac	cagatgaagt	tacaaaattt	4980
caattaacgt	tccttctctc	ttctcaacct	aatggaaata	tccaagtata	tcaagctctg	5040
gtttaccgag	aagatgatcc	tactgctgtc	cagattcaca	acctcagtat	tatacagaaa	5100
accaacacat	togtcatgtc	aatgctagaa	ggactaaaag	gtggacatac	atacaatatc	5160
agtgtttacg	cagtcaatag	tgtctgggtg	gggtccaaagg	ttccgatgag	aataacatg	5220
gatatacaag	ctccagcacg	acaaaaaacc	aaaccaaccc	ctattttatga	tgccacagga	5280
aaactgcttg	tgaacttcaac	aacaattaca	atcagaatgc	caatatgtta	ctacagtgat	5340
gatcatggac	caataaaaaa	tgtacaagtg	cttgtgacag	aaacaggagc	tcagcatgat	5400
ggaaatgtaa	caaagtggta	tgtatgcatat	tttaataaag	caaggccata	ttttacaaat	5460
gaaggctttc	ctaaccctcc	atgtacagaa	ggaaagacaa	agtttagtgg	caatgaagaa	5520
atctacatca	taggtgctga	taatgcatgc	atgattcctg	gcaatgaaga	caaaatttgc	5580
aatggaccac	tgaaaaccaa	aaagcaatac	ttattttaaat	ttagagctac	aaatattatg	5640
ggacaattta	ctgactctga	ttattctgac	ctgtttaaga	ctttaggggga	aggactttca	5700
gaagaaccg	tagagatcat	tctttccgtc	actttgtgta	tcctttcaat	aattctcctt	5760
ggaacagcta	tttttgcatt	tgcgagaatt	cgacagaagc	agaaagaagg	tggcacatac	5820
tctctcaggg	atgcagaaat	tattgacact	aaattgaagc	tggatcagct	catcacagtg	5880
gcagacctgg	aactgaagga	cgagagatta	acgcgggttac	ttagttatag	aaaatccatc	5940
aagccaataa	gcaagaaatc	cttctctgca	catgttgaag	agctttgcac	aaacaacaac	6000
ctaagtttcc	aagaagaatt	ttcggaatta	ccaaaatttc	ttcaggatct	ttcttcaact	6060
gatgtgtatc	tgccttggaa	tagagcaaaa	aaccgcttcc	caaacataaa	accatataat	6120
aataacagag	taaagctgat	agctgacgct	agtgttccag	gttcggatta	tattaatgcc	6180
agctatattt	ctgggttattt	atgtccaaat	gaatttattg	ctactcaagg	tccactacca	6240
ggaacagttg	gagattttttg	gagaatgggtg	tgggaaacca	gagcaaaaac	attagtaatg	6300
ctaacacagt	gtttttgaaa	aggacggatc	agatgccatc	agtattggcc	agaggacaac	6360
aagccagtta	ctgtcttttg	agatatagtg	attacaaagc	taatggagga	tgttcaaata	6420
gattggacta	tcaggggatct	gaaaattgaa	aggcatgggg	attgcatgac	tgttcgacag	6480
tgtaaacttta	ctgcctggcc	agagcatggg	gttcttgaga	acagcgcccc	tctaattcac	6540
tttgtgaagt	tgggttcgagc	aagcagggca	catgacacca	cacctatgat	tgttcaactgc	6600
agtgtctggag	ttggaagaac	tggagttttt	attgctctgg	accattttaac	acaacatata	6660
aatgaccatg	attttgggga	tatatatgga	ctagtagctg	aactgagaag	tgaaggaatg	6720
tgcattggtg	agaatctggc	acagtatata	tttttacacc	agtgcattct	ggatctctta	6780
tcaataaagg	gaagtaatca	gcccatctgt	tttgtttaact	attcagcact	tcagaagatg	6840
gactcttttg	acgccatgga	aggtgatgtt	gagcttgaat	gggaagaaac	cactatgtaa	6900
atattcagac	caaaggatac	aattggaaga	gattttttaa	tcccagggggc	caaagttacc	6960
ccctcattct	tccgaattga	aatgtgcaac	cttaaagaaa	tatctatgct	tctctcactg	7020
tgcctttcca	acggattgaa	cattttaaga	ctagttcttg	aaaatagcta	atacagaata	7080
attatttgtt	ttgtacagaa	taaatattat	gcatttttaa	tgtttaagaa	aagacatccc	7140
atatgttttt	gaagtctctc	atattttggg	ataagccaaa	tagaaaatta	ttatttatatt	7200
agcattaatg	tttcaatgcg	aaaaa				7225

<210> 11
 <211> 1691
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7482931CB1

<400> 11
 cgggtcccgcg tgccgagggt taacccccgc cgggtcccgcg cctgagctgg accagagccc 60
 tcctccagaa acccctgcgt ccgccacggc ccagggttaaa tggaaaccac ccttgggaaac 120
 tggatgcctg tgtagctgtt ctaccatata agtgattatgc aatgagtgagg ggaggagagc 180
 agctggatat cctgagtggt ggaatcctag tgaaagaaaag atggaaaagtg ttgagaaaaga 240
 ttgggggtgg gggcttttga gaaatttacg atgccttggg catgctcacc agggaaaatg 300
 ttgcactgaa ggtggaatca gctcaacaac caaaacaagt tctgaaaatg gaagttgctg 360
 ttttgaaaaa gctgcaaggg aaagaccatg tttgtagatt tattggctgt gggagggaatg 420
 atcgattcaa ctatgtgggt atgcagttgc aggggtcgaaa tctggcagat cttcgccgta 480
 gccagtcccg aggcacattc accattagta ccactctccg gctgggtaga cagatttttg 540
 agtctattga aagcattcat tctgtgggat tcttgcatcg agacatcaaa ccgtcgaaact 600
 tcgctatggg tcgcttttct agtacatgta ggaaatgtta catgcttgat tttggcttgg 660
 ctcgacaatt taccaattcc tgtgggtgacg tcagaccacc tcgagctgtg gcagggttttc 720
 gagggacagt tcgttatgca tcaatcaacg cacatcggaa cagggaatg ggaagacatg 780
 atgacctttg gtccttattc tacatgttgg tggagtttgt gggttggtcag ctgccctgga 840
 aaaaaataaa ggacaaggag caagtaggct ctattaagga gagatatgac cacagggtca 900
 tgttgaaca tctccctcca gaattcagca tctttctaga ccatactctt tctttggatt 960
 attttacaaa accagactac cagcttctta catccgtgtt tgacaatagc atcaagactt 1020
 ttggagtaat tgagagtgc ccttttgact gggagaagac tggaaatgat ggctccctaa 1080
 caaccaccac tacttctacc accctcagt tgcacactcg cttgaccctt gctgcaattg 1140
 gaattgccaa tgctactccc atccctggag acttgcttcg agaaaaataca gatgagggtat 1200
 ttccagatga acagcttagc gatggagaaa atggcatccc tgttggtgtg tcaccagata 1260
 aattgcctgg atctctggga ccccccgtc cccaggagaa ggatgtttgg gaagagatgg 1320
 atgccaacaa aaacaagata aagcttggaa tttgttaagg tgctactgaa gaggagaaca 1380
 gccatggcca ggcaaatggt cttctcaatg ctccaagcct tgggtcacca attcgtgtcc 1440
 gctcagagat tactcagcca gacagagata ttccactggg gcgaaaagtta cgttccattc 1500
 acagctttga gctggaaaaa cgtctgaccc tggagccaaa gccagacact gacaagttcc 1560
 ttgagacctg gtataaaata gtgtattttt ctttttaaaag cttctaagggt accattatta 1620
 ttgttgtcat tgttgttatt attattgtat atttctgtta cataaagtct ttcaataaag 1680
 ccaaaaaaaa a 1691

<210> 12
 <211> 6146
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2080788CB1

<400> 12
 ccggctggct gggaagatgg cggcgggagc ctgggcccgc gccgcgcgcg ccgcgcgcgc 60
 ggagcgaacc aggggtgtcc ggggtgcgcg gtccaggggc ggggcccggc catgagcgcg 120
 ccgtcctcga gtccccgagc cgcggagccc gccgcgcgcc ctcgggccgc cccgcgtccc 180
 tcgccatggc gggctcgcg gactacttcg tgcctggggc gtccggggcg caccgcgcgc 240
 ggagtgggga aggccagggc cagattctgc agcgttccc agagaaggac tgggaggaca 300
 acccatcccc ccagggcacg gagctgtttt gccagcccag cgggtggcag ctgtgtcccc 360
 agaggaatcc accgacctt tttgttgctg tctcaccga catcaactcc gagcgccact 420
 actgcgcctg cttgaccttc tgggagccag cggagccttc acaggaaaac acgcgcgtgg 480
 aggatgccac agagaggggag gaagaggggg atgagggagg ccagaccac ctgtctccca 540
 cagcacctgc ccatctgctc cagctgtttg caccgaagac gctgggtact gtgtcgcgac 600
 tcgaccacac ggaggtgttc aggaacagcc ttggcctcat ctatgccatc cacgtggagg 660
 gcctgaatgt gtgcctggag aacgtgattg ggaacctgct gacgtgcact gtgcccctgg 720
 ctgggggctc gcagaggacg atctcttttg gggctgggtga ccggcaggtc atccagactc 780

cactggccga	ctcgtctgcc	gtcagccgct	gcagcgtggc	cctgctcttc	cgccagctag	840
gcatcaccaa	cgtgctgtct	ttgtttctgt	cgcgcctcac	ggagcacaag	gttctcttcc	900
tgtcccgag	ctaccagcgg	ctcgccgatg	cctgtagggg	cctcctggca	ctgctgtttc	960
ctctcagata	cagcttcacc	tatgtgcccc	tcttgccggc	tcagctgctg	gaggctccca	1020
gcacacccac	gcccttcata	attgggggtca	acgcggcctt	ccaggcagag	acccaggagc	1080
tgctcgatgt	gattgtttgt	gatctggatg	gagggacggg	caccattcct	gagtgtgtgc	1140
acattccacc	cttgccagag	ccactgcaga	gtcagacgca	cagtgtgctg	agcatgggtc	1200
tggacccgga	gctggagttg	gctgacctcg	ccttccctcc	gcccacgaca	tccacctcct	1260
ccctgaagat	gcaggacaag	gagctgcggg	cggctcttct	gcggtctgtc	gtcagctgct	1320
tgcagggcta	tcgctgggtg	ctgcacgtcg	tgcgcataca	cccggagcct	gtcatccgct	1380
tccataaggc	agccttcctg	ggccagcgtg	ggctggtaga	ggacgatttc	ctgatgaagg	1440
tgctggaggg	catggccttt	gctggccttt	tgtcagagcg	tggggtccca	taccgcccta	1500
cggacctgtt	cgatgagctg	gtggccccac	aggtggcaag	gatgcggggc	gatgagaacc	1560
acccccagcg	tgtcctgctg	cacgtccagg	aactggcaga	gcagctctac	aagaacgaga	1620
acccgtaccc	agccgtggcg	atgcacaagg	tacagaggcc	cggtagagag	agccacctgc	1680
gacgggtgcc	ccgagccttc	ccccggctgg	atgagggcac	cgtgcagtg	atcgtgggac	1740
aggctgcagc	caagatgcag	gggtgcacccc	cagctgtgaa	ggccgagagg	aggaccaccg	1800
tgccttcagg	gccccccatg	actgccatac	tggagcgggt	cagtgggctg	catgtcaaca	1860
gcgcccggcg	gctggaggtt	gtgcgcaact	gcatactcta	cgtgttttag	gggaaaatgc	1920
ttgaggccaa	gaagctgctc	ccagccgtgt	tgaggggcct	gaaggggcca	gctgcccgcg	1980
gtcgctctgc	ccaggagctg	cacctgcattg	tgcagcagaa	ccgtgcggtc	ctggaccacc	2040
agcagtttga	ctttgtcgtc	cgtatgatga	actgctgcct	gcaggactgc	acttctctgg	2100
acgagcatgg	cattgcggcg	gctctgctgc	ctctggtcac	agccttctgc	cggaaagctga	2160
gcccgggggt	gacgcagttt	gcatacagct	gtgtgcagga	gcacgtgggt	tggagcacgc	2220
cacagttctg	ggaggccatg	ttctatgggg	atgtgcagac	tcacatccgg	gccctctacc	2280
tggagcccac	ggaggacctg	gccccgcgcc	aggaggttgg	ggaggcacct	tcccaggagg	2340
acgagcgctc	tgccttagac	gtggcttctg	agcagcgcg	cttgtggcca	actctgagtc	2400
gtgagaagca	gcaggagctg	gtgcagaagg	aggagagcac	ggtgttcagc	caggccatcc	2460
actatgccaa	ccgcatgagc	tacctcctcc	tgcctctgga	cagcagcaag	agccgcctac	2520
ttcggggagc	tgcggggctg	ggcgacctgg	agagcgccag	caacagcctg	gtcaccaca	2580
gcatggctgg	cagtgtggcc	gagagctatg	acacggagag	cggcttcgag	gatgcagaga	2640
cctgcgacgt	agctggggct	gtggctcctg	tcatcaaccg	ctttgtggac	aaggtctgca	2700
cggagagtg	ggtcacagc	gaccacctca	aggggtctga	tgtcatgggt	ccagacattg	2760
tccagatgca	catcgagacc	ctggaggccg	tgcagcggga	gagccggagg	ctgccgcca	2820
tccagaagcc	caagctgctg	cggccgcgcc	tgctgccggg	tgaggagtgt	gtgctggacg	2880
gcctgcgcgt	ctacctgctg	ccggatgggg	gtgaggagg	cgcggggggc	agtgtctggg	2940
gaccagcatt	gctcccagct	gagggcgccg	tcttctcac	cacgtaccgg	gtcatcttca	3000
cgggcatgcc	cagcgacccc	ctgggtgggg	agcaggtggt	ggtccgctcc	ttcccgttgg	3060
ctgcgctgac	caaggagaag	cgcatacagc	tccagacccc	tgtggaccag	ctcctgcagg	3120
acgggctcca	gctgcgctcc	tgcacattcc	agctgctgaa	aatggccttt	gacgaggagg	3180
tggggctctga	cagcgccgag	ctcttcctga	agcagctgca	taagctgcgg	taccgcggcg	3240
acatcagggg	cacctttgcg	ttcaccttgg	gctctgcca	cacacctggc	cggccaccgc	3300
gagtcaccaa	ggacaagggt	ccttccctca	gaacctgtgc	ccggaacctg	gtcaagaacg	3360
ccaagaagac	catcgggcgg	cagcatgtca	ctcgcaagaa	gtacaacccc	ccagcttggg	3420
agcaccgggg	ccagccgcgc	cctgaggacc	aggaggacga	gatctcagtg	tccgaggagc	3480
tggagcccag	cacgctgacc	ccgtcctcag	ccctgaagcc	ctccgaccgc	atgacatga	3540
gcagcctggt	ggaaagggtc	tgctgtcgcg	actaccagcg	cctcgggtctg	ggcaccctga	3600
gcagcagcct	gagccggggc	aagtctgagc	ccttccgcat	ttctccgggtc	aaccgcatgt	3660
atgccatctg	ccgcagctac	ccagggctgc	tgatcgtgcc	ccagagtgtc	caggacaacc	3720
ccctgcagcg	cgtgtccgcg	tgtaccgcgc	agaaccgctt	ccccgtgggtc	tgttggcgca	3780
gcggggcggtc	caaggcggtg	ctgctgcgct	ctggaggcct	gcattggcaaa	ggtgtcgtcg	3840
gcctcttcaa	ggcccagaac	gcaccttctc	caggccagtc	ccaggcggac	tcgagtagcc	3900
tggagcagga	gaagtacctg	caggctgtgg	tcagctccat	gccccgctac	gccgacgcgt	3960
cgggacgcaa	cacgcttagc	ggcttctcct	cagccacat	gggcagtcac	ggtaagtggg	4020
cgagtgtccg	gaccagtggg	cgcagcagtg	gccttggcac	cgatgtgggc	tcccggctag	4080
ctggcagaga	cgcgctggcc	ccaccccagg	ccaacggggg	ccttcccgac	ccgggcttcc	4140
tgcgtccgca	gcgagcagcc	ctctatatcc	ttggggacaa	agcccagctc	aagggtgtgc	4200
ggtcagaccc	cctgcagcag	tgggagctgg	tgcacattga	ggtattcgag	gcacggcagg	4260
tgaaggctag	cttcaagaag	ctgctgaaag	catgtgtccc	aggctgcccc	gctgctgagc	4320
ccagcccagc	ctccttctg	cgtcactggg	aggactcaga	gtggctgac	cagatccaca	4380
agctgctgca	ggtgtctgtg	ctgggtgggtg	agctcctgga	ttcaggctcc	tccgtgctgg	4440
tgggcctgga	ggatggctgg	gacatcacca	cccagggtgg	atccttgggtg	cagctgctct	4500
cagacccctt	ctaccgcacg	ctggaggggt	ttcgctgct	ggtggagaag	gagtggctgt	4560

ccttcggcca	tcgcttcagc	caccgtggag	ctcacaccct	ggccgggcag	agcagcggct	4620
tcacacccgt	cttcctgcag	ttcctggact	gcgtacacca	gggtccacctg	cagttcccca	4680
tggagtttga	gttcagccag	ttctacctca	agttccctcgg	ctaccaccat	gtgtcccgcc	4740
gtttccggac	cttcctgctc	gactctgact	atgagcgcat	tgagctgggg	ctgctgtatg	4800
aggagaaggg	ggaacgcagg	ggccagggtgc	cgtgcaggtc	tgtgtgggag	tatgtggacc	4860
ggctgagcaa	gaggacgcct	gtgttccaca	attacatgta	tgcgcccag	gacgcagagg	4920
tcctgcggcc	ctacagcaac	gtgtccaacc	tgaagggtgtg	ggacttctac	actgaggaga	4980
cgctggccga	gggcccctccc	tatgactggg	aactggccca	ggggccccct	gaacccccag	5040
aggaagaacg	gtctgatgga	ggcgctcccc	agagcaggcg	ccgcgtggtg	tggccctgtt	5100
acgacagctg	cccgcgggcc	cagcctgacg	ccatctcacg	cctgctggag	gagctgcaga	5160
ggctggagac	agagttgggc	caaccgcgtg	agcgtctgga	ggacacctgg	gaccgggtga	5220
aggctgcaca	gcgcctcgag	ggccggccag	acggccgtgg	cacccttagc	tccctccttg	5280
tgteccaccg	accccaaccac	cgctcgctcg	tgggtgtgta	cctgcaggag	gggcccgtgg	5340
gtccaccct	gagcctcagc	ctggacagcg	accagagtag	tggctcaacc	acatccggct	5400
ccgctcaggc	tgcccgcgcg	agcaccagca	ccctgtacag	ccagttccag	acagcagaga	5460
gtgagaacag	gtcctacgag	ggcactctgt	acaagaaggg	ggccttcatg	aagccttgga	5520
aggcccgctg	gttcgtgctg	gacaagacca	agcaccagct	gcgctactac	gaccaccgtg	5580
tggacacaga	gtgcaagggg	gtcatcgact	tggcggagg	ggaggctgtg	gcacctggca	5640
cgcccactat	gggtgcccc	aagaccgtgg	acgagaaggg	cttctttgac	gtgaagacaa	5700
cgcgtcgctg	ttacaacttc	tgtgccccag	acgtgccctc	ggcccagcag	tgggtggacc	5760
ggatccagag	gacgcctgtg	gacgccagcc	ctgcccgct	ctgctgcttc	gctctgcttc	5820
cggtcgttac	cgaccactag	gggtgggcag	ggccgcggcg	gccatgttta	cagccccggc	5880
cctcgacagt	attgaggccc	cgagccccc	gcacttgtgt	gtacagcccc	cgtccccgcc	5940
ccgccccgcc	cgcccgggcc	taacttattt	tggcgtcaca	gctgagcacc	gtgccgggag	6000
gtggccaagg	tacagcccg	aatgggcctg	taaatagtcc	ggccccgtca	gcgtgtgctg	6060
gtccagccag	cggctgcagg	cgagtttcta	gaaccagagt	ctatataaag	agagaactaa	6120
cgccaaaaaa	aaaaaaaaaa	aaaaaa				6146

<210> 13

<211> 2362

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 71918969CB1

<400> 13

gctctcagct	gtgaatatgt	gtctagtga	tccttaacct	gaggacttca	ccagttcgaa	60
attacagttt	tcaccatcaa	ctaccttate	ctttttggcc	tggttttctt	cctcaaacag	120
tggaaacatt	tttaaagttg	cttttgttgc	agagttaa	aaatggctga	tagtggctta	180
gataaaaaat	ccacaaaatg	ccccgactgt	tcactctgct	ctcagaaaga	tgtactttgt	240
gtatgttcca	gcaaaaacag	ggttcctcca	gttttgggtg	tggaaatgtc	acagacatca	300
agcatttgta	gtgcagaatc	tttaatttca	ctggagagaa	aaaaagaaaa	aaatatcaac	360
agagatatata	cctccaggaa	agattttgcc	tcaagaacct	caaatgtaga	gagaaaagca	420
tctcagcaac	aatgggggtc	gggcaacttt	acagaaggaa	aagttcctca	cataaggatt	480
gagaatggag	ctgctattga	ggaaatctat	acctttggaa	gaatattggg	aaaagggagc	540
tttggaaatag	tcattgaagc	gacagacaag	gaaacagaaa	cgaagtgggc	aattaaaaaa	600
gtgaacaaaag	aaaaggctgg	aagctctgct	gtgaagttac	ttgaacgaga	ggtgaacatt	660
ctgaaaagtg	taaaacatga	acacatcata	catctgggaac	aagtatttga	aacgccaaag	720
aaaatgtacc	ttgtgatgga	gctttgtgag	gatggagaac	tcaaagaaat	tctggatagg	780
aaagggcatt	tctcagagaa	tgagacaagg	tggatcattc	aaagtctcgc	atcagctata	840
gcatactctc	acaataatga	tattgtacat	agagatctga	aactggaaaa	tataatgggt	900
aaaagcagtc	ttattgatga	taacaatgaa	ataaacttaa	acataaagg	gactgatttt	960
ggcttagcgg	tgaagaagca	aagtaggagt	gaagccatgc	tgcaggccac	atgtgggact	1020
cctatctata	tggccccctga	agttatcagt	gcccacgact	atagccagca	gtgtgacatt	1080
tggagcatag	gcgtcgtaat	gtacatgtta	ttacgtggag	aaccaccctt	tttggcaagc	1140
tcagaagaga	agctttttga	gttaataaga	aaaggagaac	tacattttga	aaatgcagtc	1200
tggaaattcca	taagtgactg	tgctaaaagt	gttttgaaac	aacttatgaa	agtagatcct	1260
gctcacagaa	tcacagctaa	ggaactacta	ataaaccagt	ggttaacagg	caataaactt	1320
tcttcggtga	gccacaacaa	tgtattagag	atgatgaagg	aatggaaaaa	taaccagaa	1380
agtgttgagg	aaaacacaa	agaagagaag	aataagccgt	ccactgaaga	aaagttgaaa	1440
agttaccaac	cctggggaaa	tgtccctgat	gccaattaca	cttcagatga	agaggaggaa	1500

```

aaacagtcta ctgcttatga aaagcaatth cctgcaacca gtaaggacaa ctttgatatg 1560
tgcagttcaa gttttcacatc tagcaaaactc cttccagctg aaatcaaggg agaaatggag 1620
aaaacccctg tgactccaag ccaaggaaca gcaaccaagt accctgctaa atccggcgcc 1680
ctgtccagaa ccaaaaagaa actctaagggt tccctccagt gttggacagt acaaaaacaa 1740
agctgctctt gtttagcactt tgatgagggg gtaggagggg aagaagacag ccctatgctg 1800
agcttgtagc ctttttagctc cacagagccc cgccatgtgt ttgcaccagc ttaaaattga 1860
agctgcttat ctccaaagca gcataagctg cacgtggcat taaaggacag ccaccagtag 1920
gcttggcagt gggctgcagt ggaaatcaac tcaagatgta cacgaagggt ttttaggggg 1980
gcagatacct tcaatttaag gctgtgggca cacttgctca tttttacttc aaattcttat 2040
gttttaggcac agctatttat aggggaaaac aagaggccaa atatagtaat ggaggtgcc 2100
aataattatg tgcactttgc actagaagac tttgttagaa aattactaat aaacttgcca 2160
tacgtattac agcagaagtg cttcagtcac tcacatgtgt tcgtgagatt ttaggttgc 2220
atagattgtt taagacagct tattttaaat gtagaaaaat aggagatttt gtaactgctt 2280
gccattaact tgctgctaaa ttcccaatgt attgattaaa tcaatcaaaa aacagatgtt 2340
cctcagcaca aacacacaaa aa 2362

```

```

<210> 14
<211> 1535
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 8187571CB1

```

```

<400> 14
ccaccacctc ccttagcctc ctgtgtggga ggagtttatg ggtatgtggc tcctgcccag 60
tccaggtggg ctttcaactc tactctatth cagttcctct tcccgatct gggctggaga 120
gcttcctcat tgttaaggca gcagaaactt tcgctggatg gttttaggat aaggggtcat 180
caatgctggc aagagtcggc acaatgagga ccaggttgc tgtgaagtgg tgtatgtgga 240
aggctcggagg agtggtacag gactacctag ggagcctagc cgaggccagg gactctgctt 300
ctactactgg ggcctatttg atgggcatgc agggggcgga gctgctgaaa tggcctcacg 360
gctcctgcat cgccatatac gagagcagct aaaggacctg gtagagatac ttcaggaccc 420
ttcgccacca cccctctgcc tcccaaccac tccggggacc ccagattcct ccgatccctc 480
tcaattgctt ggccctcagt cctgctgggc ttcacagaag gaagtgaagg acgagagcct 540
ggtagtgggg gccattgaga atgccttcca gctcatggat gagcagatgg cccggggagcg 600
gcgtggccac caagtggagg ggggctgctg tgcactgggt gtgatctacc tgctaggcaa 660
gggtgacgtg gccaatgcag gcgatatcag ggccatcatt gtccggaatg gtgaaatcat 720
tccaatgtcc cgggagttta ccccgagac tgagcgccag cgtcttcagc tgcttggtt 780
cctgaaacca gagctgctag gcagtgaatt caccacactt gagttcccc gcagagttct 840
gcccaaggag ctggggcgaga ggatgttgta ccgggaccag aacatgaccg gctgggccta 900
caaaaagatc gagctggagg atctcaggtt tcctctgggc tgtggggagg gcaaaaaggc 960
tcgggtgatg gccaccattg gggtagcccg aggttggga gaccacagcc ttaagggtctg 1020
cagttccacc ctgcccatac agccctttct ctctgcttc cctgaggtag gtagtgtatga 1080
cctgacacaa tatgagcact gccagatga tgtgctagtc ctgggaacag atggcctgtg 1140
ggatgtcact actgactgtg aggtagctgc cactgtggac aggtgctgt cggcctatga 1200
gcctaattgac cacagcaggt atacagctct ggcccaagct ctggctcctgg gggcccgggg 1260
taccctccac gaccgtggct gggtctctcc caacaacaag ctgggttccg gggatgacat 1320
ctctgtcttc gtcaccccc tgggagggcc aggcagttac tctgagggg ctgaacacca 1380
tccctccac tagcctctcc atacttactc ctctcacagc ccaaattctg aagttgtctc 1440
cctgaccctt ctttagtggc aacttaactg aagaagggat gtccgctata tccaaaatta 1500
cagctattgg caaataaacg agatggataa aaaaa 1535

```

```

<210> 15
<211> 1376
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 7494145CB1

```

```

<400> 15

```

```

gggaggagga atcagcaaag atggttgagc aggagtcccc agagaggcag gaggaaaacc 60
aaggaagtgc ccacttcaca gaatcaagga ggctttcaaa aaggggtggca tgattatggg 120
gttaaattgcc accaaagagt aaagcaagct gcctcgtttt cagttgtgca catctgaatg 180
caagcaatcc ctgtctgatg tggagtttct tgcactgata aggaaaaaact gctgaagtgt 240
tgaggctgct ccaggcagag ccatcatcta acagacctaa aagaagcatc atgttccatg 300
acttcatttc accccagggg acttcaagct gcccgtgccc agaagttcaa gagtaaaagg 360
ccacggagta acagtgattg ttttcaggaa gaggatctga ggcaggggtt tcagtggagg 420
aagagcctcc cttttggggc agcctcatct tacttgaact tggagaagct ggggtgaaggc 480
tcttatgcga cagtttaciaa ggggattagc agaataaatg gacaactagt ggctttaaaa 540
gtcatcagca tgaatgcaga ggaaggagtc ccatttacag ctatccgaga agcttctctc 600
ctgaagggtt tgaacatgc caatattgtg ctctgcatg acataatcca caccaaagag 660
acactgacat tcgtttttga atacatgcac acagacctgg ccagtatat gtctcagcat 720
ccaggaggggc ttcatcctca taatgtcaga cttttcatgt ttcaactttt gcggggcctg 780
gcgtacatcc accaccaaca cgttcttcac agggacctga aacctcagaa cttactcatc 840
agtcacctgg gagagctcaa actggctgat ttgggtcttg cccggggccaa gtccattccc 900
agccagacat actcttcaga agtcgtgacc ctctggtagc ggccccctga tgctttgctg 960
ggagccactg aatattctct tgagctggac atatgggggtg caggctgcat ctttattgaa 1020
atgttccagg gtcaaccttt gtttctctgg gtttccaaca tccttgaaca gctggagaaa 1080
atctgggagg tgctgggagt ccctacagag gatacttggc cgggagctct caagctacct 1140
aactacaatc cagagcagtc tttgtttaca gtttcaggag tgaggctaaa gccagaaatg 1200
tgtgaccttt tggcctccta ccagaaagggt caccacccag cccagtttag caaatgctgg 1260
tgaaaagaaa gggcgagatc accaagggtt ttcagggtt gtatttctgc agtttcgggt 1320
ttcatttget tcagcttact aagaagcttc aaatctaact ccatactgaa caaggg 1376

```

<210> 16

<211> 1482

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5807954CB1

<400> 16

```

gccgccgacc aggcctcgaa cgggatggca gatgaggtga ggaggaggga agcgtccgga 60
gtggggcggg cccggactcc gacccccggg gcgcttcgag cccccagct ggtcaccgag 120
gcaccgccgc ttccaccagg ccagtagccg ccccttcgag cccccggcc ccgcctcaca 180
cgcgcgcccg agcagacccc ggggtcccc tggggccagc gtggcgaggg ggtcagtggt 240
tctctcgggt ctcgggacag gtgagcacc tgatgaaggc cagggtcctg atgcggcagc 300
ctgggcgggt gcaggagatc gtgggcgccc tccgcaaggg cggcgagagc cggttacagg 360
tgatttctga ttttgacatg accttgagca ggtttgcata taatggaaag cgatgccctt 420
cttcttaciaa tattctggat aatagcaaga tcatcagtga ggagtgtcgg aaagagctca 480
cagcgtcctt tcaccactat tacccaattg agatcgaccc acaccggacc gtcaaggaga 540
agctacctca tatgggtggaa tgggtggacca aagcgcacaa tctcctatgt cagcagaaga 600
ttcagaagtt tcagatagcc cagggtggta gagagtccaa tgcaatgctc agggagggat 660
ataagacctt cttcaacaca ctctaccata acaacattcc ccttttcatc ttttctgcgg 720
gcattggtga tctctggaa gaaattatcc gacagatgaa agtgttccac cccaacatcc 780
acatcgtgtc taactacatg gattttaatg aagatggttt tctccaggga tttaagggcc 840
agctcatata cacatacaac aagaacagct ctgcgtgtga gaactctggt tacttccagc 900
aacttgaggg caaaaccaat gtcactctgc tgggagactc tatcggggac ctaccatgg 960
ccgatggggg tctgtgtgtg cagaacattc tcaaaattgg ctctctgaat gacaagggtg 1020
aggagcggcg ggagcgctac atggactcct atgacatcgt gctggagaa gacgagactc 1080
tggatgtggt caacgggcta ctgcagcaca tctgtgcca ggggtccag ctggagatgc 1140
aaggccctg aaggcgagc ctccagccg gcctgcaggc cgtgggtgag aggggcgct 1200
ccccagagtc tgctccccg tgaacacaga gcagaggcca ggggtggccag cagtggctgg 1260
gtccttccgc gccctccgt cctcctttcc ctgagcacct tcatcaccag aggcctgaag 1320
gaaccccgcc atgtggcagg gcacaggcac tgttctgggt gaaccttgga ccacagcatg 1380
tcagtgtctt agggattgtc tactccaggg attttcttca aaatttttaa acatgggaag 1440
ttcaaacaaa tataatgtgt gaaacagaaa aaaaaaaaaa aa 1482

```